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Treatment of major depressive disorder (MDD) currently relies on a prolonged trial and error 
process to identify the best pharmacological regimen. This process is further prolonged in older 
adults with major depressive disorder (Late-Life Depression or LLD), where it is associated with 
a host of negative outcomes, including suicide, worsening medical comorbidity, and poor quality 
of life. Functional magnetic resonance imaging (fMRI) brain changes have been associated with 
depression severity and treatment outcomes. Previous studies have shown that recovery from 
depression can be predicted using both pre-treatment neuroimaging as well as follow-up scans 
from the early treatment period. Pharmacological functional magnetic resonance imaging 
(phMRI) is an approach that utilizes multiple fMRI scans to investigate changes in functional 
neuroimaging following acute doses of pharmacotherapy. It has been demonstrated that 
antidepressants have a fast uptake period, effecting resting state networks as well as functional 
brain activation after only a single dose. We aimed to evaluate the efficacy of phMRI to identify 
these very early (single dose) functional changes, and use these to predict remission. Data was 
collected from an open-label pharmacologic treatment study of LLD (N=51). Multi-modal MRI, 
including phMRI, were acquired at 5 time-points. Results showed accurate prediction of 
depression remission from pre-treatment, as well as phMRI after only a single dose of 
pharmacotherapy. The trajectory of the neuroimaging changes across the treatment trial suggest 
an initial engagement of large scale resting networks, followed by engagement of implicit 
emotion control networks, and later changes in explicit emotion regulation. Utilizing kernel-
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based (multi-factor principal components) machine learning, we found that leveraging both 
pharmacological neuroimaging and clinical data improved prediction efficacy of remission. In 
this body of work, we have integrated multiple imaging modalities to explain the long delay in 
clinical response to antidepressants, and to identify early markers of response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   vi 
TABLE OF CONTENTS 
PREFACE ................................................................................................................................. XIV 
1.0 INTRODUCTION AND SPECIFIC AIMS ....................................................................... 1 
2.0 MAGNETIC RESONANCE IMAGING (MRI) ................................................................ 4 
2.1 MRI: NON-INVASIVE IMAGING OF THE BRAIN ............................................. 4 
2.2 MR SCANNER, PHYSICS, AND IMAGE ACQUISITION ................................... 5 
2.2.1 MR Components .............................................................................................. 5 
2.2.1 MR Physics and Signal .................................................................................... 5 
2.2.1 Image Acquisition and Parameters ................................................................ 6 
2.3 STRUCTURAL NEUROIMAGING ......................................................................... 9 
2.4 DIFFUSION WEIGHTED IMAGING .................................................................... 10 
2.5 ARTERIAL SPIN LABELING (ASL) .................................................................... 10 
2.6 FUNCTIONAL MRI (FMRI) ................................................................................... 11 
2.6.1 Blood Oxygen Level Dependent (BOLD) Response .................................... 11 
2.6.2 Intrinsic Resting State Activation ................................................................. 13 
2.6.3 Task-Based Activation ................................................................................... 13 
3.0 PROCESSING NEUROIMAGING DATA ..................................................................... 16 
3.1 PRE-PROCESSING NEUROIMAGING DATA ................................................... 16 
   vii 
3.1.1 Slice-Time Correction .................................................................................... 17 
3.1.2 Coregistration and Motion Correction ........................................................ 18 
3.1.3 Unified Segmentation and Normalization .................................................... 21 
3.1.4 Effects Of White Matter Disease On The Accuracy Of Automated 
Segmentation .................................................................................................. 22 
 
3.1.5 Smoothing ....................................................................................................... 24 
3.2 LONGITUDINAL GRAY MATTER DENSITY ESTIMATION ........................ 25 
3.3 WMH SEGMENTATION ........................................................................................ 27 
3.4 DIFFUSION TENSOR IMAGING: FA AND MD ................................................. 28 
3.5 ASL: PERFUSION .................................................................................................... 29 
3.6 RESTING STATE FMRI: EIGENVECTOR CENTRALITY ............................. 30 
3.7 TASK-BASED FMRI ACTIVATION ..................................................................... 33 
3.8 STATISTICAL GROUP INFERENCE .................................................................. 34 
4.0 MACHINE LEARNING .................................................................................................... 36 
4.1 REGRESSION ........................................................................................................... 36 
4.1.1 Logistic Regression ........................................................................................ 37 
4.2 SUPPORT VECTOR MACHINES (SVM) ............................................................. 40 
4.2.1 Functional and Geometric Margins ............................................................. 41 
4.2.2 Defining the Minimization Problem ............................................................. 42 
4.2.3 Dual Form of the Minimization Problem .................................................... 44 
4.2.4 Kernels ............................................................................................................ 45 
4.2.5 Sequential Minimal Optimization (SMO) .................................................... 46 
4.3 MACHINE LEARNING MODEL BUILDING PROCEDURE ........................... 47 
4.4 PRACTICAL PROBLEMS AND SOLUTIONS .................................................... 51 
   viii 
4.4.1 Common Machine Learning Problems ........................................................ 51 
4.4.2 A Practical Solution: Principal Components Analysis ............................... 52 
4.4.3 Kernel-Based Regression ............................................................................... 54 
4.4.4 Multi-Factor Analysis .................................................................................... 56 
4.5 MULTI-FACTOR KERNEL BASED MACHINE LEARNING .......................... 57 
4.5.1 Single Feature: Kernel Based Learning ....................................................... 57 
4.5.2 Multiple Features: Multi-Factor Kernel Based Learning .......................... 58 
5.0 NEURAL CORRELATES OF LATE-LIFE DEPRESSION ......................................... 61 
5.1 MAJOR DEPRESSIVE DISORDER ...................................................................... 61 
5.2 LATE-LIFE DEPRESSION (LLD) ......................................................................... 63 
5.2.1 Treatment of LLD .......................................................................................... 64 
5.3 NEURAL PREDICTORS OF RESPONSE TO PHARMACOTHERAPY ......... 65 
6.0 INTRINSIC FUNCTIONAL CONNECTIVITY IN LATE-LIFE DEPRESSION 
(LLD): TRAJECTORIES OVER THE COURSE OF PHARMACOTHERAPY IN 
REMITTERS AND NON-REMITTERS ......................................................................... 70 
 
6.1 ABSTRACT ............................................................................................................... 70 
6.2 INTRODUCTION ..................................................................................................... 71 
6.3 METHODS ................................................................................................................. 75 
6.3.1 Study Design and Subjects ............................................................................ 75 
6.3.2 MRI Data Collection ...................................................................................... 77 
6.3.3 Preprocessing .................................................................................................. 77 
6.3.4 Eigen-Vector Centrality (EVC) and ROI to Voxel Maps ........................... 78 
6.3.5 Statistical and Cluster Analysis .................................................................... 79 
6.4 RESULTS ................................................................................................................... 80 
ix 
6.4.1 Executive Control Network (ECN) ............................................................... 83 
6.4.2 Default Mode Network (DMN) ..................................................................... 83 
6.4.3 Anterior Salience Network (ASN) ................................................................ 83 
6.4.4 Eigen-Vector Centrality (EVC) .................................................................... 86 
6.5 DISCUSSION ............................................................................................................. 88 
7.0 FUNCTIONAL BRAIN ACTIVATION DURING EMOTION REACTIVITY 
FOLLOWING PHARMACOTHERAPY IN LATE-LIFE DEPRESSION: MARKERS 
OF REMISSION ................................................................................................................. 93 
7.1 ABSTRACT ............................................................................................................... 93 
7.2 INTRODUCTION ..................................................................................................... 94 
7.2.1 MDD: Disruption of Emotional Face Processing ........................................ 95 
7.2.2 High Emotion Reactivity ............................................................................... 96 
7.2.3 Impaired Emotion Regulation ...................................................................... 97 
7.2.4 Functional Changes Following Treatment .................................................. 99 
7.3 METHODS ............................................................................................................... 101 
   x 
7.3.1 Study Design and Participants .................................................................... 101 
7.3.2 MRI Data Collection .................................................................................... 102 
7.3.3 Functional Tasks .......................................................................................... 103 
7.3.4 Structural Processing ................................................................................... 105 
7.3.5 BOLD Pre-Processing .................................................................................. 107 
7.3.6 Modeling Task Activation: Face/Shapes and IAPS .................................. 108 
7.3.7 Resting State BOLD: Eigenvector Centrality (EVC) ............................... 109 
7.3.8 Pre-processing pCASL and Perfusion Calculation ................................... 109 
7.3.9 DTI Preprocessing and Mean Diffusivity .................................................. 110 
7.3.10 Statistical Analysis ....................................................................................... 110 
7.4 RESULTS ................................................................................................................. 112 
7.4.1 Clinical Group Differences .......................................................................... 112 
7.4.2 Faces-Shapes Task: Robust Activation of Emotional Circuits ................ 113 
7.4.3 Baseline Hyperactivation in Non-Remitters Relative to Remitters ......... 115 
7.4.4 Decreased Activation Following Ineffective Pharmacotherapy (Non-
Remitters)...................................................................................................... 117 
 
7.4.5 Increased Insula Activation Following Effective Pharmacotherapy 
(Remitters) .................................................................................................... 119 
 
7.4.6 Single Dose Engagement in Parahippocampus ......................................... 121 
7.5 DISCUSSION ........................................................................................................... 123 
xi 
7.5.1 Baseline Hyperactivation ............................................................................. 123 
7.5.2 Decreased Activation in Non-Remitters ..................................................... 124 
7.5.3 Increased Left Anterior Insula Activation ................................................. 124 
7.5.4 Acute Parahippocampal Engagement ........................................................ 125 
7.5.5 Chronic Behavioral Changes and Implicit Improvement ........................ 125 
7.5.6 Relevance to Late-Life and Limitations ..................................................... 126 
7.5.7 Conclusion ..................................................................................................... 127 
8.0 PREDICTING REMISSION IN LLD: MULTI-FACTOR KERNEL BASED 
MACHINE LEARNING .................................................................................................. 128 
8.1 INTRODUCTION ................................................................................................... 128 
8.2 METHODS ............................................................................................................... 130 
8.2.1 Single Feature Set: Principal Components Learning ............................... 130 
8.2.2 Multiple Feature Sets: Multi-Factor Learning.......................................... 134 
8.3 RESULTS ................................................................................................................. 136 
8.4 DISCUSSION ........................................................................................................... 145 
9.0 SUMMARY AND CONCLUSIONS ............................................................................... 147 
9.1 ACKNOWLEDGEMENTS .................................................................................... 148 
BIBLIOGRAPHY ..................................................................................................................... 149 
   xii 
LIST OF TABLES 
Table 1. Clinical/demographic differences between groups. ........................................................ 81 
Table 2. Resting state results summary table. ............................................................................... 82 
Table 3. Group differences in clinical/demographic features (full sample). .............................. 113 
Table 4. Results of all statistical analyses on emotion reactivity task. ....................................... 114 
Table 5. AUC of each of the single feature models. ................................................................... 138 
Table 6. Features predictive in model that utilized clinical/demographic features. ................... 139 
Table 7. AUC of each of the multiple feature models. ............................................................... 144 
 
 
xiii 
LIST OF FIGURES 
Figure 1. The study design protocol. ............................................................................................ 76 
Figure 2. Connectivity changes where the interaction (group x time) was significant. ................ 85 
Figure 3. Group differences in connectivity. ................................................................................ 87 
Figure 4. Group differences in emotion reactivity at baseline. ................................................... 117 
Figure 5. Baseline vs. end emotion reactivity in non-remitters. ................................................. 118 
Figure 6. Baseline vs. end emotion reactivity in remitters. ........................................................ 120 
Figure 7. Acute single-dose changes in activation of the emotion reactivity task. ..................... 122 
Figure 8. Model building procedure for single feature sets. ....................................................... 133 
Figure 9. Model building procedure for multiple feature sets. ................................................... 135 
Figure 10. ROC curves for the most accurate models. ............................................................... 140 
Figure 11. Most predictive voxels in emotion reactivity at baseline model. .............................. 141 
Figure 12. Most predictive voxels in mean diffusivity at baseline model. ................................. 142 
   xiv 
PREFACE 
Many people have contributed to the successful completion of this dissertation. My advisor, Dr. 
Howard Aizenstein, provided me with so much support, guidance, and wisdom. I am also 
grateful to my committee (Dr. Carmen Andreescu, Dr. George Stetten, and Dr. John Galeotti) for 
the support and advice they gave throughout this project, especially Dr. Carmen Andreescu for 
being so heavily involved in my projects and work. Howard and Carmen provided me with 
invaluable advice and wisdom, I am also grateful for their friendship – it is rare to have such 
great advisors and even more rare to have such great friends.  
I would also like to thank all the lab members of the Geriatric Psychiatry Neuroimaging 
(GPN) lab for all of their support and help. They have made the time in the lab unforgettable.  
Finally, I would like to express my gratitude to my friends and family for their love, 
unfailing encouragement, and support.  
 
 
   1 
1.0 INTRODUCTION AND SPECIFIC AIMS 
Major depressive disorder (MDD) is a complex neuropsychological disorder that has a second 
peak of incidence in late-life, known as late-life depression (LLD). LLD carries additional risk of 
suicide, worsening comorbidity, and care-giving burden (Katon et al, 2010; Mulsant et al, 2006; 
Nelson et al, 2013). While research has made significant strides in our understanding of 
depression and its treatment, its translation has lagged severely as currently there are not any 
accepted neural or genetic biomarkers to aid in the diagnosis, treatment, or management. This 
may be the result of the complex nature of the underlying etiology and pathophysiology (high 
heterogeneity) as well as the complexity of the available treatments. Currently, clinicians work to 
find an effective regimen (of antidepressants) or other treatment option using a prolonged trial 
and error process that delays overall improvement, increases risk of suicide, and may lead to 
patient dropping from care (Andreescu and Reynolds, 2011; Reynolds et al, 2006). In LLD, 
approximately 6-8 weeks are needed to identify whether the current regimen is effective (Patel et 
al, 2017), and if it is not then they will be tapered off and started on a new regimen. This period 
worsens risk of suicide especially in LLD (Katon et al, 2010; Mulsant et al, 2006; Nelson et al, 
2013), thus it is critical to find early treatment biomarkers. Previous work suggests that 
functional magnetic resonance imaging (fMRI) may be a potentially useful tool in finding such 
markers and by utilizing machine learning methods we may further improve this search. 
   2 
  While markers pre-treatment are often an important predictor of overall improvement 
(remission), they may not be sufficient. Recent research has found that following single doses of 
antidepressants there are significant changes in brain activation and connectivity (Bruhl et al, 
2010; Loubinoux et al, 2002; Miskowiak et al, 2007; Murphy et al, 2009; Rawlings et al, 2010; 
Schaefer et al, 2014). These changes may be an important clinical predictor of remission. This 
may reflect an early engagement of functional networks but may have a significant latency 
period to translate to behavioral changes. This is further supported in studies using positron 
emission tomography (PET) that have found that antidepressant uptake occurs acutely (Meyer et 
al, 2001; Parsey et al, 2006). We collected fMRI data in an LLD sample during and after a full 
trial of pharmacotherapy. The fMRI data was collected pre-treatment and post-treatment, but also 
following acute periods (after a single dose and following a week). We investigated changes in 
functional brain connectivity and brain activation (during an emotion reactivity task) and 
whether any acute changes occurred and critically whether machine-learning approaches could 
be applied to predict remission (using only acute data).  
Thus, the goal of this dissertation is to: 
• Aim 1: Investigate changes in brain activation and connectivity in LLD. Determine acute 
and chronic changes in the brain.  
o Hypothesis 1a: We hypothesize that there will be acute and chronic changes in 
resting state connectivity, specifically increased executive control network 
connectivity paired with decreased default mode network connectivity.  
o Hypothesis 1b: Functional activation during an emotional reactivity task will 
show differentially acute and chronic changes in activation.  
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• Aim 2: Develop and test machine-learning models that utilize the multi-modal nature of 
the neuroimaging data that leverages clinical measures.   
o Hypothesis 2a: Certain features will be more predictive of remission, mainly that 
structural markers may not be great markers of state (since this is expected to 
change rapidly). Further, some pre-treatment markers will work well to predict 
remission, however acute changes may act as better markers since they reflect the 
acute pharmacological change.  
o Hypothesis 2b: Leveraging the multi-modal nature of neuroimaging data and 
clinical features will provide the best predictive capability.   
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2.0 MAGNETIC RESONANCE IMAGING (MRI) 
This chapter is intended to introduce the basic concepts of magnetic resonance imaging (MRI). It 
describes the hardware components, basic MR physics, and generation of the MR signal as well 
as details the different imaging modalities: structural imaging, diffusion weighted sequences, 
arterial spin labeling, and functional imaging. These sequences are utilized throughout to extract 
essential structural and functional measures. We also describe functional sequences used as well 
as functional tasks used throughout the study this dissertation utilized.      
2.1 MRI: NON-INVASIVE IMAGING OF THE BRAIN 
MRI is a non-invasive technique that has become one of the most commonly used methods to 
study the human body and brain. It is safe, non-invasive, and non-ionizing (no radiation or 
harmful contrast agents needed) and thus can be utilized heavily to study the structure and 
function of the human brain with low risk (Kanal et al, 2002). The technique utilizes several 
components to generate a signal based on the spin of protons in the body and has a wide range of 
imaging modalities that can be generated, including: structural (images that enhance gray/white 
matter contrast), diffusion weighted imaging (study of white matter tracts), arterial spin labeling 
(measuring perfusion), and functional activation (blood oxygen-level dependent response, 
BOLD).  
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2.2 MR SCANNER, PHYSICS, AND IMAGE ACQUISITION 
2.2.1 MR Components 
There are several critical components to the MR scanner: the magnet, gradient coils, and the 
(transmitter/receiver) radiofrequency (RF) coil. The magnet is used to generate a uniform 
magnetic field and is typically in the range of 0.5 Tesla (T or 5,000 Gauss) to 7T (for reference, 
earth’s magnetic field is ~0.5 Gauss). This aligns protons in the same direction as the magnetic 
field (i.e. this is the lowest energy state). The RF coil is used to force the protons into a high-
energy state and as they return to the lower energy state (equilibrium), they release RF energy 
that can be picked up the RF receiver. The gradient coils are used to localize the signal in three 
dimensions.  
2.2.1 MR Physics and Signal 
MRI takes advantage of precessing water in the body and their magnetic properties (mainly 
differences in relaxation times). Without the presence of a uniform magnetic field, water 
precesses randomly (direction and frequency) in the body with no net magnetic moment. 
However, a superconducting magnet can be used to generate a homogenous magnetic field that 
aligns the protons’ precession creating a net magnetic moment. The number of protons that align 
in that direction is proportional to the strength of the scanner, thus a stronger magnet is able to 
generate a stronger signal.  
The aligned protons are in a low-energy state that is then disrupted using a RF pulse that 
energizes them into a high-energy state (reverse direction of the net magnetic field and in-phase). 
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Protons then seek to return to an equilibrium (low-energy) state and relax. This relaxation is the 
basis of the MR signal, as they return they release RF energy that is then measured by an RF 
receiver coil. There are two types of relaxation: T1 and T2 relaxation. T1 (spin-lattice) relaxation 
is the recovery of the net magnetization in the direction of the net magnetic field. T2 (spin-spin) 
relaxation is due to the de-phasing of the protons as they precess out of phase. Critically, 
different tissues have differences in the T1 and T2 relaxation, thus allowing for a natural contrast 
between different tissue types.  
2.2.1 Image Acquisition and Parameters 
An MR image is usually a 3-dimensional (3D) image that is generated by collecting multiple 2D 
images that contain a value representing intensity at each volumetric element (voxel or 3D 
pixels). In neuroimaging, the individual’s head is placed in the scanner and RF coil. Typically, 
the Z-direction is along the direction of the scanner (head to toe) and the X-/Y- is left/right and 
bottom/top of the scanner, respectively. The following sections describe the general linear 
procedure that generates an image.  
 After, the magnet applies a net magnetic field (B0) that aligns protons along the Z-
direction (where they continue to precess); slice encoding is performed to choose which “slice” 
of the brain is going to be imaged. The Gz gradient coil applies a gradient magnetic field that 
causes protons to precess at different frequencies along the Z-direction. The transmitter RF coil 
applies an RF pulse at a pre-defined frequency that generates a magnetic field (B1) that excites 
only protons with the same frequency (thus choosing the slice to excite). These protons are now 
aligned along the B1 field. The Gz gradient coil is then turned off.  
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 Phase encoding is done to encode the location in the Y-direction by turning on the Gy 
gradient coil that applies a gradient magnetic field in the Y-direction. This causes protons to 
along the Y-direction to precess at differing frequencies and once the Gy gradient coil is turned 
off then the protons precess at the same frequencies however they are now out of phase. 
Similarly, this allows protons along the Y-direction to be precessing with different phases, which 
encodes the information along the Y-direction.  
 The Gx gradient is then turned on to apply a gradient in the X-direction causing protons 
along that direction to precess at different frequencies. At this point, the RF receiver coil is used 
to read the emitted RF energy of the relaxing protons. This signal however is complicated and is 
composed of differing frequencies, phases, and amplitudes. This process of slice, phase, and 
frequency encoding are conducted at different amplitudes of phase encoding gradients.  
 This data is best represented in a k-space image that represents the frequency and phase 
information for each slice (where the center represents zero frequency and phase). The most 
common way to fill this k-space image is known as echo-planar imaging (EPI) due to its speed 
where multiple phase encoding gradients are applied consecutively with the RF receiver coil 
collecting data after each consecutive excitation. Each 2D complex k-space image can be 
reconstructed into a corresponding image (from frequency domain into original space domain) 
using a 2D Fourier transform (which encodes the relationship between the original signal and 
frequency domain information) (Bracewell, 1989). The multiple 2D images are then stacked to 
create a single 3D image with intensities that reflect the emitted energy at each voxel.  
 The procedure involves several key parameters that control the size of the image, 
resolution, contrast, and modality (e.g., T1- vs. T2-weighted). The number of slices, field of 
view, and matrix size affect the resolution of the image. The greater the number of slices, the 
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greater the resolution in the Z-direction, while a greater matrix size and/or field of view has a 
similar effect in the X-/Y-direction.  
 Several other parameters affect the contrast of the image and can be used to create 
different images that weight different properties of the tissues. The repetition time (TR) is the 
time between each RF pulse. The longer the RF pulse, the greater the time allotted for the T1 
signal to relax. Conversely, the echo time (TE) is the time between the RF pulse and data 
acquisition, which affects the amount of time for T2 relaxation. Thus, different combinations of 
TR and TE can generate T1-weighted or T2-weighted images. When the RF pulse is applied, the 
B1 field is generated at an angle (which affects signal to noise, SNR) from the B0 field and is 
called the flip angle (FA).   
 There are several variations on this image acquisition process that are important to 
define: spin echo, gradient echo, and inversion recovery sequences. Spin echo involves applying 
an additional re-phasing RF pulse between the initial pulse and data acquisition. The FA of this 
excitation depends on the FA of the first (180o if initially 90o) and causes the de-phasing protons 
to re-phase that improves the signal and compensates for local field inhomogeneities (from 
several sources). The gradient echo sequence uses the frequency-encoding gradient to rephase 
the protons by applying a negative polarity and then a positive polarity (fast precessing protons 
take longer to rephase than slow precessing protons), which causes a rephasing of the protons 
and emits a stronger signal. While this sequence is faster than spin echo, it does not compensate 
for local inhomogeneities leading to greater artifacts in the image. The inversion recovery 
sequences are exactly the same as the spin echo, however there is an initial RF pulse (1800) 
before the sequence starts and allows for a long T1 relaxation period (no T2 relaxation). This 
allows for greater T1 contrast, however is much longer as the T1 relaxation is doubled.  
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2.3 STRUCTURAL NEUROIMAGING 
Utilizing differences in T1- and T2-relaxation between different tissues, we can generate T1-
weighted vs. T2-weighted images. Short TR sequences allow for greater tissue contrast in T1-
weighted images, while longer TR (longer T1 relaxation) measures the number of protons 
(proton density). Consequently, short TE (short T2 relaxation) does not allow for sufficient 
dephasing of protons thus tissues have similar intensities compared to longer TE that allow for 
greater differences between tissue intensities. T1-weighted images have short TR and TE and 
typically have the greatest tissue contrast. T2-weighted images have long TR and TE and allow 
for greater contrast between CSF and other brain tissue, but lower gray/white matter contrast. 
Consequently, T1-weighted images are used to study structure of the brain, while T2-weighted 
images are utilized for studying pathology. The magnetization prepared rapid gradient echo 
(MPRAGE) is a structural T1-weighted sequence that is heavily used due to the rapid acquisition 
(Mugler and Brookeman, 1990). These images are typically used to segment the gray matter and 
determine gray matter density within a voxel.  
 The fluid attenuated inversion recovery (FLAIR) is a T2-weighted image that improves 
the visualization of age-related tissue lesions, specifically white matter hyperintensities (WMH) 
(Hajnal et al, 1992). The sequence is used specifically as it suppresses signal from the CSF 
(appearing dark). WMH appear white (hyperintense) and can be used to segment these lesions 
more accurately. This can be used to measure global WMH burden.  
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2.4 DIFFUSION WEIGHTED IMAGING 
Diffusion weighted imaging is used to track the diffusion of water within the body specifically 
the white matter (Bammer, 2003). This is possible as free water diffuses randomly in most 
spaces, however within the white matter tracts it is constrained to diffuse along the tract, which 
can be detected and measured. Structural damage and pathological changes may alter the 
diffusion of water within the white matter but also the diffusion in the gray matter.  
 A pulsed gradient spin echo sequence is used to acquire diffusion-weighted images. This 
is very similar to the gradient spin echo sequence, however two gradient pulses with a defined 
direction are placed on both sides of the rephasing pulse. If water molecules do not move, then 
the phases induced by the two gradient pulses would cancel out resulting in greater signal. Due 
to this, greater diffusion would attenuate the signal. Usually multiple images of multiple 
directions are acquired, where a greater number of directions can resolve greater diffusion 
information. Using this acquired data, it is possible to identify the mean diffusivity and primary 
direction of tracts and can be used to measure tract integrity.  
2.5 ARTERIAL SPIN LABELING (ASL) 
Arterial spin labeling involves the labeling (or tagging) of proximally flowing blood, which after 
a transit time flows into a slice or area of interest and is paramagnetically labeled (Detre et al, 
1992). This inflowing tagged blood alters tissue magnetization, reducing the overall signal. An 
unlabeled (control) image is collected as well, where the difference in the unlabeled and labeled 
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image is the cerebral blood flow/perfusion of blood in that region. This requires no contrast as 
the labeled blood acts like a contrast agent altering local tissue magnetization.  
 Pulsed continuous ASL (pCASL) is the currently most preferred method to acquire 
perfusion imaging (Dai et al, 2008). A train of short RF pulses is used to first invert the blood 
proximally, followed by a full brain acquisition. The refocusing portion of the slice selection 
gradient (Gz) is not balanced, which causes an accumulation of additional phase after each RF 
pulse. The control sequence, however, uses a balanced gradient that removes this effect. 
Typically, tagged and untagged images are collected one after another. This process is repeated 
over an extended period of time (at rest) and generates a 3D perfusion image across time (4D) 
that is typically averaged to measure mean perfusion.  
2.6 FUNCTIONAL MRI (FMRI) 
This section introduces the blood oxygen level dependent (BOLD) response and how this is 
measured using fMRI. Similar to ASL, a 4D image is generated that measures activation across 
time – however it is divided into task-based and resting state fMRI.  
2.6.1 Blood Oxygen Level Dependent (BOLD) Response 
The BOLD response is measured using fMRI, which utilizes T2*-weighted imaging (Ogawa and 
Lee, 1990a; Ogawa et al, 1990b). The BOLD response is thought to be an indirect measure of 
neuronal activity. When an individual performs a task (e.g., tapping their right finger), neuronal 
activity within the left motor cortex increases and due to increased activation there is a change in 
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metabolism as well as an increase in deoxygenated blood in the venous capillaries (Attwell and 
Iadecola, 2002). This is typically followed by an increase in local cerebral blood flow (and 
possibly volume) that results in an overall increase in oxygenated hemoglobin (venous) and 
decrease in deoxygenated hemoglobin (known as ‘washout’) (Attwell et al, 2002). While 
oxygenated hemoglobin is diamagnetic, deoxygenated hemoglobin is paramagnetic, which 
creates magnetic field distortions (altering local magnetic susceptibility) thus reducing the MR 
signal. Specifically, the T2*-weighted signal is a combination of the T2-signal and 
inhomogeneities (hence T2*). As the deoxygenated hemoglobin decreases, the MR signal 
increases in amplitude. Thus the BOLD signal is an indirect and delayed measure of neuronal 
activity. Usually this delay is approximately 6-8 seconds, thus we can construct a canonical 
hemodynamic response function (HRF). Multiple of these images are acquired while participants 
perform tasks. Typically a task of interest and a control are performed (e.g. viewing faces vs. 
viewing houses).  
 By designing certain tasks (as well as sufficient control tasks), we can understand and 
map functional activation of the brain. This process has been used heavily in the past decade to 
map the human brain and more importantly understand how these are altered in certain disease 
states (e.g. depression). However, even without performing a task – the brain has intrinsic 
changes in brain activation. It is now well-known that this intrinsic activation can be used to 
better understand the connectivity of the brain (at rest) and is essential for understanding 
depression as it is thought that resting state activation represents introspective functioning. The 
next two sections describe in greater detail resting state and task-based designs (specifically the 
tasks used in this study).  
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2.6.2 Intrinsic Resting State Activation 
Even without an explicit task, the brain is intrinsically active and this spontaneously fluctuating 
signal can be measured using fMRI. Usually participants are asked to lie awake in the scanner 
viewing a fixed object (e.g., a cross-hair to prevent sleep). This has been used to measure the 
intrinsic connectivity of brain regions as well as define stable networks (Fox et al, 2005). This is 
especially important in MDD, as it is thought that a large change in the intrinsic activation in the 
brain is altered as the majority of intrinsic activation is thought to reflect an introspective aspect 
of human thought. MDD is associated with an alteration in this introspective thought process as 
it becomes ruminative in nature leading to changes in resting state activation (Hamilton et al, 
2011; Sheline et al, 2010b; Zhu et al, 2012). The data utilized acquired a resting state scan where 
participants were instructed to lie awake in the scanner viewing a white cross hair (black 
background) for five minutes.  
2.6.3 Task-Based Activation 
Task-based fMRI designs typically involve a task of interest and a control task (to control for 
unrelated effects). In this section we describe several of the tasks used throughout this study: 
emotion reactivity task (face/shapes), explicit emotion regulation task, and a memory-encoding 
task.   
 Emotion Reactivity Task (Face/Shapes): During functional scanning participants 
performed the face/shapes emotion reactivity task to study the effect of emotional reactivity to 
faces (Hariri et al, 2003). Participants were instructed to match either a face cue or a shapes cue. 
A cue was shown on the center of the screen and they were instructed to respond with an MR-
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compatible glove (left or right index finger) by matching to one of two simultaneously presented 
faces. The facial expressions shown were either angry or fearful. During the shapes, they 
matched a shape to one of two simultaneously presented shapes. The shapes task (5 blocks) was 
interleaved with the faces task (4 blocks) and each block lasted 24 seconds containing 6 trials (4 
seconds each). Before the beginning of each block participants are instructed visually to “match 
emotion” or “match form” (2 seconds). The faces images are presented from a set 12 different 
images (six per block, three of each gender) and are all derived from a standard set of pictures of 
facial affect. Stimulus presentation and responses were controlled using E-prime software 
(Psychology Software Tools, Inc., Pittsburgh). This task has been shown to robustly activate the 
human amygdala (generates emotional responses as part of the limbic system) even in healthy 
participants (Hariri et al, 2003). Critically, this is thought to have an implicit regulation aspect, 
where participants regulate their emotional responses automatically.  
 Explicit Emotion Regulation Task: Participants were shown emotionally neutral or 
negative images from the standardized International Affective Picture System (IAPS) and were 
instructed to either “Look” or “Decrease” (Lang et al, 2008). During the look instruction, 
participants were to view content naturally. During the decrease instruction, participants were 
instructed to reappraise the image to actively alter the elicited emotion. Reappraisal involves 
actively altering emotional responses to a viewed image (e.g., a picture of someone in the 
hospital may be reappraised as someone who is getting life-saving treatment). Participants were 
sufficiently trained in this process prior to scanning. After each image they were asked to rate 
how negatively they felt from 1 to 5. The neutral (11 events), negative (15 events), negative 
regulate (15 events) conditions were interleaved and each event lasted 6 seconds. The stimulus 
presentation and responses were controlled using E-prime software (Psychology Software Tools, 
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Inc., Pittsburgh). This task measures their ability to explicitly regulate their emotions and 
significantly activates explicit areas implicated in regulation (dorsolateral prefrontal cortex) 
(Gyurak et al, 2011; Ochsner et al, 2002).  
 Memory Encoding Task: This task has been used widely to measure memory encoding 
and significantly activates the hippocampus (Sperling et al, 2001). Participants first encoded two 
face-name pairs outside of the scanner (i.e., two faces were presented each with a name). 
Participants are shown face-name pairs in a block design. During the control blocks, the two 
already encoded face-name pairs are shown. During the novel blocks, new pairs of face-names 
are presented. They are instructed during both blocks to state whether the name “fits” and are 
told that this helps with encoding the face-name pairs. They are told that they will have to recall 
the name that was presented with each face at the end of the scan – thus they are instructed to 
encode these faces into memory. Each run contains four blocks alternating between the control 
and novel blocks (48-seconds each). Each block presents 8 faces for five seconds each (1 second 
fixation in between) that results in 32 novel and 2 familiar faces. Between each block is a 25 
second fixation. Stimulus presentation and responses were controlled using E-prime software 
(Psychology Software Tools, Inc., Pittsburgh).  
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3.0 PROCESSING NEUROIMAGING DATA 
This chapter introduces the basic concepts of processing neuroimaging data as well as details 
regarding spatial pre-processing, coregistration and motion correction, as well as segmentation 
and normalization (coregistration to a standard anatomical space). It also describes how to 
compute outputs that are relevant to this dissertation including: gray matter density (structural), 
white matter hyperintensity (WMH) burden, fractional anisotropy and mean diffusivity 
(diffusion weighted imaging), perfusion (arterial spin labeling, ASL), eigenvector centrality 
(resting state functional MRI), and task-based fMRI activation. 
3.1 PRE-PROCESSING NEUROIMAGING DATA 
There are several key pre-processing methods that are essential for processing neuroimaging 
data. Slice time correction of functional data involves accounting for differences in the timing of 
slice acquisition during data collection, because during the functional sequence the first slice 
collected is an entire TR away from the last slice collected. Coregistration is the process of 
aligning two images together and can refer to registering similar images within a sequence 
(typically called realignment or motion correction in fMRI), or images within a subject of 
different modalities (e.g., MPRAGE and FLAIR), or even images between several subjects or a 
template space (usually referred to as normalization). Segmentation involves the labeling of 
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neuroimaging data into separate tissue classes (e.g., gray vs. white matter). Smoothing is a 
process that blurs the image but reduces spurious noise. We describe these processes in greater 
detail in the following sections.  
3.1.1 Slice-Time Correction 
Functional MRI scans usually have multiple 2D images (slices) collected over a short period (a 
single TR) to generate a single 3D image that is collected over a certain period of time. If the TR 
is long, then the collection of the first slice is approximately one TR away from the last slice. 
Slice-time correction is a method to resolve this issue following data acquisition (Sladky et al, 
2011). If the TR is sufficiently short, or if the design of the task is presented in blocks rather than 
as single events, or if the data is not resting state – then this processing is not necessary. A short 
TR means that there are small differences in the timing of the acquisition and thus is not 
necessary in the described scenarios. The precise timing within a long block does not affect the 
determination of activation.  
 As we know the order of the collected slices, we can use this information to shift the 
signal in a certain direction. Critically, this process is performed using Fourier transforms. The 
Fourier transform represents any signal as a linear weighted combination of sinusoids. For each 
signal, depending on when they were collected – we can shift the sinusoid by adding some 
constant (dependent on slice order) to the phase of each frequency. This will have an effect of 
shifting the data in time (Sladky et al, 2011).  
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3.1.2 Coregistration and Motion Correction 
Registration is a process where a transformation that spatially aligns two images (usually based 
on intensity): the reference (image that does not move) and the source (image that is 
transformed). The intensities of the images are used to help align the two images, usually 
involving several key components: similarity metric, optimizer of the alignment, transformation 
matrix, and the interpolation method.  
 The similarity metric is used to minimize the difference between two images’ intensities. 
Thus, the similarity metric is the cost function that is to be minimized. The selection of the cost 
function is dependent on the image types of the reference and source image. If the reference and 
source are of a similar image type, then they have similar intensity distributions. Thus, we can 
compare their intensities directly using measures like least squares (sum of squared differences) 
or normalized correlation (correlation between each voxel intensity). However, if the images are 
of different types – then their intensities do not directly match. Normalized mutual information is 
a metric commonly used in neuroimaging methods. Mutual information determines how much 
uncertainty about the reference image’s intensity values is reduced by the knowledge of the 
source image’s intensity values (thus the image intensities do not need to match). This can 
assume a linear or non-linear relationship and is a robust measure of similarity. In this way, if 
two images are aligned well – then their intensities match (or are predictive) and its minimization 
will allow for a local minima that represents the coregistered images.  
 The optimizer is used to minimize the cost function (similarity metric). This process 
usually involves several key steps: initialization, iterative parameter optimization search 
involving assessment and modification, and finally convergence. In the first step, the similarity 
metric is calculated. The initial parameters are updated (both value and direction of change) and 
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are done using several possible methods (e.g., gradient descent, Quasi-Newton, Gauss-Newton, 
Levenberg-Marquardt). The similarity metric is thus calculated again and the process is iterated 
over several steps. Some convergence criteria determine when the algorithm should stop (e.g., 
difference of similarity metric between current and previous metric is sufficiently low).  
 The transformation is the matrix that is applied to the source image to coregister it to the 
reference image. However, depending on the type of transformation – a different number of 
degrees of freedom may be allotted. Linear transformations refer to those with lower degrees of 
freedom allowing for only small alterations. Transformations may have the following linear 
changes: 3 translations, rotations, and scaling (total 9 degrees of freedom) as well as 3 degrees of 
freedom for skewing along all three axes (3D space). Some well known combinations include: 
rigid body (6 translations/rotations but no scaling) and affine (12 degrees of freedom). A simple 
4x4 matrix can be used to represent such transformations. Non-linear transformations can have a 
much larger number of degrees of freedom – thus allowing for even small local changes. Linear 
transformations are well suited for coregistering images within an individual (as they have 
similar structural properties, e.g., gray matter folds), however non-linear transformations are 
better suited for coregistering across individuals with highly varying structural properties.  
 There are several types of interpolation methods that can be utilized during this process. 
Nearest-neighbor interpolation involves assigning each new voxel of the coregistered image the 
intensity value of the spatially closest voxel from the source image prior to the transformation. 
This is most commonly used when interpolating masks, which are binary images that represent 
some prior segmentation. B-spline interpolation is another common interpolation method that 
uses polynomial functions to weight the intensities of neighboring voxels from a large 
neighborhood of voxels. The degree of the B-spline is a reference to the size of the polynomial 
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function used. This is one of the most commonly used methods as it has high accuracy with low 
computation cost relative to other methods. The trade-off between accuracy and computational 
cost is an important consideration when determining the interpolation method.  
 Generally, in the processing of neuroimaging data we have several key types of 
coregistration that are performed: within session motion correction, within subject functional-
structural or structural-structural coregistration, or across subject coregistration. Across subject 
coregistration is a process called normalization that we cover in the next section along with 
segmentation (due to the unified nature of some algorithms).  
 Within session motion correction refers to coregistration between images collected within 
a single 4D image (e.g. BOLD or ASL data) (Ashburner et al, 1999). The 4D image is a set of 
3D images across time – and during this period the participant was likely to move their head. To 
correct for this we perform multiple coregistrations between each image and one of the images is 
used as a reference. Typically, the first image is chosen as the reference, the other images are 
coregistered to the reference, a mean image is computed and is now treated as the reference, then 
the true coregistration is performed between all images and the mean. This process corrects for 
the motion within a session and is usually done as a rigid body coregistration process (as the 
images are similar in type and size). This also outputs a six parameter matrix that represent the 
motion in each of the six directions that can be used to further remove residual motion.  
 Within subject coregistration (functional-structural or structural-structural) involves 
coregistering images that are different types (e.g., MPRAGE and FLAIR), however they are 
from the same participant thus they do not differ structurally (e.g., gray matter folds) (Ashburner 
et al, 1999). Typically, one of these images is chosen to be the reference and the other is 
coregistered using an affine transformation. 
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3.1.3 Unified Segmentation and Normalization 
Segmentation is a process in which a set of tissues are identified in an image and classified. In 
neuroimaging this process usually involves segmenting images into six tissue types: gray matter, 
white matter, cerebrospinal fluid, soft-tissue, skull, and air. There are many different processes 
that are used to segment neuroimaging data, however we will focus solely on the unified 
segmentation and normalization algorithm as it is utilized most throughout the dissertation 
(Ashburner and Friston, 2005).  
 The segmentation algorithm utilizes a Gaussian mixture model based approach with 
tissue priors. The basic concept is that if we consider segmenting gray vs. white matter, then 
their intensities (depending on the imaging type) could be represented using two Gaussian 
distributions (bimodal) with one representing gray matter tissue and another representing white 
matter tissue. Thus, we can fit a Gaussian mixture model and then segment the entire brain into 
several tissue classes. This considers all the brain voxels as a mixture of multiple Gaussian 
distributions and attempts to identify them. To further improve that, we can give an initial guess 
as to the location of these tissues using an average tissue prior (a probability map indicating the 
likelihood that some tissue is represented at any one voxel) generated from healthy neuroimaging 
data of a large cohort of participants (e.g., we can give probability maps of where we expect the 
gray and white matter should be) (Penny et al, 2011). This involves coregistering the 
neuroimaging data to a standard anatomic space (with tissue probability maps) and using the 
probability maps to weight the classification according to Bayes theorem (describing the 
probability of some occurrence based on knowledge of some other condition).  
 In the unified segmentation and normalization framework several processes are unified to 
improve the overall efficacy of each individual process. This process details how to classify 
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tissues in a structural image and then coregister it to a standard anatomical space. We first 
coregister (using linear methods) the structural image and a template structural image in a 
standard anatomic space (Montreal Neurological Institute or MNI space). We then perform an 
initial segmentation of the voxels into six tissue classes using a Gaussian mixture model 
weighted by a prior distribution. We can now iterate through this process to improve both and 
output a final segmentation (each voxel contains an individual probability for each tissue class) 
as well as a deformation field. The deformation field is a set of cosine bases that map each voxel 
into MNI space and is utilized to normalize most neuroimaging data by first coregistering an 
image to the native structural image and then applying the deformation field to warp it into MNI 
space (Penny et al, 2011).  
3.1.4 Effects Of White Matter Disease On The Accuracy Of Automated Segmentation 
This section describes previously published primary author work that investigated the effects of 
WMH on the accuracy of the automated segmentation in the statistical parametric mapping 
(SPM) toolbox (Karim et al, 2016b). We also investigated whether performing corrections 
resulted in any change in the segmentation. WMH are hyperintense regions (on T2-weighted 
images) that become more prevalent in late-life that are attributed to degenerative changes of 
long penetrating arteries, resulting in demyelination, gliosis, and axonal degeneration (Ovbiagele 
and Saver, 2006). It is associated with a wide variety of disorders (including depression) 
(Aizenstein et al, 2011; Sheline et al, 2010a; Taylor et al, 2003). WMH appear dark 
(hypointense) on the MPRAGE and typically look like gray matter intensities, thus using 
standard approaches the WMH are segmented as gray matter instead of white matter. This affects 
the overall accuracy of both the segmentation and normalization.  
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 Two common methods for performing a correction are WMH filling (Battaglini et al, 
2012; Eloyan et al, 2014) and multi-spectral segmentation (Ashburner et al, 2005). WMH filling 
involves first identifying voxels with WMH then filling them with normal appearing white 
matter values (NAWM). The WMH segmentation process is described later in section 3.5, but to 
fill them - all NAWM (white matter voxels that are not classified as WMH) are used to generate 
a distribution. Then each WMH voxel is filled with a random value from this distribution 
effectively disguising this region as not hyperintense thus correcting for the WMH (Eloyan et al, 
2014). However, the main issue is that this is a brute force method that forces WMH to appear 
like normal white matter.  
Multi-spectral segmentation methods instead rely on multiple tissue types (e.g., 
MPRAGE and FLAIR). The differences in distributions help better classify each tissue class. 
Consider that four separate tissues on the MPRAGE and FLAIR have differing properties. On 
the MPRAGE the increasing ordered rank of the mean intensities are: gray matter, WMH, 
caudate, and NAWM. Thus, WMH appear most like gray matter and caudate (a subcortical gray 
matter region). On the FLAIR, however, the increasing ordered rank of the mean intensities is: 
NAWM, gray matter, caudate, WMH. Thus, the properties of the intensities are altered in each 
image. Leveraging that information improves the Gaussian mixture model and helps better 
classify the tissues. Critically, we also set the number of Gaussians to fit for white matter to two 
instead of one, because there is a separate Gaussian distribution associated with the WMH.  
We computed intraclass correlation coefficients (ICC) between the original uncorrected 
segmentation and each of the correction methods segmentations (McGraw and Wong, 1996). We 
found that both significantly altered the segmentation globally and locally. We found that the 
multi-spectral segmentation more greatly affected the overall segmentation. Further, it seemed to 
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more greatly affected the local segmentation/normalization as well – affecting subcortical 
structures like the caudate and amygdala most. This highlights a need to correct for WMH in 
studies where they are prevalent. The results from this experiment only suggest that the multi-
spectral segmentation seems to more greatly affect the initial inaccurate segmentation – but not 
which is better. Multi-spectral segmentations utilize the full nature of multi-modal data 
acquisition in modern neuroimaging studies and seem to be an effective approach to perform 
correction without having to force WMH to appear like normal white matter.  
3.1.5 Smoothing 
Smoothing is a process where data is interpolated using some function to reduce the effects of 
large outliers by essentially blurring the data. Typically, a Gaussian smoothing kernel is used to 
interpolate the image that is described by its size or the full-width at half-maximum (FWHM). If 
for instance the FWHM is 8mm then the Gaussian distributions value at 4mm from the center is 
half the maximum value of the Gaussian distribution (e.g., if the max of the distribution is 1 then 
the value 4mm away from the center is 0.5). This describes the extent of the Gaussian 
distribution, and greater FWHM cause greater blurring/smoothing.  
 There are multiple reasons that this process is typically done, mainly: increased signal to 
noise ratio, to account for differences in structural anatomy, and finally this becomes critical for 
statistical group inference. Signal to noise increases because there can be (at the individual and 
group level) high amounts of noise (especially in ASL and fMRI) and smoothing removes large 
outliers (or noise). Further, as the structural coregistrations are not perfect there can be high 
variability between subjects structurally and functionally. Smoothing blurs functional/structural 
clusters – which increases the overlap between subjects (improving sensitivity). Finally, when 
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performing group statistical inference – neuroimaging methods rely heavily on Gaussian random 
field theory (described in detail in section 3.8). Smoothing decreases the number of independent 
statistical tests (by blurring neighboring voxels), and this increases the overall sensitivity (Mikl 
et al, 2008). Briefly, imagine performing four independent statistical tests in four neighboring 
voxels that generates four p-values. Bonferonni correction is a method to control for multiple 
comparisons (joint inference on all four voxels), which states that dividing the acceptable false 
positive rate by the number of independent statistical tests sufficiently controls the false positive 
rate across multiple tests. Using Bonferonni correction, this means that to control the false 
positive rate (alpha) at 0.05 then we need to divide by four. However, consider that two voxels 
are highly correlated (or smoothed) then the number to divide by should actually be three (as 
only three of them are truly independent). Similarly, smoothing reduces the severity of the 
multiple comparisons problem (described in greater detail in section 3.8).  
3.2 LONGITUDINAL GRAY MATTER DENSITY ESTIMATION 
Structural imaging data can be used to estimate gray matter density. This is a common variable 
of interest in neuroimaging studies as these are often associated with a wide range of disorders 
like depression severity. Depending on the disease being investigated the healthy brain templates 
used when segmenting and coregistering the brain may not be good proxies for diseased or aging 
brains. Thus utilizing study specific templates help improve the overall estimation of gray matter 
density.  
 After performing segmentation, a single probability map is output in a standard anatomic 
space. The probability maps can be coregistered in an iterative process where the mean of all the 
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probability maps is taken; they are then registered to the mean. The process is repeated, which 
increases the smoothness of the mean of each subsequent iteration. This generates a new study 
specific template in the same standard anatomical space that is better suited to the current sample 
(Ashburner, 2007). Consider that aging populations tend to have greater sized ventricles – 
however the template has much smaller ventricles affecting the overall normalization process. 
By creating a template, we circumvent to some degree as now we coregister to a template with 
larger ventricles. This normalizes each map into a standard anatomical space while relaxing the 
large deformations needed for certain structures (e.g., the ventricles).  
Along with the segmentation, this process outputs what is known as the Jacobian (or the 
matrix of all first order partial derivatives of the deformation field, i.e., the gradient or local 
changes in deformation) (Ashburner and Friston, 2000). Without the Jacobian, the current 
segmentations represent the probability at each voxel that it is gray matter – however because the 
local tissues have been warped, the probabilities do not truly represent the amount of gray 
matter. By multiplying by the Jacobian, we can compute the gray matter density (Ashburner et 
al, 2000). Consider, a region that has to be shrunk to fit as part of the template – it then follows 
that we are forcing a certain amount of gray matter into a smaller region, thus it should have 
greater gray matter density. Conversely, a region that is increased to fit onto the template should 
have lower gray matter density.  
We can improve this process even further longitudinally where we have multiple 
structural images for each participant across time. Similar to the previous process, we can 
generate a subject specific template prior to creating a study specific template. The subject 
specific template uses each of the tissue probability maps from each time point and creates a 
subject specific template. This subject specific template is then used to create a study specific 
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template. This further improves the overall estimation of gray matter density. Thus we compute a 
single gray matter density map for each time point.  
To further improve the initial segmentation, a multi-spectral segmentation that utilizes 
multiple spectra/image types (e.g., MPRAGE and FLAIR) can be used (Ashburner et al, 2005). 
The Gaussian mixture model can thus consider two sets of distributions when trying to fit the 
model. The FLAIR significantly improves the classification of WMH as white matter (Karim et 
al, 2016b).  
3.3 WMH SEGMENTATION 
WMH burden (amount of WMH in the brain) has been shown to be associated with a wide range 
of neurological disorders and is thought to be a good marker of cerebrovascular disease 
(Alexopoulos et al, 1997; Sheline et al, 2010a). We describe the vascular depression hypothesis 
in a later section, however it states that WMH may be a driving factor late-onset depression due 
decreased cerebral blood flow and impaired cognitive function (Alexopoulos et al, 1997). Thus, 
segmenting and quantifying WMH burden is important for understand late-life depression.  
 Segmentation of WMH has been performed using a wide variety of methods – however 
one effective method uses the FLAIR image and an automated approach to select seeds and then 
grow them using fuzzy connectedness (Wu et al, 2006). The images are first intensity 
normalized, by calculating the mean and standard deviation of the cerebellum white matter 
(which is relatively devoid of WMH) and calculating a Z-score of the whole brain using that 
mean and standard deviation. We then choose voxels that are 3.5 standard deviations (chosen 
based on previous data at improving the segmentation) above the mean as seeds. These seeds are 
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then grown using a fuzzy connectedness algorithm (on the original data and not the Z-score data) 
(Wu et al, 2006). In this region-growing algorithm, the fuzzy adjacency and affinity are 
calculated between a seed and all voxels, which measure how strongly the seed and each 
corresponding voxel associate in space and intensity, respectively. This image is then threshold 
to generate a fuzzy segmentation for that seed – which is iterated through each seed and then 
combined across seeds. This generates a single WMH segmentation. We can compute the 
volume of the WMH (number of voxels x resolution in mm3) and then divide by intracranial 
volume (ICV) to normalize the measure as a percentage of ICV (accounts for differences in head 
size).  
3.4 DIFFUSION TENSOR IMAGING: FA AND MD 
Diffusion weighted images are 4D and contain b0 images (no diffusion) as well as diffusion 
images in different directions. Using this data we can compute fractional anisotropy and mean 
diffusivity, which are important neural correlates. Diffusion data is first eddy corrected – 
misalignment of the images due to the presence of eddy currents in the scanner. This is typically 
resolved using image registration methods. We then perform multiple linear regression to 
calculate diffusion tensor components from the set of diffusion images with differing directions/ 
orientations with respect to water diffusion. A tensor is a three by three matrix representing the 
diffusion of water in all three directions (3D) in a single voxel. After diagonalization of each 
corresponding matrix, we compute the eigenvalues and eigenvectors (the primary, secondary, 
and tertiary diffusion directions) (Behrens et al, 2003).  
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 Two main measures are utilized commonly (although others exist): fractional anisotropy 
(FA) and mean diffusivity (MD) (Behrens et al, 2003). Consider the three eigenvalues and the 
mean eigenvalue then FA is computed as the square root of the sum of the squared difference 
between eigenvalues and the mean eigenvalue divided by the square root of the sum of squares 
of each eigenvalue multiplied by square root of 1.5. The higher FA translates to greater 
anisotropy or a more “oblong” shaped ellipsoid, and thus an FA of zero is perfectly spherical. 
This indicates the primary direction of diffusion. The MD is simply the mean of the eigenvalues, 
which represents the total diffusion within a voxel. FA is thought to be most sensitive to 
microstructural integrity in the white matter. MD is thought to be an inverse measure of 
membrane density sensitive to cellularity, edema, and necrosis. Thus, we compute a single 
voxel-wise FA and MD map. These maps can be coregistered to the structural image and then 
warped to MNI space using the deformation field.  
3.5 ASL: PERFUSION 
ASL data is first motion corrected and is performed as a two-stage process where tagged and 
untagged are motion corrected separately and then together. The images are then subsequently 
smoothed to improve estimation of perfusion. The perfusion is a measure of cerebral blood flow 
(CBF) normalized by volume of the each voxel (Detre et al, 1992). To calculate CBF we used an 
equation that is dependent on the following: difference between tagged/untagged images 
(deltaM), the blood/tissue water partition coefficient (lambda), longitudinal relaxation rate of 
blood (R), tagging efficiency (alpha), equilibrium magnetization of the brain (Mo usually 
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calculated from white matter), post-labeling delay (w), and duration of the labeling RF pulse 
train (tau). The following equation (Wang et al, 2008b) describes this relationship: 
Equation 1. . 
 This measure represents CBF at each voxel and can be used to estimate the perfusion. 
Typically, this is only calculated in voxels inside the brain. This measure is highly correlated 
with measures of metabolism in positron emission tomography as well as CBF as measured 
using actual contrast agents (gold standard for CBF measurements) (Chen et al, 2011). These 
maps can be coregistered to the structural image and then warped to MNI space using the 
deformation field. 
3.6 RESTING STATE FMRI: EIGENVECTOR CENTRALITY 
Resting state involves several stages of processing: slice-timing correction, motion correction, 
normalization to MNI space, smoothing, wavelet despiking, covariate regression and band-pass 
filtering, and then estimation of eigenvector centrality (Whitfield-Gabrieli and Nieto-Castanon, 
2012). After performing slice-timing correction, motion correction, normalization, and 
smoothing (described in previous sections) the data are despiked, which removes large motion 
artifacts. The wavelet-despiking algorithm used identifies non-stationarity events across multiple 
frequencies using the following generalized steps: time-series decomposition into wavelet 
domain, identification of non-stationarity events, removal of those events, and reconstruction to 
the time domain (Patel et al, 2014). Spike artifacts are prioritized, as they are most likely due to 
motion (Patel et al, 2014).  
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 In the next stage we removed several covariates that may corrupt our true resting state 
fluctuations, including: residual motion artifacts, low frequency noise, high frequency noise 
above a certain frequency, and global signal from the white matter and cerebrospinal fluid 
(Behzadi et al, 2007; Whitfield-Gabrieli et al, 2012). This is conducted by performing a mass-
univariate regression between our observed data and a set of covariates. We then subsequently 
can analyze the residuals, which are essentially not ‘corrupted’ by these factors. Removing the 
motion parameters removes the effect of any residual motion not accounted for in the motion 
correction. Band-pass filtering removes non-resting state fluctuations, as it has been shown that 
resting state fluctuations seem to occur at a certain frequency band and other frequencies 
‘corrupt’ this resting state signal. Finally, some regions are ‘corrupted’ by white matter of CSF 
signal, thus we can remove canonical signals from these tissues to account for their effects.  
To remove motion artifacts we use the six motion parameters from the motion correction 
stage. As the data is discrete and has a low sampling rate (high TR, usually around 2 seconds), 
we can use a set of cosines of varying frequency to remove low and high frequencies that are of 
no interest. Mainly, we remove frequencies not in the band 0.008 to 0.15 Hz (Whitfield-Gabrieli 
et al, 2012). Thus, we can generate a set of cosines for the discrete valued signal that represent 
signals with frequencies above and below these bands and regress them against the observed 
data.  
Previous studies included only two covariates: one for the mean white matter signal and 
one for the mean CSF signal, however current techniques utilize multiple signals to account for a 
larger proportion of the variance in signals in the each of these tissues. Segmentations of the 
white matter and CSF can be used to determine where to extract a matrix of time-series. 
Principal components analysis (PCA) can be conducted on these signals to generate several 
   32 
principal (typically 5 components) time-series that represent a proportion of the variance within 
the matrix. Briefly, it is a method used to estimate a set of bases that are orthogonal (not 
correlated) and explain the variance in the data (i.e., it is a low dimensional feature space that the 
original data can be represented in). The observed matrix (‘t’ time points by ‘v’ voxels) can be 
represented as a set of scores (original data in the low dimensional space that is ‘t’ by ‘c’ 
components) times as set of loadings (‘c’ by ‘v’). The first five scores could then be used to 
represent the signals in the white matter and CSF and are regressed out.  
After regressing out six motion parameters, a set of cosines that represents frequencies of 
no interest, five components from the white matter and CSF combined, as well as the mean of 
the time series, we can compute eigenvector centrality. Centrality is a graph theoretical measure 
that represents how important a voxel as a node, where higher centrality represents voxels that 
have greater connectedness (Wink et al, 2012). One way to compute centrality at a voxel is to 
correlate that voxel’s time series with all other voxels and then compute an average. This is 
essentially mean centrality or the mean connectedness of a voxel, where if a voxel is highly 
correlated to most other voxels then its centrality will be greater (consider a region like dorsal 
anterior cingulate which has high involvement in many cognitive processes and enforces top-
down control on many other brain structures). While this method is sound, it is computationally 
inefficient, because to calculate it voxel-wise a voxel-to-voxel correlation matrix must be 
computed, which is highly inefficient. However, we can utilize PCA to compute the eigenvariate 
(i.e., the scores of the PCA on the matrix of all time series) using the fast eigenvector centrality 
mapping (fastECM) algorithm (Wink et al, 2012). This allows for a similar measure (EVC) that 
is computationally efficient.  
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3.7 TASK-BASED FMRI ACTIVATION 
Task-based fMRI is first slice-time corrected (if event related), motion corrected, normalized to 
MNI space, and spatially smoothed. A generalized linear model is used to estimate the effect of 
the tasks performed in the scanner (Wink et al, 2012). Similar to the resting state we remove 
several confounds, including: six motion parameters, a set of cosine terms that represent low 
frequency signals (effectively a high-pass filter, usually 1/128 Hz), and the mean. Note that we 
do not perform low-pass filtering or remove additional confounds from white matter or CSF. 
However, to model temporal auto-correlation due to aliased biorhythms and unmodelled signal 
an auto-regressive term with order one [AR(1)] is included, which includes a shifted (by one) 
signal of the time series. This models changes in heart rate and blood pressure from the previous 
time point to account for temporal auto-correlation, as an assumption of the regression is that the 
measurements (each time point) are independent.  
 To model the activation of the task performed in the scanner the onsets and durations are 
used to create boxcar functions (zero if not tasking and one if tasking) for each of the blocks. For 
example, in the face/shapes task there are two types of blocks (conditions): matching face 
emotions and matching shapes thus two boxcar functions would be generated representing the 
onsets and durations for those two tasks. Each boxcar for each condition is then convolved with a 
hemodynamic response function (HRF), which represents the canonical hemodynamic response 
in the BOLD response after a task. Convolution is a process where the HRF is translated in time 
along the boxcar and the integral of the element-wise multiplication is computed (i.e., sum of the 
multiplication). For each condition, an expected hemodynamic response is modeled for each 
task. We regress the expected hemodynamic responses of each condition against each voxel’s 
time series (mass univariate regression) to estimate two parameter estimates representing the 
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activation during each condition (e.g., activation during faces vs. activation during shapes) 
(Wink et al, 2012). The greater the parameter estimate translates to a greater observed 
association with the expected response, thus the greater the actual activation (Penny et al, 2011). 
A contrast is essentially a difference in parameter estimates and is usually used to estimate the 
relative activation of one task while adjusting for another (e.g., faces minus shapes indicates 
activation during the faces while controlling for visual, motor, and matching aspects of the 
shapes). The output is a contrast value (difference in parameter estimates) at each voxel (a map) 
(Penny et al, 2011).  
3.8 STATISTICAL GROUP INFERENCE 
Voxel-wise group inference relies on several core principles: regression and random field theory. 
Regression can be used to determine the voxel-wise association between voxel-wise maps (gray 
matter density, FA/MD, EVC, or activation during a task) and a variable of interest (e.g., group 
differences or association with depression severity). A voxel-wise mass-univariate regression 
(similar to the previous section) can be used to determine the group level association between a 
variable of interest and a voxel-wise map. Each voxel has a corresponding parameter estimate, a 
degree of freedom, a statistical test, and a p-value. If we set our acceptable rate of false positive 
at alpha less than 0.05, then it does not suffice to threshold voxels whose p-value is below this 
threshold as we inflate our true rate with each independent statistical test.  
 This is the core of the multiple comparisons problem. Consider performing two 
independent statistical tests and setting our acceptable false positive rate alpha at 0.05. Then to 
make joint inference on both of those findings, we need to account for the inflation in the false 
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positive rate with each additional statistical test (i.e., adding more statistical tests increases the 
overall likelihood of false positives). The Bonferroni correction (a type of family-wise error 
correction) is one method that adjusts the false positive rate by dividing alpha by the number of 
statistical tests (e.g., 0.05/2 or 0.025). However, this is far too conservative of a measure when 
correcting for multiple comparisons in a voxel-wise analysis due to the high number of voxel-
wise tests. Many voxel-wise data have statistical tests on the order of hundreds of thousands, 
thus for example if we adjust for multiple comparisons for 100,000 statistical tests we need a p-
value of 5x10-7 using this correction method. However, Bonferroni correction requires correction 
for the number of independent t-tests. As the voxels are highly spatially and structurally 
correlated, and were spatially smoothed (which introduces even greater correlation between 
voxels) then the voxels are not necessarily independent statistical tests.  
 Random field theory can be used to estimate the number of independent statistical tests 
based on spatial correlation (smoothness) of the voxel-wise data (Poline et al, 1995). A 
resolution element (resel) is a unit of measure that determines the number of independent tests. 
Assuming we know that data that was ‘x’ by ‘y’ by ‘z’ number of voxels had ‘V’ smoothness 
then the number of resels is computed as the product of the number of voxels divided by the 
cubed smoothness (Poline et al, 1995). Consider the example with 100,000 voxels then if we 
assume a smoothness of 12mm (typical for functional neuroimaging data) then the number of 
resels is approximately 58 thus only a p-value less than 8.6x10-4 is needed to correct for multiple 
comparisons.  
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4.0 MACHINE LEARNING 
This chapter introduces basic concepts of regression (logistic regression) and support vector 
machines (two commonly used algorithms), as well as introducing machine learning concepts, 
including: cross-validation, validation metrics (area under the curve, AUC), and permutation 
testing. After introducing core concepts, the common pitfalls and problems in machine learning 
are described: how high dimensionality causes over fitting and multi-collinearity issues; and then 
how these are overcome using kernel based machine learning methods. Finally, the keystone 
algorithm is described in the final two sections: multi-factor kernel based machine learning.  
4.1 REGRESSION 
Regression is the process of estimating a set of parameters that linearly model the association 
between an observed variable of interest and set of observed features. In the context of machine 
learning, we are often interested in how well the estimated parameters predict the observed 
variable of interest. Thus, after fitting a model we can predict new data and investigate how well 
the predicted variable matches the measured outcome. Consider the following problem: 
Equation 2a. , 
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where y is a vector that is length n subjects, X is a feature matrix that is n subjects by f features, 
and beta are the set of parameters that linearly model their association (vector length f) that we 
want to estimate. Then the following is the ordinary least squares solution: 
Equation 2b. . 
This solution has several key assumptions: (1) linearity which states that the observed variable is 
a linear combination of the features; (2) homoscedasticity which states that the variables have 
constant variance (i.e., they do not have skewed variance along the full set of values) as well as 
normality which states that features must be normally distributed; (3) independence of response 
variables (more specifically their errors) which states the each measurement is independently 
measured; and (4) no multi-collinearity which states that features should not be highly correlated. 
 The two most important assumptions to consider are linearity and multi-collinearity. 
When fitting models with low number of subjects, it is often best to assume linearity as non-
linear models may over-fit and not generalize well (i.e., model may be specific to the current data 
set and would not do well in a larger sample). Multi-collinearity occurs when features are highly 
correlated and thus there exists no unique solution to the parameter estimates. High dimensional 
data with large number of features tends to easily suffer from multi-collinearity as the probability 
that two features are highly correlated increases as the number of features increases.  
4.1.1 Logistic Regression 
Logistic regression is a scenario where the outcome variable is binary (or non-continuous). 
Unlike linear regression, logistic regression has no closed form solution for the parameter 
estimate, thus it is estimated through an iterative process. Parameters are usually estimated using 
maximum likelihood estimation where an initial solution is computed; it is updated using one of 
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several methods (e.g., Newton’s method); and repeats until the solution maximizes the likelihood 
function.  
 To understand the mathematical formulation, consider a simple example where we 
predict a variable y (vector with length n subjects) that is either zero or one with a single feature 
x (vector with length n subjects). In this scenario, we are estimating a probability that y equals 
one or zero given x, which can be written as: 
Equation 3a.  
Equation 3b.  
where the beta terms model the mean and contribution of x, respectively. As we are trying to 
estimate a probability, the solution for the probability should be bounded by zero and one – 
however the right hand side of the equation is unbounded (negative to positive infinity). Thus, 
we can use what is known as the logit function (defined here as F), which is one at positive 
infinity and zero at negative infinity. This can be written as: 
Equation 3c. , 
Equation 3d. , 
where these can be combined to a general form as: 
Equation 3e. . 
Note that if yi is one then equation 3e becomes 3c and if it is one it becomes 3d (thus the 
generalization, or equation 3e, works). The likelihood (which is what we would like to 
maximize) is the product of these probabilities for all individuals: 
Equation 3f. , 
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thus to estimate the probability, we should compute the derivative of the log-likelihood and solve 
for the parameters when it equals zero (as this maximizes the likelihood). However, the 
derivative of a set of products is not easily computed. However, we utilize a well-known 
property that the solution using the derivative of the log-likelihood is the same as the derivative 
of the likelihood. Thus we define the log-likelihood: 
Equation 3g. . 
Note that the log-likelihood reduces to a sum due to the property that the log of two products is 
the sum of the individual logs, and that the power terms are multiplicative due to the property 
that the log of a variable to a power is equal to the power times the log of the variable. At this 
moment, a derivative is computationally possible and we estimate the parameters such that the 
derivative with respect to each parameter of the log-likelihood is equal to zero. In reality, 
optimization algorithms that identify the maximum of the log likelihood function are able to 
estimate an initial approximation, then iteratively update the parameters (e.g., using Newton’s 
method, gradient descent, etc.), and then define some convergence criteria for the iteration to 
halt. This process can be scaled for more than one feature.  
We can fit a sparse logistic function (i.e. with fewer features included in the model) using 
step-wise regression. Step-wise regression is a model building approach that attempts to only 
include features that are highly predictive and generates the ‘best’ predictive model with the 
‘lowest’ number of features (attempts to generate the most parsimonious model). This process 
involves first starting with an initial model that only includes modeling the mean. The algorithm 
then iterates over multiple steps where each step it tests all possible features to include and 
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includes those that are most predictive (or none), but simultaneously also tests for which features 
should be removed. Once there are no more features to add or remove – the procedure stops. 
This generates a sparser model, which can be useful when considering high dimensional feature 
sets.  
4.2 SUPPORT VECTOR MACHINES (SVM) 
Support vector machines (SVM) are machine-learning algorithms that (similar to regression) 
generate a model that separates two groups by attempting to find a hyperplane that best separates 
the data with the largest margin between both groups. The basic concept is that there exist some 
boundaries that separate the data into several classes and these boundaries confidently predict 
classes on both extreme ends of the boundary. This section is divided into the following: 
notation, definition of margins, optimizing margins, define the Lagrangian, we define the 
optimization problem using the Lagrangian, introduce the concept of kernels, and briefly 
describe the optimization algorithm sequential minimal optimization (SMO).  
 Let y be one of two class labels (-1 and 1), while x is a feature. Then, a classifier can be 
defined with the intercept being defined as b and parameters as w:  
Equation 4a. . 
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4.2.1 Functional and Geometric Margins 
The functional margin represents the confidence of the accuracy of the prediction, where a large 
functional margin represents high confidence of a correct prediction. We can define the 
functional margin as the following: 
Equation 4b. , 
for a given training set [x(i),y(i)], where given a large set of training data then we would minimize 
across functional margins. The functional margin suffers as it does give you a measure of 
confidence but not how close it is to the decision boundary and this is due to the scalability of w 
and b. This allows for the functional margin to be arbitrarily large without meaning, thus we can 
constrain it using the L2-norm: 
Equation 4c. , 
where the magnitude of w is constrained.  
 Consider now the geometric margin, which is the distance between a training point (A) 
and the decision boundary. Let’s consider a point (B) that is orthogonal to A and lies on the 
decision boundary, while defining the distance between A and B as gamma. Thus, we can find 
the point B on the decision boundary using the following: 
Equation 4d. ,  
where the point A is by definition x, and gamma times the unit vector results in subtracting a 
value that is length gamma (distance from A to B) and direction orthogonal to the decision 
boundary. We can now use the value of B, which lies on the decision boundary, into the equation 
of the decision boundary: 
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Equation 4e. ,  
and then solving for gamma results in: 
Equation 4f. ,  
which can be generalized to the definition of the geometric margin: 
Equation 4g. . 
Given a large training set, we would then define the geometric margin as the smallest of the 
geometric margins across all the training data.  
4.2.2 Defining the Minimization Problem 
The goal is to find a decision boundary that maximizes the geometric margin, as this would 
reflect a high confidence set of predictions (results in a classifier or model that separates two 
classes with a margin or gap whose center is the decision boundary). This maximization problem 
can be written as: 
Equation 5a. . 
 While we could attempt to solve this problem – it is not well constrained, mainly the L2-
norm constraint is not convex (i.e., may have multiple local minima). However, we can alter this 
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problem using two ideas developed in section 4.2.1. The first is that the geometric margin is 
equal to the functional margin divided by the L2-norm: 
Equation 5b. ,  
and if we replace the geometric function in equation 5a then we get: 
Equation 5c. . 
From the previous section, we know that the functional margin can be scaled without changing 
the solution, which we know take advantage of and scale the functional margin such that: 
Equation 5d. , 
and further since the maximization problem in 5c is reduced by equation 5d, then we are now 
maximizing one over ||w|| then we can instead define the problem as a minimization like this: 
Equation 5e. . 
The current optimization problem is convex (squared term) and thus has an optimal solution. 
Note that minimizing the squared term is the same as maximizing the inverse term, and also that 
we have included a constant (1/2, which does not change the solution) but does simplify some of 
the computation in later stages. While this optimization problem is well constrained and 
solvable, we can define a better form (dual form) that performs much better and has some 
desirable properties regarding kernels (defined later).   
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4.2.3 Dual Form of the Minimization Problem 
Using the Lagrangian we can define the dual, and so if we consider a general form of an 
optimization problem: 
Equation 6a. . 
Then the Lagrangian is essentially the following: 
Equation 6b. , 
where beta are known as the Lagrangian multipliers, and we can calculate two partial derivatives 
to estimate the two parameters: 
Equation 6c. . 
This is a well-defined construct that we do not review (except for equation 6a-6c). We can thus 
input these into the original equation to get the dual form. However, applying this concept to 
equation 5e, we can further simplify the minimization problem. Thus, the Lagrangian for this 
problem is: 
Equation 7a. , 
where alpha are the Lagrangian multipliers. The partial derivatives are  
Equation 7b. ,  
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Equation 7c. . 
Inserting these into the original problem (equation 5e) and after rearranging, we reach the dual 
form of the problem: 
Equation 8a. . 
The dual form of this problem has several unique properties that can be utilized, and by utilizing 
kernels these algorithms can learn in high dimensional spaces.  
4.2.4 Kernels 
Consider that instead of learning using the feature set x, that it may be beneficial to learn using 
the squared and cubic terms as well. We can then define such a function: 
Equation 9a. , 
where phi is a mapping between an input feature and some new feature set that may be more 
informative than the original feature set. Equation 8a can be written entirely as dot products and 
so we can define a Kernel as: 
Equation 9b. . 
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The dot products can thus be replaced by K(x,z) or the Kernel. In practice, we never compute 
phi, but rather the Kernel is often inexpensive to calculate. A particularly useful Kernel is known 
as the radial basis function (rbf): 
Equation 9c. , 
where sigma is a parameter and “exp” refers to the exponential function. These functions can 
thus learn different boundaries (not just a straight line) using such an exponential function. The 
‘kernel trick’ is that we can use linear algorithms to learn non-linear kernels (e.g., rbf).  
4.2.5 Sequential Minimal Optimization (SMO) 
The SMO algorithm is one of the most frequently used algorithms to solve the maximization (of 
alpha) problem in equation 8a. In this algorithm two alphas are chosen (based on a heuristic that 
picks alphas that progresses towards global maximum maximally), they are updated, then W is 
optimized with respect two updated alphas, and then this is repeated until convergence. 
Critically, two alphas are chosen because the sum of all alphas must equal one – thus by 
changing one, another must be updated as well.  
 The major reason this optimization scheme works well is that the update for alpha is 
computationally very efficient. Thus, even though the first step (which chooses alpha based on 
some heuristic) is not an optimized step, we can update alpha quite easily. Further, any update is 
bound to go towards the maxima (albeit some may have smaller step sizes). Finally, this method 
is guaranteed to converge.  
   47 
4.3 MACHINE LEARNING MODEL BUILDING PROCEDURE 
Several key concepts are needed to understand the basics of fitting machine learning models and 
testing their efficacy. Specifically, five core concepts are introduced: cross-validation, feature 
selection and parameter optimization, validation and the measures used, and permutation testing. 
The basic procedure for training and testing a model is: (1) divide data into a training set (used to 
fit the models) and a test set (used to validate its efficacy); (2) using only the training data choose 
features and optimize parameters of the machine learning model; (3) predict the testing set 
outcomes using the trained model; (4) compare the outcome of the test set to the predicted 
outcomes using validation measures.   
 Cross-Validation. The first step of most model building is determining which data will be 
used as training sets (i.e., data to fit the model) and subsequently which data will instead be the 
testing set (i.e., data to validate the final built model). If we fit the model and test it on the same 
dataset – we will inflate the accuracy thus it is critical to separate the data into training and test 
sets. If there are large samples, a good recommendation is to use approximately 70 percent of the 
data as training and 30 percent as testing. This is by far the most principled way of determining 
the accuracy and efficacy of the machine-learning model. However, if the sample size is small 
then this may not be possible, thus if the number of samples is very small then leave-one-out 
cross-validation may be a good option. In this approach, the model building process is repeated 
‘n’ times (number of subjects) where in each fold one subject is left out as the test and the others 
are used as training data. The model is built then we predict the outcome on the test holdout. If 
we repeat this process then we will have built ‘n’ models and predicted each point (where on 
each fold that individual was left out of the model training). However, this approach can be 
highly biased towards the sample and often it is better to use a larger number of folds. Thus, we 
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can perform a similar iterative holdout procedure however instead of leaving just one individual 
out on each fold, we instead leave out a higher number (e.g., if N=50 then a 10-fold cross-
validation would result in 10 folds with 5 individuals each, where the model training is done 10 
times and the data of 5 individuals is left out as the test set).  
 Feature Selection and Parameter Optimization. In high dimensional feature sets, it is 
important to select features prior to fitting the machine learning models. If there are too many 
features, the model may over-fit (described in section 4.4.1). The most principled way to select 
features is to use some percentage (e.g., 15 percent) of the training data set to determine a set of 
relevant features that are then used in the model training. Again if the number of samples is small 
then this may have to be cross-validated as well. Often this can mean using another cross-
validation inside the loop that performs the training. We can determine the best features inside 
this nested cross-validation. Similarly, we may want to optimize parameters of the machine 
learning models (e.g., box constraint in SVM) and we can allow for this to occur inside this 
nested cross-validation as well.  
 Notice that while allowing for a nested cross-validation allows for a good optimization of 
the parameters and good feature selection, it may be biased because the parameters chosen and 
the features selected may not be consistent for each fold of the original cross-validation. Thus, at 
best we can assume that the model training procedure is generalizable to a larger population – 
but not necessarily the specific model that we train.  
 Validation Metrics. For each fold of the cross-validation a model was fit and the outcome 
of the test set was predicted. Thus, after this procedure each subject has a single predicted 
outcome (ŷ), which is either a set of probabilities or a set of predicted labels, and a single actual 
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outcome (y). Two common measures to validate the efficacy of the trained model are: accuracy 
and area under the curve (AUC) of a receiver-operating characteristic (ROC) curve.  
 If a label is output, accuracy is a measure that determines percentage of accurately 
identified individuals. The following are needed to compute accuracy: true positives are the 
number of positives successfully identified and true negatives are the number of negatives 
successfully identified. Subsequently, false positives are the number of negatives identified as 
positives (type I error), and false negatives are the number of positives identified as negatives 
(type II error). Accuracy is the number of true positives and negatives combined divided by the 
total number of individuals. We can also identify two other important values: sensitivity or how 
accurately we identify positives (true positives divided by true positives plus false negatives) as 
well as specificity or how accurately we identify negatives (true negatives divided by true 
negatives plus false positives). While accuracy identifies how well we can identify labels, it does 
not identify how accurately we can identify positive and negative classes. In a scenario where 
there are a high number of negative classes, the model (for example) may just predict that all 
labels should be negative. This would result in a higher accuracy and specificity, but low 
sensitivity. A good model balances sensitivity and specificity.  
 If a probability is output (instead of a label), an ROC curve can be generated and AUC 
can be calculated. For a set of ‘m’ thresholds, we can threshold those probabilities and calculate 
the false positive rate (number of false positives divided by total negative) and plot it against the 
true positive rate (or sensitivity). This plot is known as the ROC curve, and the area under the 
ROC curve (the integral) is known as the AUC. An AUC of 1 indicates a perfect prediction, 
while an AUC of 0.5 indicates at chance prediction.  
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 Permutation Testing. While a model may have high accuracy, we may want to test 
whether this accuracy is significant. A possible concern is that the model building procedure is 
so good that given any training labels, it is still able to achieve a high accuracy. A basic 
procedure that can be done is known as permutation testing, which involves establishing a 
distribution for some measure of interest (whose distribution is unknown, e.g., accuracy) and 
determine a significance based on this distribution.  
 This process involves: (1) randomly permuting (mixing) the labels in the outcome 
measure; (2) performing the entire model training process; (3) calculating the validation measure 
(e.g., accuracy). This process is repeated a large number of times (e.g., 5,000 times). For each 
permutation a single accuracy measure has been computed, which establishes the distribution of 
this specific measure. We can then investigate whether the accuracy measure we computed lies 
on the tails of the distribution (indicating its significance). To calculate a p-value directly, we can 
add the number of times the permuted validation measures are greater than the actual accuracy 
measure then divide by the number of permutations. Thus, if the accuracy is significant (defined 
as alpha < 0.05) it should be greater than the randomly permuted accuracy 95% of the time (as 
alpha is 5%). If not, then it means that our model building procedure is able to predict any given 
set of labels and thus the current model may be accurate but would not generalize to another 
sample.  
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4.4 PRACTICAL PROBLEMS AND SOLUTIONS 
4.4.1 Common Machine Learning Problems 
There are several common problems that plague machine learning, however the core problem is 
high dimensionality of features and low number of samples (especially in neuroimaging 
literature). This tends to also be the underlying cause of many other issues including: over fitting 
and biased feature selection and another separate problem is multi-collinearity.  
 High dimensional data (i.e., too many features) often suffers from generalizability issues, 
and models built in high dimensional feature spaces tend to perform well on the training data but 
worse on the test data. Often this may be because there are too many semi-random features that 
do not accurately and reliably model the data. One example where this may occur is that a single 
individual may be an outlier on some feature, and that feature may be chosen as predictive – 
which may bias the entire model. High dimensional problems tend to also be more complicated 
to understand, as there may be multiple interacting features. This tends to lead to over-fitting of 
the model as a high number of features (even random features) are able to generate a single 
model, but these tend to do well only on the training data. This can complicate feature selection 
as well; mainly if there are a lot of features it may be difficult to either know which features to 
include a priori or even determine algorithmically. 
 The number of samples needed to fit generalizable machine learning models should be 
considerably greater than the number of features. Similar to high dimensional data, this results in 
over-fitting and high variance in accuracy. Further, a small sample size is more likely to suffer 
from selection bias (i.e., sample may represent only a small subsample of the entire population) – 
thus even if the model is stable it may not generalize to a larger more general population or just 
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generalizes to specific subsample. If we select features algorithmically, because this process is 
usually done in either a separate sample or a nested loop – the number of samples becomes 
severely limited when trying to select the best features.  
 Multi-collinearity refers to the association between features. If two or more features are 
highly correlated, it may be difficult for the model to differentiate between them and many 
models often involve assumptions regarding feature independence. High dimensional data is 
more likely to contain features that are linearly correlated (based on central limit theorem). 
Often, a feature selection procedure is needed to remove highly collinear features.  
 As a result of multiple of these problems, another issue is that often many of these 
problems do not have an idealized solution. For example, the ordinary least squares solution for 
regression (equation 2b) is not an ideal solution when the number of features is greater than the 
number of samples or if the features are highly collinear. Thus, often we have to regularize the 
solution to penalize highly over-fit models (e.g., usually a penalty term with a corresponding 
parameter is used to reduce the number of features contributing to the overall model).     
4.4.2 A Practical Solution: Principal Components Analysis 
A powerful tool that is often utilized is known as principal components analysis (PCA), and is 
potentially able to resolve each of the problems in section 4.4.1 in a single step. PCA is a 
deterministic process that identifies a low dimensional feature space that can be used to represent 
higher dimensional data. To understand PCA intuitively, several critical concepts are needed.  
Theoretically, it is a method that identifies an orthogonal (i.e., not correlated) basis set of 
the high dimensional feature space. Some examples of common orthogonal bases are the 
Cartesian coordinate system or the cosine basis. The Cartesian coordinate describes all points in 
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a 3D space by defining three points on three linear but orthogonal vectors (x, y, and z). Similarly, 
the cosine basis can define all signals in time as a set of cosine functions of varying frequency 
and amplitude. Thus the discrete cosine basis can define any signal as a linear combination of 
many cosines and so it forms a basis or a low dimensional feature space (cosines) that defines a 
very high dimensional feature space (all discrete signals). In the same way, PCA attempts to 
identify orthogonal vectors (called eigenvectors) that represent the entirety of the data in a low 
dimensional space.  
Another intuition important in PCA and basis sets is that of rank, which represents the 
nondegenerateness of the feature space. Consider the Cartesian coordinate system again, to 
define a 3D data set a minimum of three vectors are needed to identify all points in space, 
however if we added another vector it would be rank deficient. These four vectors are not 
orthogonal when defining a 3D space, as a maximum of 3 vectors is needed (i.e., only three 
numbers are needed to understand where in a 3D space a point is located while the fourth adds 
no new information). Similar to the high dimensionality issues described earlier, having a fourth 
dimension or vector is similar to having too many features. 
Singular value decomposition (SVD) is a method that can be used to decompose any 
matrix into a combination of three matrices: two unitary matrices (i.e., conjugate transpose is 
also its inverse) and a rectangular diagonal matrix. Using SVD, we can perform PCA on any 
given matrix. Given a matrix ‘X’ (‘n’ subjects by ‘f’ features) then SVD can be represented as: 
Equation 10a. , 
where U (n by n) and V (f by f) are square unitary (e.g., U*UT=I) matrices and Σ (n by f) is a 
diagonal matrix. Critically, U and V represent the left and right eigenvectors while Σ contains the 
eigenvalues along its diagonal. While PCA is usually described as decomposition on the 
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covariance matrix, SVD allows for a simpler decomposition (i.e., U and V of X are the same as 
the eigenvectors of X*XT). The UΣ is also known as the scores while V is known as the 
coefficients or loadings, where the scores represent the original data in the principal component 
bases while the coefficients are the transformation between the original and principal component 
bases.  
The scores is a square matrix that is n by n, where the n-rows represent each individual 
subject and the n-columns represent the n-bases (or principal components). Further, UΣ*(UΣ) is 
the identity matrix, thus the n-bases are not correlated. We have now constructed a feature space 
that is not collinear, has as many features as number of subjects (thus not rank deficient), and 
because of this has an idealized solution in regression problems. This is the basis of principal 
components regression or kernel (since the scores from PCA are a kernel) based machine 
learning. The basic approach is to first reduce the feature matrix using PCA to get scores, fit a 
machine-learning model between the scores and the outcome, and transform the parameters back 
to the original space using the coefficients. Section 4.4.3 describes the general process of kernel-
based regression.  
4.4.3 Kernel-Based Regression 
Consider a feature matrix X (n by f) and a vector of outcomes y (length n) then while we could 
solve the general regression problem (y=XB), it may suffer from some of the problems described 
previously. An alternative is to first perform PCA on X (which we first center by removing the 
mean of each column): 
Equation 11a. , 
where W is the scores and V is the coefficients. Then we can solve the following problem: 
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Equation 11b. , 
where we now instead solve for a new set of regression parameters (one for each component in 
the PCA), which does not suffer some of the typical pitfalls described in previous sections. We 
can then back-project these parameters into the original space (if we are interested in 
understanding the model) using the coefficients: 
Equation 11c. , 
which is an ideal solution for the original problem and has several unique properties, but most 
importantly it addresses the multi-collinearity problem and has a regularization effect. Thus, by 
utilizing this ‘kernel trick’ we are able to fit a well-defined and efficient model.  
Choosing Number of Principal Components: This model is improved further by choosing 
a set of principal components instead of utilizing the entire feature space. There are several 
methods for choosing the number of components, the most common being to investigate a scree 
plot (cumulative variance explained by number of components) and either choosing the number 
of components that explain a certain percentage of variance or by finding the ‘elbow’ of the scree 
plot (i.e., find the maximum of the second derivative of the scree plot also known as the 
inflection point). However, another method, which is one of the most recommended but most 
under utilized, is called Horn’s parallel analysis. This method utilizes permutation testing and 
permutes the data matrix into uncorrelated normal variables and performs PCA getting a set of 
eigenvalues over several permutations. For each eigenvalue we can compute a p-value by adding 
the number of times the random eigenvalue is greater than the actual eigenvalue and dividing by 
the total number of permutations. Eigenvalues with p-values less than some pre-determined 
alpha (e.g., alpha < 0.05) are considered significant and are retained.  
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4.4.4 Multi-Factor Analysis 
Multi-factor analysis (MFA) is an extension of PCA that seeks to balance several feature sets 
(Abdi et al, 2013). Consider an example where some outcome (e.g., depression severity) is 
dependent on two feature sets (e.g., clinical surveys and genetic data), where we assume that the 
number of clinical surveys (f) is much less than the number of genetic features (g). We could 
investigate the association between depression severity and each clinical survey or each genetic 
variable using principal components regression (PCR). While we could perform these analyses 
separately, it may be useful to understand their joint association with depression (i.e., the 
association between depression severity and both feature sets). We could combine these feature 
sets into one dataset (which has f plus g features) and then perform PCR. However, the surveys 
suffer greatly because the kernel that is generated using PCA is influenced by the genetic data 
solely due to its size (as it has a much larger number of features, g). 
 MFA extends upon this by performing PCA twice. We compute a set of scores for both 
feature sets (i.e., one kernel for the surveys and one for the genetic data) and then these scores 
(which are identical in size) are then input into another PCA where another set of scores is 
generated. This assumes that the genetic data and clinical surveys both serve an important role in 
understanding the depression severity and does not bias the kernel towards either feature set. 
This becomes essential as in neuroimaging studies we often collect multiple neuroimaging data 
(structural and functional that are very high dimensional on the order of hundreds of thousands 
of voxels), but also collect clinical measures (with much lower number of features) that may be 
just as important. Thus, MFA can be used to balance the predictive capabilities of each set of 
features without the loss of balance between features. Such an approach will enable a unique 
combination of multiple feature sets and will utilize the full set of features within a study.  
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4.5 MULTI-FACTOR KERNEL BASED MACHINE LEARNING 
Two major algorithms are used in this work: (1) single feature set learning and (2) multi-feature 
set learning. Single feature set learning uses kernel-based (PCA) learning while the multi-feature 
set uses an extension using another kernel based on the MFA instead of PCA.  
4.5.1 Single Feature: Kernel Based Learning 
Given a single feature set X (n subjects by f features, which can be images, surveys, or any other 
data) and a vector of outcomes (y, length n subjects) then the implemented algorithm (PCR) is as 
follows:  
1. Horn’s Parallel Analysis is conducted on X to determine the number of components (or c, 
where c < f) to keep in the PCA.  
2. Perform PCA on X to calculate scores (W, n by c) and coefficients (V, c by f).  
3. Conduct a 10-fold cross-validation dividing data into training and test sets. Then for each 
fold perform the following: 
a. Fit a model (using either SVM, Logistic Regression, or step-wise Logistic 
Regression) between the training scores (Wtrain) and the outcomes (y). 
i. Optimize the models using the training data (if needed). 
b. Using the model predict a set of outcomes (ŷ) using the test scores (Wtest). 
4. After we iterate through all 10 folds, the predicted outcomes (ŷ) are compared to the 
actual outcomes (y). We compute AUC and accuracy.  
5. As the cross-validation in step 3 is non-exhaustive (i.e., it does not learn and predict on 
all possible ways to divide the data into training and test sets), it benefits to generate a 
   58 
large set of cross-validations. Thus, we repeat steps 3 and 4 several (50) times where on 
each repetition we generate another cross-validation scheme. This will output a 
distribution on the validation measure (i.e., 50 AUC and accuracy measures are 
generated).  
6. We fit a single model on all W and y to get a set of parameters (βpcr, length c) that are 
projected back into the original space using the coefficients (β=Vβpcr, length f). We 
perform permutation testing (step 7) to determine which parameters in the original space 
significantly contribute to the prediction model.  
7. Generate a set of 1,000 random permutations of y. For each permutation: 
a. Fit a single model between W and ypermuted to get a set of (βpcr_permuted) that are 
projected back into the original space using the coefficients 
(βpermuted=Vβpcr_permuted). 
8. For each parameter (β), add the number of times its absolute value is less than the 
absolute value of the permuted parameter (βpermuted) then divide by the number of 
permutations (1,000) to generate a single p-value for each parameter. This determines 
whether the parameter significantly contributes to the overall model.  
4.5.2 Multiple Features: Multi-Factor Kernel Based Learning 
Consider two feature sets X (n subjects by f features) and S (n subjects by g features) and a 
vector of outcomes (y, length n subjects). Note that this process extends the previous algorithm 
to have two instead of one PCA (hence multi-factor), thus fit parameters are projected twice. The 
implemented algorithm (MFA) is as follows:  
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1. PCA is conducted on both X and S to generate scores (W and S, both n by n matrices) 
and coefficients (V, length n by f; and N, length n by g). We generate a single scores 
matrix from all scores (R, n by 2n).  
2. Horn’s Parallel Analysis is conducted on R to determine the number of components (or c) 
to keep in the PCA.  
3. Perform PCA on R to calculate scores (Q which is n by c) and coefficients (P which is c 
by 2n).  
4. Conduct a 10-fold cross-validation dividing data into training and test sets. Then for each 
fold perform the following: 
a. Fit a model (using either SVM, Logistic Regression, or step-wise Logistic 
Regression) between the training scores (Qtrain) and the outcomes (y). 
i. Optimize the models using the training data (if needed). 
b. Using the model predict a set of outcomes (ŷ) using the test scores (Qtest). 
5. After we iterate through all 10 folds, the predicted outcomes (ŷ) are compared to the 
actual outcomes (y). We compute AUC and accuracy.  
6. As the cross-validation in step 3 is non-exhaustive (i.e., it does not learn and predict on 
all possible ways to divide the data into training and test sets), it benefits to generate a 
large set of cross-validations. Thus, we repeat steps 4 and 5 several (50) times where on 
each repetition we generate another cross-validation scheme. This will output a 
distribution on the validation measure (i.e., 50 AUC and accuracy measures are 
generated).  
7. We fit a single model on all R and y to get a set of parameters (βMFA, length c) that are 
projected back into the MFA space using the coefficients (βpcr=PβMFA, length 2n). 
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Another projection allows the parameters to be projected to the first PCA space 
(βX=Vβpcr, length f; or βS=Nβpcr, length g). We perform permutation testing (step 7) to 
determine which parameters in the original space significantly contribute to the 
prediction model.  
8. Generate a set of 1,000 random permutations of y. For each permutation: 
a. Fit a single model between Q and ypermuted to get a set of (βMFA_permuted) that are 
(twice) projected back into the original space using the coefficients (βpermuted). 
9. For each parameter (β), add the number of times its absolute value is less than the 
absolute value of the permuted parameter (βpermuted) then divide by the number of 
permutations (1,000) to generate a single p-value for each parameter. This determines 
whether the parameter significantly contributes to the overall model.  
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5.0 NEURAL CORRELATES OF LATE-LIFE DEPRESSION 
This chapter introduces major depressive disorder (MDD) and late-life depression (LLD) as well 
as the structural and functional neural correlates of pharmacotherapy. The neuroimaging 
prediction literature is also reviewed briefly. The introduction sections of chapters 6 to 8 cover 
the resting state, emotion reactivity, and prediction of response literature, respectively.  
5.1 MAJOR DEPRESSIVE DISORDER 
Depression is characterized by several core symptoms: low/depressed mood, anhedonia (inability 
to feel pleasure), low energy or fatigue as well as disturbed sleep, pessimism, feelings of guilt, 
loss/gain of weight, and suicidal tendencies. It is a complex disorder dependent on genetic, 
environmental, and neural factors. Depression has a high prevalence (16.6% of individuals will 
meet criteria for MDD at least once in the US (Kessler et al, 2005)) and is associated with high 
medical comorbidity and mortality resulting in more years lived with disability than any other 
disease (Alexopoulos and Kelly, 2009; Moussavi et al, 2007). Depression ranks fourth in 
disability-adjusted life years (Moussavi et al, 2007). It is projected (by 2020) that it will only be 
second to heart disease in its contribution to global disease burden (Hinrichsen and Hernandez, 
1993). Further, individuals with MDD have worse cognitive functioning, greater prevalence and 
severity of chronic medical conditions such as arthritis, hypertension, and diabetes, as well as 
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increased utilization of medical services and greater health care costs (Bruce et al, 2004; 
Charney et al, 2003; Stevens et al, 1999). Despite significant strides in our understanding of 
MDD etiology, pathophysiology, and mechanisms for treatment, it has proven challenging to 
prevent, diagnose, and treat depression effectively. 
 While MDD has a strong genetic susceptibility component (first-degree relatives carry a 
threefold increase in risk compared to the general population (Sullivan et al, 2000)) it is also 
associated with a wide variety of neurobiological factors. The most well-known and well-
characterized hypothesis is the dysfunction of monoamine systems, specifically serotonin, 
dopamine, or norepinephrine (Bunney and Davis, 1965; Schildkraut et al, 1965). This was 
largely supported in studies that showed that decreased synaptic concentrations of these 
neurotransmitters could cause depression symptoms (Bunney et al, 1965; Schildkraut et al, 
1965). Further, treatment with drugs that increased synaptic serotonin and norepinephrine would 
ameliorate depressive symptoms (Charney, 1998; Delgado et al, 1990; Miller et al, 1996). Other 
systems are also affected such as the corticotropin-releasing hormone, which affects the 
hypothalamus-pituitary-adrenal axis, and substance P, which is involved in the response to stress 
(Gold et al, 1984; Holsboer et al, 1984; Kramer et al, 1998; Nemeroff et al, 1984). Circadian 
dysregulation are also described in MDD (Kupfer et al, 1982), where sleep deprivation can result 
in a short-lived remission to depression.  
 Other environmental and demographic factors are also associated with the susceptibility 
to depression (reviewed in (Vink et al, 2008; Wong and Licinio, 2001)). Women and older 
individuals are more susceptible to depression. Prior depression is also a significant predictor, 
though it is unclear whether this is due to genetic susceptibility or chronicity. Social aspects like 
marital status (unmarried), lower socio-economic status, living alone or without a support 
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structure, and recent bereavement are also associated with greater risk. Current or past health is 
also strongly associated with depression, including disability, current poor health, new medical 
illness, and a history of medical illness. Cognitive impairment is also a strong predictor of risk 
for depression. Thus, a variety of factors increase the risk of depression and likely remission as 
well.   
5.2 LATE-LIFE DEPRESSION (LLD) 
There is a second peak of incidence of depression in late-life (first peak in youth) that is 
associated with greater risk of suicide, medical comorbidity, disability, and family caregiving 
burden (Katon et al, 2010; Mulsant et al, 2006; Nelson et al, 2013). In late-life, there are several 
age-related factors that may further influence symptoms. For example, comorbid anxious-
depression is more prevalent in late-life (Chou, 2009). Aging individuals have greater illness 
burden as well cognitive decline or dementia - both of which increase susceptibility to 
depression.  
Additionally, in late-life a novel mechanism may drive some subtypes of depression. The 
‘vascular depression hypothesis’ states that cerebrovascular disease may further predispose, 
precipitate, or perpetuate depressive symptoms (Taylor et al, 2013). Cerebral perfusion deficits 
induce microbleeds and infarcts in the white matter tracts, and consequently result in the 
dysconnectivity of various brain regions, thus worsening both cognitive function and mood 
symptoms (Taylor et al, 2013). The white matter lesions are noticed as hyperintense regions on 
T2-weighted MRI images.  
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5.2.1 Treatment of LLD 
The most common treatment of LLD is antidepressant pharmacotherapy. Treatment of 
depression often involves a trial and error process of multiple antidepressants before an effective 
regimen is found. Approximately 40-50% of patients fail to respond to initial pharmacologic 
treatments (Andreescu et al, 2011). Typically, for midlife MDD, a clinician needs 3-4 weeks to 
determine whether the current regimen will be effective, an interval which increases in LLD to 
approximately 6-8 weeks (Andreescu et al, 2011; Reynolds et al, 2006). This interval is 
associated with increased risk of suicide and dropping from care. This is one of the most 
challenging features of treatment in LLD, thus it is particularly important to detect early 
treatment markers (prior to the behavioral response period) that indicate future clinical 
improvement (Aizenstein et al, 2014).  
 While current treatments often improve symptom severity, achieving full remission and 
maintaining remission is more difficult and likely explains why depression has more years lived 
with disability than other disorders. Although approximately two-thirds of patients eventually 
respond to some antidepressant therapy, relapse rates are high (especially in late-life) (Andreescu 
et al, 2011). This is further complicated by increased side effects from antidepressants, which 
reduces compliance with treatment and thus likelihood to achieve remission of symptoms 
(Andreescu et al, 2011).  
Previous studies have identified several biomarkers of treatment response (reviewed in 
(Aizenstein et al, 2014; Breitenstein et al, 2014)). Two biological predictors include the 
serotonin transporter gene (S allele) and the decreased rapid eye movement sleep latency which 
are both associated with poor response. Further, glucose metabolism in the subgenual and the 
dorsal anterior cingulate is associated with better response. There are a host of clinical variables 
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that are predictive of better response such as low medical burden, early symptom improvement, 
early age of onset, no sleep disturbance, lower pre-treatment depression and anxiety severity, low 
suicidal ideation, and previous response to antidepressants. Thus, a broad category of social, 
genetic, and neural markers are associated with remission. In the next section, we describe in 
greater detail the neural changes associated with treatment response in LLD.  
5.3 NEURAL PREDICTORS OF RESPONSE TO PHARMACOTHERAPY 
Currently, MRI is only used clinically to screen whether depression symptoms are related to 
structural atrophy or cerebrovascular disease (Botteron et al, 2012; Gelenberg et al, 2010). 
However, several studies have investigated the pre-treatment structural and functional MRI 
predictors of response to antidepressants in LLD or the MRI changes associated with successful 
pharmacotherapy.  
 There are several common structural neuroimaging features associated with resistance to 
treatment. The most common is the white matter hyperintensities (WMH) burden, which 
correlates with the overall vascular burden described in the vascular depression hypothesis 
(Taylor et al, 2013; Taylor et al, 2003). High pre-treatment WMH burden has been associated 
with poor response to antidepressant pharmacotherapy. This is one of the most consistent 
findings in the neuroimaging literature in LLD and further supports the notion that LLD, 
especially the vascular subtype, may have a different mechanism to remission. To further support 
this, some studies have also reported a trend increase in WMH burden in non-responders during 
the course of a trial (Sheline et al, 2010a). These results have been interpreted as a product of the 
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vicious pathophysiologic circle (vascular lesions trigger depression which increases 
inflammation and worsens the vascular burden).  
 A smaller literature implicates several other pre-treatment structural markers (reviewed in 
(Aizenstein et al, 2014; Breitenstein et al, 2014)). Low pre-treatment dorsal and rostral anterior 
cingulate volumes predict poor response to antidepressants, which have been functionally 
implicated in depression and are related to emotion reactivity and regulation. Similarly, lower 
dorsolateral prefrontal cortex volumes also correlate with poor response to pharmacotherapy and 
are thought to be associated with lowered cognitive control over emotions. Lower hippocampus 
volumes have also been shown to be associated with poor response, however its relation to 
depressive symptoms is less clear. While amygdala (emotion reactivity and memory) volume and 
activity has also been shown to be associated with depressive symptoms and response to 
antidepressants, this result is less robust in LLD. Fractional anisotropy (FA, which measures 
microstructural integrity of the white matter) has also been implicated in response, mainly that 
low FA in the frontal cortex and anterior cingulate predicts poor response – however it is unclear 
whether this is driven by WMH (since WMH burden tends to accumulate in the anterior and 
posterior cingulum). Further, much of the literature regarding pre-treatment structural predictors 
of response in LLD is mixed and it is unclear how specific these predictors are to individual 
antidepressants (since each of these studies varied in the course and antidepressant used).  
 The literature directly investigating LLD and functional neural markers is more limited, 
however some of the functional changes in mid-life may be important in understanding the 
context of changes in late-life. Resting state studies indicated that high pre-treatment amygdala-
cingulate and insula-cingulate connectivity was predictive of poor response (Lui et al, 2011). 
Mainly limbic structures are strongly implicated. High pre-treatment default mode network and 
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low executive control network connectivity was associated with better response to 
antidepressants (McGrath et al, 2013). While presenting visual images of sadness, previous 
studies found that high anterior cingulate activation was predictive of better response and that 
during presentation of happy images, higher hippocampal activation was predictive of better 
response (Chen et al, 2007; Fu et al, 2008; Fu et al, 2007; Langenecker et al, 2007; Lemogne et 
al, 2010; Lisiecka et al, 2011). Limbic reactivity during emotional face matching has also been 
shown to predict response to antidepressants and greater orbitofrontal-cerebellar connectivity 
was predictive of better response during this task (Lisiecka et al, 2011). A meta-analysis of 
positron emission tomography using fluorodeoxyglucose further implicated the following: high 
subgenual cingulate and medial prefrontal cortex metabolism and low putamen as well as 
insula/inferior frontal gyrus metabolism were associated with better response (Fu et al, 2013). 
The amygdala however showed high heterogeneity – some showing high and others showing low 
reactivity in responders (Fu et al, 2013). These changes reflect altered resting state default mode 
network and executive control network connectivity (hypothetically related to ruminative aspects 
of depressive symptoms), altered limbic reactivity (high emotional response), and low activation 
in cognitive regions (low emotional control). 
 LLD studies have shown a similar pattern of altered cognitive and limbic networks. LLD 
studies showed alterations in pre-treatment resting state executive control network connectivity 
and default mode network connectivity (Aizenstein et al, 2009; Alexopoulos et al, 2012; 
Andreescu et al, 2013; Brassen et al, 2008; Wang et al, 2008a). One study reported decreased 
posterior cingulate-striatum connectivity following treatment response (Andreescu et al, 2013). 
Several studies during a wide set of tasks reported low prefrontal cortex activation that 
normalized after treatment.  
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The treatment of depression and depressive symptoms is complicated by individual 
differences in etiology, pathophysiology, and treatment response. Machine learning approaches 
use high volume data to create a computational model that considers a large number of features 
outside of what is typically considered. A clinician typically considers a host of features, 
including time of onset, single vs. recurrent vs. chronic depressive symptoms, severity of 
symptoms, whether the individual is in partial or full remission, presents with/without psychotic, 
catatonic or melancholic features, seasonal patterns, and whether the symptoms are associated 
with other medical illnesses. However, even the most experienced clinicians may draw from past 
and learned experiences but may not be able to interpolate from the most current research. A 
machine-learning model may be able to help identify and summarize a much larger host of 
features (including genetic, neuroimaging, surveys, as well as exercise and diet information) 
from a large dataset. These models can also incorporate new technological advances and their 
use in modern society (e.g., internet usage as a predictor). Producing such summaries may help 
further guide clinicians when making decisions on the best course of treatment. However, most 
models fail to produce highly desirable and/or reproducible effects, as they were not designed for 
use in prediction models.  
We can design studies that are biased to high number of samples instead of towards non-
useful markers. While structural MR markers are useful and may be predictive – they are not 
cost-effective, as it would require an MRI, which is expensive. However, functional 
measurements can be made using a wide variety of techniques that are more cost-effective (e.g., 
electroencephalogram or EEG). Surveys are a cheap and effective method to determine the 
current depressive state as well as a host of important variables (e.g., age, gender, socioeconomic 
status, education, etc.). Genetic sampling can be done and is cost-effective mainly as it need only 
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be done once, while other clinical measures can be performed easily (e.g., blood pressure as well 
as blood biomarkers). Thus using such designs, it may be possible to generate sophisticated 
models of response. In the next sections we present results of a large multi-modal LLD cohort.  
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6.0 INTRINSIC FUNCTIONAL CONNECTIVITY IN LATE-LIFE DEPRESSION 
(LLD): TRAJECTORIES OVER THE COURSE OF PHARMACOTHERAPY IN 
REMITTERS AND NON-REMITTERS 
This chapter is a modified version of work that has been previously published in Molecular 
Psychiatry (Karim et al, 2016a). This work (including only a subset of the full data as this is 
what was available) was intended to fulfill the first half of aim 1 to investigate resting state 
connectivity changes in the brain following antidepressant treatment, how this differed between 
remitters and non-remitters, and if any acute changes (e.g., following a single dose of 
antidepressants) was observed. The paper is reprinted here (with permission from Nature 
Publishing Group).  
6.1 ABSTRACT 
Previous studies in late-life depression (LLD) have found that patients have altered intrinsic 
functional connectivity in the dorsal default mode network (DMN) and executive control 
network (ECN). We aimed to detect connectivity differences across a treatment trial among LLD 
patients as a function of remission status. LLD patients (N=37) were enrolled into a 12-week trial 
of venlafaxine and underwent five functional magnetic resonance imaging (fMRI) resting state 
scans during treatment. Patients had no history of drug abuse, psychosis, 
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dementia/neurodegenerative diseases, or medical conditions with known effects on mood. We 
investigated whether there were differences in three networks: DMN, ECN, and ASN (anterior 
salience network) connectivity as well as a whole brain centrality measure (eigenvector 
centrality, EVC). We found that remitters showed increases in ECN connectivity in the right 
precentral gyrus as well as decreases in DMN connectivity in the right inferior frontal gyrus and 
supramarginal gyrus. The ECN and DMN had regions (middle temporal gyrus and bilateral 
middle/inferior temporal/fusiform gyrus, respectively) that showed reversed effects (decreased 
ECN and increased DMN, respectively). Early changes in functional connectivity can occur after 
initial medication exposure. This study offers new data indicating that functional connectivity 
changes differ depending on treatment response and can occur shortly after exposure to anti-
depressant medication. 
6.2 INTRODUCTION 
Treatment of major depression often requires multiple trials of medications before identifying an 
effective regimen. Forty percent of patients drop from care within the first month of treatment 
(Gaynes et al, 2009; Holtzheimer and Mayberg, 2011) (an important risk of incomplete response 
(Warden et al, 2007)), and for those who remain in treatment; over half do not respond (Trivedi 
et al, 2006). Although conventional methods of increasing dose and using augmentation 
strategies increase overall response rates (Trivedi et al, 2006), these trials require patients to 
endure prolonged episodes of depression. Failure to respond to treatment can increase suicide 
risk, contribute to worsening of medical co-morbidities, disability, cognitive impairment, and 
death (Katon et al, 2010; Mulsant et al, 2006; Nelson et al, 2013). Because depressed older 
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adults are at increased risk for all of these negative heath consequences, shortening the window 
from clinical presentation to effective treatment is particularly important. 
Several prior functional MRI (fMRI) studies have identified potential biological 
correlates, or markers of mid- and late-life depression (Aizenstein et al, 2014). They suggest that 
depression is associated with changes spanning multiple resting state networks. Specifically, 
depression has been linked to changes within the executive control network (ECN), default mode 
network (DMN), and anterior salience network (ASN) (Aizenstein et al, 2014). We have defined 
these networks based on previous work by Greicius (Shirer et al, 2012). We utilized a region of 
interest (ROI) based connectivity approach.   
Late-life depression (LLD) has been associated with decreased functional connectivity in 
the ECN (Alexopoulos et al, 2012). The left dorsolateral prefrontal cortex (dlPFC) is highly 
correlated with emotion regulation and often used as the ROI for ECN (Banks et al, 2007; 
Ochsner et al, 2012). The ECN is important for goal-directed behaviors and complex cognitive 
tasks such as working memory, cognitive control, and decision-making (Menon and Uddin, 
2010). In LLD, poor cognitive control is often reported (Aizenstein et al, 2009; Alexopoulos, 
2002) and ECN connectivity has been associated with certain features of executive dysfunction, 
including rigidity in processing information/learning (Aizenstein et al, 2006; Aizenstein et al, 
2005), deficits in working memory, and attention and cognitive inhibition (Alexopoulos et al, 
2012; Carter and van Veen, 2007).  
Several studies in mid-life depression and LLD suggest that depression is associated with 
greater connectivity in the DMN (Andreescu et al, 2013; Lui et al, 2011). The midline posterior 
cingulate cortex (PCC) has been used extensively as a central node of the DMN (Damoiseaux et 
al, 2008; Fransson and Marrelec, 2008; Leech et al, 2012). Previous studies have shown that 
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greater DMN activity is associated with negative bias, increased self-referential thoughts, and 
rumination (Alexopoulos et al, 2012; Greicius et al, 2007; Gusnard et al, 2001; Hamilton et al, 
2011; Marchetti et al, 2012; Sheline et al, 2010b). In mid-life depression it has been shown that 
PCC and ventro-medial prefrontal cortex (vmPFC) connectivity predicted rumination severity 
(Berman et al, 2011). Further, therapeutic effects of antidepressants are associated with 
decreased neural response to negative self-referential stimuli (Nejad et al, 2013). 
Finally, greater functional connectivity in the ASN is associated with increased anxiety 
and somatization (Andreescu et al, 2015; Paulus and Stein, 2006). The right anterior insula 
(RAI) is a central node of the ASN, and has been shown to be more greatly activated (relative to 
the left) in studies of emotion reactivity and regulation (Feinstein et al, 2006; Klumpp et al, 
2012; Paulus et al, 2003). The ASN is extensively connected with regions involved in 
motivation, reward, as well as salience (cognitive, homeostatic, or emotional) (Craig, 2009; 
Menon et al, 2010). Increased ASN connectivity has also been associated with interoceptive 
hijacking, which may represent the neural basis of increased anxiety and somatization described 
in LLD (Paulus et al, 2006; Simmons et al, 2013).  
Whole brain networks were examined using eigenvector centrality (EVC), which 
identifies important nodes that are densely connected (Zuo et al, 2012). These nodes may play an 
important compensatory role in damaged networks (Binnewijzend et al, 2014), and they provide 
a measure of how central a node is within the brain (summarizing the number of connections and 
their relative strength). This metric is particularly responsive to acute exposure to selective 
serotonin reuptake inhibitor (SSRI) (Schaefer et al, 2014). Early changes in these networks 
might signal whether a treatment is likely to succeed.  
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By pairing fMRI scans with a pharmacological challenge, it is now possible to track 
whether/how brain activity changes in response to particular medications by looking at changes 
in functional connectivity after a single dose (Bourke and Wall, 2015). It is possible that early 
markers of circuit engagement, in response to LLD treatment, will help identify remitters with 
greater accuracy than pre-treatment imaging alone. This dynamic fMRI approach that can help 
refine current hypotheses regarding the correlation between treatment response and activity in 
functional circuits. Furthermore, by using early changes in brain activity, this early change can 
help predict clinical outcomes for individual patients.  
The feasibility of fMRI markers is supported by recent studies showing functional 
imaging changes as early as 1–7 days after starting a new medication (Godlewska et al, 2012; 
Takahashi et al, 2005). Positron emission tomography (PET) studies have indicated similar 
potential: increases in monoaminergic occupancy rates are detectable after a single dose of an 
SSRI (Meyer et al, 2001; Parsey et al, 2006). However, no longitudinal study has examined 
dynamic functional connectivity changes that occur during an LLD treatment trial. 
We investigated how changes in functional brain connectivity over a 12-week trial of 
venlafaxine differed between remitters and non-remitters. Patients underwent five resting state 
fMRI scans. We would expect that early in the treatment trial that the DMN and ASN would 
decrease in connectivity, while the ECN would increase (decreased rumination and anxiety, and 
increased cognitive control, respectively). We hypothesized that these early changes would be 
sustained until the end of the treatment trial. 
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6.3 METHODS 
6.3.1 Study Design and Subjects 
This project was part of a five-year multi-site study of treatment of LLD, which used venlafaxine 
in the first phase and then followed up with aripiprazole in non-remitters in the second phase. 
This was based on a study that found that augmentation of venlafaxine with aripiprazole 
improved treatment outcomes in treatment resistant patients (Rutherford et al, 2007). It was also 
chosen due to its dual mechanism of action (at low versus high doses). Participants were 
included if they were >65 years of age, meeting DSM-IV criteria for major depressive episode 
(non-bipolar, non-psychotic), with Montgomery-Asberg Depression Rating Scale (MADRS)>15 
(Montgomery and Asberg, 1979). Exclusion criteria: history of mania/psychosis, 
alcohol/substance abuse within the last 3 months, dementia/neurodegenerative disease, and 
conditions with known effects on mood (e.g. stroke, multiple sclerosis, vasculitis, significant 
head trauma, and unstable hypertension and hypothyroidism). After informed consent, five MRI 
scans were performed: baseline, following the placebo lead-in (placebo), after first exposure to 
venlafaxine (day one), a week after beginning treatment (week one), and at the end (figure 1).  
A total of 37 participants signed consent, but four were excluded due to venlafaxine side 
effects (N=2), non-adherence to protocol (N=1), and an inaccurate diagnosis of major depressive 
disorder (N=1). Thus 33 subjects were included in this analysis. All subjects completed the first 
four scans, but six failed to complete the fifth scan (but were included). Nine participants were 
on benzodiazepines (12 hour exclusion period prior to scanning) during the study (mean 
lorazepam dose=0.61 mg). There were no significant differences (p=0.19) of lorazepam dose 
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between remitters (N=4, 0.5mg) and non-remitters (N=5, 0.7mg). Four participants were on anti-
hypertensive medications throughout the study.  
Detailed dosage information has been published (Joel et al, 2014) and are available in the 
supplement. Patients were designated as remitters at 12 weeks if they had a MADRS≤10 for 2 
consecutive weeks during the trial (Joel et al, 2014; Riso et al, 1997).  
Figure 1. The study design protocol. Functional and structural MRI (fMRI and sMRI, 
respectively) was performed throughout the treatment period. All scanning was done in the 
morning. On day one, participants came in for an fMRI scan (Baseline) and then were given a 
placebo following the scan. On day two (~12 hours after placebo) they returned for another fMRI 
scan (Placebo) and then were started on venlafaxine following the scan. They returned the next 
day (~12 hours later) for another fMRI scan (Day One, i.e. day one of treatment). They 
continued on their medication as normal and came in for scans on week one (Week One) and at 
the end of the trial (End). 
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6.3.2 MRI Data Collection 
Scanning was conducted using a 3T Siemens Trio TIM scanner located at the MR Research 
Center at the University of Pittsburgh. A high-resolution T1-weighted sequence was collected 
(TR=2300ms, TI=900ms, FA=9°) with a field of view 256x224 with 176 slices. T2*-weighted 
BOLD acquisition using gradient-echo echoplanar imaging (EPI) was also collected 
(TR=2000ms, TE=34ms, in-plane resolution=128x128, 28 slices, voxel size=2x2x4mm3). 
During resting scans, subjects (while awake, eyes open) observed a cross-hair.  
6.3.3 Preprocessing 
Data were preprocessed using statistical parametric mapping software (SPM12) (Penny et al, 
2007). Functional volumes were first slice-time corrected then motion corrected. There were no 
significant differences between groups/time in mean relative motion and max absolute motion 
(see Supplement for descriptive statistics). Manual skull stripping was done, using ITK-SNAP 
(Yushkevich et al, 2006), to improve functional to structural coregistration. The stripped 
structural image was then co-registered to the mean functional volume.  
The structural image was segmented using six spatial priors (including gray/white 
matter). This generated a deformation field that was applied to the functional images (Ashburner 
et al, 2005). Smoothing was applied using a Gaussian kernel with full-width half-maximum 
(FWHM) of 8mm.  
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6.3.4 Eigen-Vector Centrality (EVC) and ROI to Voxel Maps 
Analyses were performed using in-house MatLab code. 
Processing in both EVC and ROI to voxel analyses 
We extracted a principal time-series from the white matter (WM) and cerebrospinal fluid 
(CSF) using singular value decomposition (SVD). We used these two signals and the motion 
parameters from the preprocessing in a multiple linear regression at each voxel. We extracted the 
residual time-series from each voxel, which represents the time-series not accounted for by WM, 
CSF, or motion. A band-pass filter (0.01-0.1Hz Butterworth) was applied. This pipeline was 
adapted from Whitfield-Gabrieli et al (Whitfield-Gabrieli et al, 2012).  
Eigen-Vector Centrality (EVC) 
A whole brain connectivity measure was calculated (EVC) (Binnewijzend et al, 2014; 
Joyce et al, 2010; Lohmann et al, 2010; Wink et al, 2012; Zuo et al, 2012). The matrix of 
covariate removed, band-pass filtered residuals across all voxels was put through an SVD. The 
principal Eigen-vector is the EVC measure. The matrix was centered then weighted by the 
inverse of the variance of each signal. In doing so, the SVD is done on the correlation rather than 
the covariance matrix. Z-scores were generated (mean zero and standard deviation one), 
smoothed, then masked for only gray matter.  
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ROI to Voxel 
The signal within the ROI was correlated to each voxel. An SVD was performed to 
generate a principal time-series for the ROI. We computed the correlation between the ROI and 
all other voxels.  
The Z-score map for these correlations was smoothed, then masked for only gray matter. 
This analysis was done for three separate ROI’s. The PCC seed (DMN) was extracted from the 
posterior cingulate (eroded by hand in ITK-SNAP) from the Automated Anatomical Labeling 
(AAL) (Wu et al, 2011). The RAI seed (ASN) is extracted from the right insular cortex defined 
in the Automated Anatomical Labeling (AAL) atlas in the WFU Pick-Atlas. The left dlPFC 
(ECN) is defined as the left Brodmann area (BA) 46 in the Talairach Daemon database from the 
WFU Pick-Atlas. The network terminology used will reflect the terminology used in another 
study that performed an independent components analysis (ICA) (Shirer et al, 2012).  
6.3.5 Statistical and Cluster Analysis 
Statistical analyses were performed using SPM12 for each ROI connectivity and EVC maps. A 
repeated-measures ANOVA was performed containing the factors: group (response to treatment, 
2 levels), time (5 levels, during treatment), an interaction between group and time, and a subject 
effect (models variability due to differences in average response of each subject). 
In this study we assessed the significance of group, time, and group by time interaction 
effects. Permutation methods for peak-cluster level error correction (AlphaSim, 
http://afni.nimh.nih.gov/afni/) were applied for this whole-brain analysis by taking into account 
the significance of the peak voxel (p-value<0.005), thereby controlling for multiple comparisons 
(returning a minimum of 195 voxels). If the F-test was significant, we extracted the mean of each 
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significant cluster (as well as 99% confidence intervals, CI) and plotted that across the five time 
points for each group to examine trends within these significant clusters.  
To show regional changes in connectivity, we performed four change score analyses for 
each of the significant interactions. We subtracted baseline connectivity from placebo, day one, 
week one, and end connectivity and performed a regression with two coefficients: a constant, and 
a grouping variable. Parameter estimate means (tests whether there is a significant difference in 
group) and 99%CI were extracted for each significant ROI and plotted.  
6.4 RESULTS 
Table 1 shows the clinical and demographic characteristics by group (remitters [N=20 (16F)] and 
non-remitters [N=13 (7F)]). We found no significant differences in any of the demographic or 
clinical measures (in the table) except for follow-up MADRS. We found no differences in white-
matter hyperintensity (WMH) burden by group either at baseline or follow-up (see supplement 
for information on WMH segmentation/quantification(Wu et al, 2006)). The average venlafaxine 
dose (mean, 99%CI) in non-remitters was 263mg (227.3, 298.7), which was significantly greater 
(as expected; see supplement for titration information) than in remitters, which was 181.3mg 
(153.9, 208.7). There were no significant group/time or interaction effects in duration of 
depression and anxiety as measured by a single item in MADRS (see supplement).  
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Table 1. Clinical/demographic differences between groups. As designed, MADRS at end of trial 
differed between remitters and non-remitters. If the number of subjects is fewer in the analysis 
then the total, it is listed in parentheses. NOTE: MDE-Major Depressive Episode, CIRSG-
Cumulative Illness Rating Scale for Geriatrics, MMSE-Mini-Mental State Examination, 
MADRS-Montgomery-Asberg Depression Rating Scale, WMH-White Matter Hyperintensity 
Non-Remitters 
(N = 13) 
Remitters 
(N = 20) Group Comparison (X/W,p) 
Age (median, IQR) 65,6 66, 11 W = 126.5, p = 0.906 
Gender (F) 7 16 Fisher’s exact p= 0.139 
Education (median, IQR) 15, 4 14, 5.25 W = 130.5, p = 0.992 
Age at first MDE (median, IQR) 29, 15.25 (N=12) 29.5, 33.50 (N=18) W = 109, p = 0.975 
CIRSG Heart (0/1/2/3) 9/2/1/1 14/2/0/4 Fisher's exact p= 0.518 
CIRSG Vascular (0/1/2) 4/0/9 4/1/15 Fisher's exact p= 0.810 
MMSE Baseline (median, IQR) 29, 1 30, 2 W = 101, p = 0.273 
MADRS Baseline (median, IQR) 26, 9 22, 8.75 W = 181.5, p = 0.058 
MADRS End (median, IQR) 19.5, 10.5 (N = 12) 
3, 5.5 
(N = 19) W = 211, p < 0.05 ** 
WMH Baseline (median, IQR) 0.0008, 0.0006 0.0011, 0.0015 W = 133, p = 0.9277 
WMH End (median, IQR) 0.0011, 0.0012 (N = 12) 
0.0013, 0.0017 
(N = 19) W = 100, p = 0.589 
Only the ECN and DMN had significant group-by-time interaction effects. ASN and 
EVC had only significant group effects (remitters vs. non-remitters). All neuroimaging results 
are summarized in table 2. These results are robust to Benzodiazepine use and baseline MADRS. 
We demonstrate the associations of connectivity and features of clinical response and 
medication. There were group differences independent of time (excluding areas with significant 
interactions) in DMN and ECN connectivity.  
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Table 2. Resting state results summary table. X, Y, Z are the locations in MNI space. F is the 
maximum F-statistic within the cluster. Voxels is the size of the cluster. NS refers to Non-
Significant results. If the Group x Time interaction is significant, then the main effects cannot be 
interpreted by themselves regardless of their significance. Since an interaction term is present 
(reaching statistical significance) that means that the relationship between the outcome variable 
and time is not the same for both groups. NOTE: ECN-Executive Control Network, DMN-
Default Mode Network, ASN-Anterior Salience Network, EVC-EigenVector Centrality, NS-Not 
significant, NA-Not Applicable, BA-Brodmann Area 
Network GroupxTime Interactions Time Group X Y Z F Voxels 
ECN Right Precentral/ Postcentral  NA NA 63 0 12 16.5 251 
Right Middle 
Temporal/Occipital NA NA 48 -80 24 16.3 246 
DMN Right Inferior/Middle Frontal  NA NA 44 24 18 16.3 670 
Left inferior/middle 
temporal gyrus/fusiform NA NA -52 -62 -10 19.8 392 
Right inferior/middle 
temporal gyrus/fusiform NA NA 48 -36 -16 22 1407 
Right Supramarginal  NA NA 60 -58 36 22.3 297 
ASN NS NS Left Inferior Frontal Gyrus -38 6 24 15.9 240 
NS NS Left Middle Frontal Gyrus -32 54 20 12.6 240 
EVC NS NS Left Inferior Frontal Gyrus -56 6 28 13.2 221 
NS NS Right Inferior Frontal Gyrus 52 34 -12 16.1 203 
NS NS Medial Frontal Gyrus/BA 10 2 64 -8 15.5 713 
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6.4.1 Executive Control Network (ECN) 
The regions with a significant group-by-time interaction (after multiple comparison correction) 
were the right precentral/postcentral gyrii (PCG) and the right middle temporal/occipital gyrii 
(rMTG/MOG), p<0.05 (corrected), see table 2 and figure 2A. The 99%CIs suggest no 
differences between remitters/non-remitters (figure 2A). The change score analysis (figure 2C, 
left) illustrates, relative to baseline, a larger change in connectivity following treatment than 
placebo. Across time rPCG increased in connectivity while rMTG/MOG decreased.   
6.4.2 Default Mode Network (DMN) 
Four clusters had significant interactions, they were the right inferior/middle frontal gyrus 
(rIFG/MFG), bilateral inferior/middle temporal gyrus/fusiform gyrii (bITG/MTG), and right 
supramarginal gyrus (rSMG), p<0.05 (corrected), see table 2 and figure 2B. Much like the ECN, 
the 99%CI suggests no differences between remitters and non-remitters at any time point. The 
99%CI suggests that, relative to baseline, there is a larger change in connectivity following 
treatment than placebo (figure 2C, right). Across time bITG/MTG increased in connectivity 
while rIFG and rSMG decreased in connectivity in remitters.   
6.4.3 Anterior Salience Network (ASN) 
After applying the multiple comparison correction, no regions had significant group-by-time 
interaction effects. We then ran a model without the interaction effect and tested whether there 
were significant group and time effects. There was no significant time effect, but there were 
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significant group effects in the left inferior frontal gyrus (lIFG) and left middle frontal gyrus 
(lMFG), p<0.05 (corrected), table 2 and figure 3A.Non-remitters had greater ASN connectivity 
in both regions.  
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Figure 2. Connectivity changes where the interaction (group x time) was significant. (A) ECN 
connectivity changes that were significant. (B) DMN connectivity changes that were significant. 
For parts A and B, Non-remitters are shown in red and remitters are shown in blue. The color bar 
indicates the value of the F-statistic. Error bars represent the 99%CI. (C) Change score analysis 
results. Different regions are shown as different colors. The values represent mean and 99%CI 
for the parameter estimate that tested whether there was a significant difference between 
remitters/non-remitters in the change scores (placebo/day one/week one/end – baseline). Dotted 
line represents beta estimate of zero.  
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6.4.4 Eigen-Vector Centrality (EVC) 
Eigen-vector centrality is a summary measure of the influence of a node (voxel) in a network. No 
interaction between group and time was found for the EVC. However, there was a significant 
effect of group (but not time) in the bilateral inferior frontal gyrus (bIFG) and the medial frontal 
gyrus (MeFG), p<0.05 (corrected), table 2 and figure 3B. Non-remitters had greater EVC in the 
bIFG but lower EVC in the MeFG compared to remitters.  
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Figure 3. Group differences in connectivity. Analyses where the interaction (group x time) was 
not significant, but where the group effect alone (not the time effect) was significant. (A) 
Regions where the ASN connectivity differed between remitters (blue) and non-remitters (red).  
(B) Regions where the EVC measure differed between groups. The color bar indicates the value
of the F-statistic. Error bars represent the 99%CI. 
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6.5 DISCUSSION 
This is the first study reporting early dynamic fMRI markers of treatment response variability in 
LLD. We evaluated changes in three functional networks and in EVC at five time-points. Two 
networks (ECN and DMN) showed significant group-by-time effects (increased ECN-rPCG and 
DMN-bMTG/ITG as well as decreased ECN-rMTG and DMN-rIFG and rSMG in remitters 
across the trial compared to non-remitters). Only significant group (but not time) effects were 
found in the ASN (left IFG and MFG greater in non-remitters compared to remitters) and EVC 
(MeFG greater in remitters compared to non-remitters but lower in the bIFG).  
 Previous LLD research suggests patients, compared with controls, have a hyperactive 
DMN and a hypoactive ECN (Aizenstein et al, 2014; Alexopoulos et al, 2012; Andreescu et al, 
2013). These may reflect clinical features of LLD such as increased rumination (hyperactive 
DMN) and cognitive impairment indicating low cognitive control of limbic regions associated 
with emotional response (hypoactive ECN). A meta-analysis in mid-life depression found that 
DMN connectivity was predictive of treatment response (Nejad et al, 2013; Pizzagalli, 2011). 
Another study found that DMN connectivity was positively associated with treatment response 
while dlPFC connectivity was negatively correlated (Aizenstein et al, 2014). Other studies have 
found a normalization of task-based response following successful treatment (Aizenstein et al, 
2014). Our novel findings demonstrate, for the first time, that these effects are seen early 
following treatment, and appeared larger in magnitude than placebo. 
 In remitters we observed increased ECN-rPCG connectivity and decreased ECN- rMTG 
connectivity relative to non-remitters. While there is an effect of placebo, there appears to be an 
even greater effect following administration and continued treatment with venlafaxine. This 
suggests that the change in connectivity is related to the administration of venlafaxine and not to 
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placebo.  ECN-rPCG increases in remitters may reflect an improvement in cognitive control as a 
predictor of successful treatment. ECN-rMTG decreases did not show a large change following 
first exposure (day one) to venlafaxine; rather this change is seen at week one. ECN-MTG 
(outside the ECN) connectivity changes may indicate increased and dispersed effort in the non-
remitters.  
 In remitters we observed decreased DMN-rSMG and rIFG connectivity and an increase 
DMN-rMTG/lITG/MTG and left fusiform gyrii connectivity relative to non-remitters. Like the 
ECN, the magnitude of the connectivity change appeared to be greater following treatment than 
following placebo. Decreased DMN-rSMG/rIFG connectivity may reflect an improvement in 
future ruminative thought processes in remitters, as suggested previously (Aizenstein et al, 2014; 
Alexopoulos et al, 2012). Increased DMN-rMTG/lMTG connectivity suggests that clinical 
correlates of neural changes (rumination–hyperactive DMN) are actually related to connectivity 
changes between specific nodes (PCC-prefrontal cortex). Thus, we may witness a “rebalance” of 
the DMN in remitters, with a decrease in the “damaged” PCC-prefrontal connectivity and an 
increase in the connectivity between the other nodes. 
 Of note, the supramarginal gyrus has been involved (together with other sensory 
processing/associative brain regions, such as the fusiform gyrus), in the disrupted DMN 
connectivity in mid-life depression (Chen et al, 2015; Peng et al, 2015). This may reflect 
disruptions in social interaction processes such as empathy (Shamay-Tsoory, 2011) and social 
engagement (Li et al, 2014), which may ameliorate with improvement in depression symptoms. 
With regard to changes in PCC-IFG connectivity, we may speculate that given the recent reports 
regarding the role of right IFG in cognitive control but also in emotional appraisal and 
alexithymia and verbalization of emotional responses/states (Khalaf et al, 2016), we may infer 
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IFG, as a key region in the emotion-cognition interplay (Okon-Singer et al, 2015) becomes less 
involved during resting state, once depressive symptoms remits. 
 Alternatively, these results could be interpreted as increased intra-network coupling 
(increased ECN-rPCG and DMN-bMTG/ITG) and decreased inter-network coupling (decreased 
ECN-rMTG and DMN-rIFG and rSMG). In healthy individuals, ECN and DMN have inverse 
activations during tasks and this is disrupted in depression (Chen et al, 2013; Menon et al, 2010; 
Sridharan et al, 2008). This may reflect an important rebalancing of this association in remitters. 
These temporal regions are not nodes of the dorsal but rather ventral DMN and rSMG is part of 
the right ECN.  
 Recent evidence that shows that changes in DMN/ECN connectivity as well as other 
functional brain activation can be achieved through meditation, trans-cranial magnetic 
stimulation (TMS), cognitive behavioral therapy, and psychotherapy (Brewer et al, 2011; Farb et 
al, 2012; Goldapple et al, 2004; Jang et al, 2011; Linden, 2006; Liston et al, 2014). These 
different therapies target different symptoms of depression and by targeting affected symptoms 
(e.g., high rumination) then it might be possible to achieve these changes through alternative 
means.  
 The early interaction may reflect a network engagement due to the increase in synaptic 
serotonin that seems to be consistently engaged (relative to the end scan). Thus, it seems that the 
network changes occur at a much earlier stage and these may be correlated with future changes 
in depression severity, rumination, and cognitive control (though we do not demonstrate that 
here).  
 ASN-left IFG and MFG connectivity was higher in non-remitters than remitters. Previous 
studies reported higher ASN connectivity in LLD participants compared with non-depressed 
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elderly (Aizenstein et al, 2014), a possible marker of increased anxiety and somatization 
(Andreescu et al, 2015). Given the lack of time differences, this may represent a trait, rather than 
a state marker in LLD.  
 Using EVC (measures node importance), we found only group effects where EVC was 
higher in remitters than non-remitters in the MeFG, but lower in the bIFG. These findings 
suggest a potential neurobiological profile indicating positive response to treatment. Thus, 
participants who start with high connectivity in the DMN (and increased EVC in the MeFG) are 
more likely to respond to treatment. This will require further empirical testing.  
 Several limitations should be noted. This study had a relatively small sample size, 
unequal group sizes, and tested treatment response using only one medication. This result may 
not generalize well to other patient groups, including mid-life depression. Our definition of 
remitter, while established, has important limitations especially in borderline cases. A well-
known observation in LLD is that white-matter hyperintensity burden differs between remitters 
and non-remitters (Taylor et al, 2013), which we failed to replicate, possibly due to the clinical 
and neurobiological heterogeneity of LLD (Taylor et al, 2013). This study utilized ROI based 
connectivity whereas others have utilized data-driven approaches. Importantly, there is a strong 
correspondence between the two methods (Rosazza et al, 2012). We limited our analyses to three 
ROI’s that represented core nodes of the default mode, executive control, and salience networks-
however each of these networks has multiple nodes that we did not explore. All participants had 
similar dosages of venlafaxine at all measurements except the final, where non-remitters had 
significantly greater mean dose than remitters. This was not controlled for in this analysis, and 
may account for some differences at the final time-point between remitters/non-remitters. 
Importantly, the dosage was equivalent over the course of the early changes (early interactions). 
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While there exists a literature that associates DMN/ECN connectivity with rumination/cognitive 
control measures, we did not specifically test this, and so future studies should perform these 
direct associations to validate these interpretations.  
 These group differences in trajectory of treatment may be important in predicting changes 
in depression symptoms, however group differences do not necessarily give the ability to 
distinguish individual subjects.  
 Despite these limitations, we validate previous findings of pre- and post- treatment 
effects. Further, we found that there were early changes in the DMN and ECN, but not ASN 
during the treatment trial and that the treatment was associated with greater magnitude of change 
than placebo. Future studies should test if an inter-network interaction between ECN and DMN 
exists, and investigate other nodes of each of these networks, as well as investigate the structural 
changes that may occur during the entire treatment trial. 
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7.0 FUNCTIONAL BRAIN ACTIVATION DURING EMOTION REACTIVITY 
FOLLOWING PHARMACOTHERAPY IN LATE-LIFE DEPRESSION: MARKERS OF 
REMISSION 
This chapter reports unpublished results using the full cohort of the same study described earlier. 
This chapter is intended to fulfill the second half of Aim 1 to characterize the changes in emotion 
reactivity in the brain following pharmacotherapy in remitters/non-remitters to depression, 
whether any acute changes (e.g., following a single dose) occur. To better understand the results 
in this chapter, we also investigated how these results related to other neuroimaging data 
collected in the same sample (structural and functional changes).  
7.1 ABSTRACT 
Major depressive disorder has a second peak of incidence in late-life (LLD), which is associated 
with an additional host of negative health outcomes. Despite the vast number of studies on 
depression, there is currently no accepted biomarker for the diagnosis, prevention, or treatment 
of depression. Neuroimaging data has shown that there exist small changes in functional 
activation/connectivity following acute pharmacotherapy, which may be associated with eventual 
response. We investigated changes in functional activation during an emotion reactivity task 
following acute pharmacotherapy as well as over the entire course of a treatment trial. We 
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recruited LLD (N=51) participants into a treatment trial and collected functional magnetic 
resonance imaging (fMRI) data at five time points: baseline, following a placebo lead-in, 
following a single dose of venlafaxine, following a week of pharmacotherapy, and the end of the 
trial (12 weeks). We found that there existed baseline differences in activation, but more 
importantly that there existed acute increases following only a single dose in the left insula in 
remitters while non-remitters showed only decreases in activation. Further, we found that the 
parahippocampus increased in activation following a single dose in remitters, but decreased in 
non-remitters and this pattern persisted through the entire trial. We found similar changes during 
an explicit emotion regulation task – thus these changes may reflect an early change in implicit 
processing and regulation during the emotion reactivity task, but a chronic change in explicit 
regulation. Emotion regulation may represent a mechanism for remission in LLD.  
7.2 INTRODUCTION 
Major depressive disorder (MDD) is a leading cause of disability and global disease burden 
(Alexopoulos et al, 2009; Moussavi et al, 2007). Depression has a second peak of incidence in 
late-life, which carries additional risk of suicide, medical comorbidity, disability, and caregiver 
burden (Katon et al, 2010; Mulsant et al, 2006; Nelson et al, 2013). Despite significant 
improvements in our understanding of course, prognosis, and the neurobiology of depression, 
new biomarkers and treatment developments have lagged. There are currently no widely 
accepted neural or genetic biomarkers to aid in the diagnosis, treatment, or its long-term 
management. This likely reflects the notable heterogeneity underlying both depression 
pathophysiology and remission mechanisms. Currently, clinicians match patients with specific 
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treatments through a prolonged trial and error process that delays improvement, and significantly 
increases the overall burden of illness. This delay is even longer in late-life depression (LLD) 
and is further associated with a host of negative health outcomes, including higher risk of 
suicide, cardiovascular disease and cognitive deterioration (Andreescu et al, 2011). Previous 
work using functional magnetic resonance imaging (fMRI) has identified some possible 
biomarkers that act as predictors of treatment response. To better understand this process, 
researchers have investigated different neural circuitry related to MDD.  
7.2.1 MDD: Disruption of Emotional Face Processing 
Some of the core neural changes in depression are associated with the emotion-reactivity and 
regulation neural circuitry. Low mood and high anxiety have been consistently associated with 
emotion dysregulation. The processing of emotional faces in MDD has been often used to 
explore different aspects of emotion dysregulation. This general process involves three major 
stages, each subserved by fairly distinct neural structures: visual processing [primary (visual area 
1/2) and secondary (fusiform, superior temporal gyrus)], emotion encoding and recognition 
[amygdala, insula] and response/appraisal [insula, orbitofrontal cortex, ventral striatum] as well 
as integration [insula and anterior cingulate], and finally monitoring affective state and emotion 
regulation [anterior cingulate, dorsomedial prefrontal cortex, dorsolateral prefrontal cortex] 
(Leppanen, 2006).  
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7.2.2 High Emotion Reactivity 
Previous studies have identified changes in emotional face processing in MDD, including a bias 
towards negative stimuli in the initial appraisal stage. However, a meta-analysis that included 44 
studies (with a total of 795 MDD and 792 never-depressed individuals) revealed hyperactivation 
beyond the amygdala and the insula, in regions like the parahippocampus, putamen, insula, and 
fusiform gyrus, while the dorsolateral prefrontal cortex has been consistently hypoactive 
(Groenewold et al, 2013).  
Each of these regions may have a distinct role in further amplifying the neural 
dysfunction. The amygdala’s role is to direct attention at emotional information, facilitate 
emotional memory, and generate responses to emotionally salient information. The fusiform’s 
early role in the visual processing stream and its hyperactivation indicates that the negative bias 
may be encoded semi-automatically (i.e. biased visual-limbic feedback loop). Anterior cingulate 
and anterior insula may be involved in working alongside the amygdala to generate the 
relationship between external/internal stimuli and the self, where the anterior cingulate 
specifically is part of the dorsal default mode network which is involved in the ruminative aspect 
in MDD. Generally, they could be involved in the attendance to negative stimuli (as opposed to 
neutral stimuli). Insula lesions following stroke have been shown to be consistently associated 
with post-stroke depression implicating them even further (Sprengelmeyer et al, 2011). The 
putamen, however, may be related to the automaticity of the learned emotional response to the 
visual stimuli. Parahippocampus may be involved in the contextual information related to the 
stimuli as past studies have identified that the amygdala’s activation can be modulated by 
presenting contextual information alongside an emotional face (e.g. decreased activation 
achieved by presenting an angry face with the sentence “they just had a bad day and are not upset 
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at you”) (Bar and Aminoff, 2003; Groenewold et al, 2013). This may be also be related to 
inaccurately contextualizing non-salient information (e.g. picture of an angry face in the MR 
scanning environment).  
7.2.3 Impaired Emotion Regulation 
Another aspect that is disrupted in MDD is the monitoring and regulation of the emotional 
response, a feature associated with changes in the insula, anterior cingulate and dorsolateral 
prefrontal cortex activation. These changes are implicated in the inability to detect and then 
down-regulate the amygdala’s response. Emotion regulation is thought to have two basic forms 
(though there is no clear boundary): explicit (or effortful) and implicit (or automatic) regulation 
(Etkin et al, 2015; Gyurak et al, 2011). Regulation is a goal-directed process that influences the 
intensity, duration, or type of experienced emotion and this can be done with conscious effort or 
without monitoring, insight, and awareness (Etkin et al, 2015). Explicit regulation involves the 
activation of dorso-/ventro-lateral prefrontal cortex as well as supramarginal gyrus, insula, 
supplemental motor, and pre-supplemental motor areas (Etkin et al, 2015). While behaviorally, it 
has been shown that MDD individuals are able to explicitly regulate their emotional response 
(i.e. feeling less negative after regulation); there is a clear difference in the neural response. 
Mainly, while both groups have decreased amygdala activation following regulation – the level 
of dorsolateral prefrontal cortex activation is severely reduced in MDD (Erk et al, 2010). 
Critically, amygdala down-regulation was associated with lower depression severity (i.e. severity 
of depression influences the intensity of the down-regulation in amygdala activation, which may 
be due to greater emotional reactivity or decreased cognitive regulation) (Erk et al, 2010). This 
may reflect this notion that individuals with MDD are still able to explicitly regulate.  
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More recently, implicit emotion regulation has been implicated in MDD. Even without 
instructing someone to explicitly and actively regulate emotions – there is an automatic 
underlying process that occurs with the presentation of any new stimuli (Gyurak et al, 2011). 
Several studies have shown that when presenting a Stroop like emotional face viewing paradigm 
(e.g. matching expressions when an angry face with either the word “angry” or “happy” 
presented simultaneously) showed that there is increased ventral anterior cingulate and 
dorsolateral prefrontal cortex activity and lower amygdala activation on incongruently presented 
faces (e.g. angry face with the word “happy” written over it) – suggesting an implicit regulation 
of emotional responses (Etkin et al, 2006; Etkin et al, 2010). To further strengthen this, when 
matching genders of neutral faces (with conflicting gender text written over the face) – there is 
an increase in dorsolateral prefrontal cortex activation coupled with fusiform activation, but no 
change in ventral anterior cingulate or amygdala (Egner et al, 2008). This suggests a dissociable 
neural pathway for implicit emotion regulation. 
Habitual emotion regulation is a form of implicit regulation that is performed daily and 
involves regulating small aspects of daily life (Gyurak et al, 2011). This has been demonstrated 
in studies that found that individuals with higher reappraisal tendencies (ability to reimagine a 
scenario in a more positive way) were able to better regulate negative emotions during anger 
provocation (Mauss et al, 2007). The ventral anterior cingulate has also been implicated in 
implicit regulation – however the anterior insula is thought to play a major role. Previous studies 
have found that during a task where participants are presented with fair or unfair offers the 
insula’s activation is associated with the degree to which individuals apply reappraisal strategies 
daily (Gross and John, 2003). This type of regulation is likely to be associated with greater 
affect, better interpersonal and social functioning, and overall better well-being (Gyurak et al, 
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2011). This is a possible mechanism through which individuals with MDD are impaired and a 
possible mechanism of remission in MDD. 
7.2.4 Functional Changes Following Treatment 
Past studies have shown that a variety of regions are normalized during emotional face 
processing following successful remission. Following successful remission, there is reduced 
activation of the amygdala (normalization) (Arce et al, 2008; Bigos et al, 2008; Godlewska et al, 
2012). Elevated baseline anterior cingulate activity has been associated with greater response to 
antidepressant medications (Davidson et al, 2003; Wang et al, 2012). One study showed an 
increase in activation of the middle frontal gyrus following fluoxetine treatment (Wang et al, 
2012). Another study showed that there was an increased insula activation following treatment 
with venlafaxine during a negative image viewing task and further replicated the anterior 
cingulate finding at baseline (Davidson et al, 2003). They showed that the change in insula 
activation occurred after only two weeks of treatment and sustained the activation – however the 
anterior cingulate changes occurred at a later stage (8 weeks) (Davidson et al, 2003). Another 
study showed normalization of amygdala reactivity following escitalopram treatment after only 7 
days (Godlewska et al, 2012).  
In this study we sought to investigate whether this change could be detected as early as 
following a single dose of medication. Positron emission tomography has shown that there is an 
increase in monoaminergic occupancy in the brain following a single dose of selective serotonin 
reuptake inhibitors (SSRI) (Meyer et al, 2001; Parsey et al, 2006). Several studies have indicated 
the early functional changes occurring following acute drug administration, including our recent 
work that showed single dose connectivity changes at rest following a single dose of venlafaxine 
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(Karim et al, 2016a). This study indicated a possible early engagement effect that is either 
sustained or diluted. In a previous study in never-depressed individuals using a double blind 
balanced crossover design, single dose or acute administration of citalopram (following a 30 
minute injection) compared to saline resulted in increased activation of the amygdala during 
emotional face viewing (Bigos et al, 2008). While studies investigating the more chronic effects 
in never-depressed individuals showed a clear decrease in activation in the amygdala and insula, 
this may reflect an early engagement effect that is down regulated chronically. 
We investigated early effects of venlafaxine in LLD as well as long-term changes in 
remitters (N=26) and non-remitters (N=25) to depression. We used an emotional face-viewing 
paradigm, and investigated activation differences at baseline (between remitters and non-
remitters), the early changes following a single dose as well as after just a week of treatment, and 
then at the end of the trial. The face/shapes task is an emotion reactivity task, which likely has an 
implicit regulation component that involves regulating to some degree the negative faces 
presented. We investigated activation differences between remitters and non-remitters at five 
time-points: at baseline, following a placebo lead-in, following a single dose of venlafaxine, after 
a week of treatment, and at the end of the trial. We hypothesize that the depression-specific 
changes in activation during emotion reactivity have correspondence in changes associated with 
emotion regulation as well as with regional structural and CBF changes in the same regions 
involved in emotional face processing.  
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7.3 METHODS 
7.3.1 Study Design and Participants 
We collected data as part of a larger 5-year multi-site study of treatment in LLD that collected 
neuroimaging data at one site (Pittsburgh, USA). Participants were recruited and were given 
Venlafaxine due to its dual mechanism of action (at high doses it is both a serotonin and 
norepinephrine reuptake inhibitor). Participants were included if they were at least 55 years old, 
met Diagnostic and Statistical Manual of Mental Disorders IV criteria for MDD and had a 
Montgomery-Asberg depression rating scale (MADRS) score of 15 or higher at baseline. 
Participants were excluded if they had a history of mania or psychosis, alcohol or substance 
abuse (within last 3 months), dementia or neurodegenerative disease as well as conditions with 
known effects on mood (e.g. stroke, multiple sclerosis, vasculitis, significant head trauma, and/or 
unstable hypertension). After informed consent approved by the University of Pittsburgh 
institutional review board, five MRI scans during the treatment trial were collected.  
All MRI scanning was conducted in the morning. Participants came in on the first day for 
a baseline scan (no medication). In the evening of that scan they were given a placebo, after 
which they returned the next day for another scan (placebo scan). The evening of that scan, they 
were given their first dose of Venlafaxine (35 mg), after which they returned the next day for 
another scan (single dose scan). They continued their medication for approximately one week 
and returned for another scan (week one scan). They returned a final time after the end of the 
treatment trial (12 weeks, end scan).  
During the trial, participants returned for weekly or bi-weekly clinical visits and the 
Venlafaxine dosage was increased as necessary (up to a maximum of 175 mg). Participants who 
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did not show signs of response by week 6 had venlafaxine increased up to a maximum of 350 
mg. At the end of the study, participants were classified as remitters if they had a MADRS less 
than 10 for at least two weeks during the trial (and remained so until the end of the trial).  
A total of 62 participants signed consent. Eleven were excluded due to: side effects of 
medication (N=2), non-adherence to protocol (N=2), inaccurate diagnosis of MDD (N=1), and 
inability to determine remission status due to lost/missing data (N=6). Among the remaining data 
(N=51), two participants did not complete all MRI scanning but did complete the treatment trial. 
Wherever possible we included the data from these two participants.  
7.3.2 MRI Data Collection 
All scanning was conducted at the University of Pittsburgh Medical Research Center on a 3T 
Siemens Trio TIM scanner (Munich, Germany) on a 12-channel head coil. Baseline and end 
scans collected both a structural and functional image, while other scans collected only 
functional sequences. While this analysis focuses solely on the emotion reactivity task 
(face/shapes), our hypothesis involves understanding the structural as well as other functional 
changes that occur concurrently in those regions. Thus we also describe the collection and 
processing of the following: resting state as well as explicit emotion regulation task (IAPS) 
BOLD sequences, a resting pseudo-continuous arterial spin labeling (pCASL) sequence, and a 
diffusion weighted imaging (DTI) sequence.  
An axial, whole brain 3D magnetization prepared rapid gradient echo (MPRAGE) was 
collected with repetition time (TR)=2300ms, echo time (TE)=3.43ms, flip angle (FA)=9 degrees, 
inversion time (TI)=900ms, field of view (FOV)=256x224, 176 slices, 1mm isotropic resolution 
and with GeneRalized Autocalibrating Partial Parallel Acquisition (GRAPPA) factor=2. An 
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axial, whole brain 2D fluid attenuated inversion recovery (FLAIR) was collected with 
TR=9160ms, TE=90ms, FA=150 degrees, TI=2500ms, FOV=256x212, 48 slices, and 1x1x3 mm 
resolution.  
An axial, whole brain (excluding cerebellum) echo planar (EPI) T2*-weighted functional 
image was collected to measure the blood oxygen level dependent (BOLD) response with 
TR=2000ms, TE=34ms, FA=90 degrees, FOV=128x128, 28 slices, 2x2x4 mm resolution. The 
face/shapes task had 117 volumes, the explicit emotion regulation task had 270 volumes, and the 
resting state had 150 volumes. Due to variability in placement by MR technicians the coverage 
of the functional scan was in general limited to above the cerebellum and below the top aspect of 
the motor cortex (though this varied slightly between functional sequences).  
An axial, whole brain (excluding cerebellum) pCASL sequence was collected at rest to 
measure perfusion in the brain with TR=4ms, TE=13ms, FA=90degrees, FOV=64x64, 32 slice, 
4mm isotropic resolution, and 80 volumes. Finally an axial, whole brain DTI sequence was 
collected with TR=5300ms, TE=88ms, FA=90degrees, FOV=128x128, 40 slices, 2x2x3mm 
resolution, 12 directions, and 4 b0 images.  
7.3.3 Functional Tasks 
Emotion Reactivity (Faces-Shapes Task) 
This task is widely used and has been tested to robustly activate the amygdala (Hariri et al, 
2002). Participants were instructed to match either a face cue or a shapes cue. A cue was shown 
on the center of the screen and they were instructed to respond with an MR-compatible glove 
(left or right index finger) by matching to one of two simultaneously presented faces. The facial 
expressions shown were either angry or fearful. During the shapes, they match a shape to one of 
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two simultaneously presented shapes. The shapes task (5 blocks) was interleaved with the faces 
task (4 blocks) and each block lasted 24 seconds containing 6 trials (4 seconds each). Before the 
beginning of each block participants are instructed visually to “match emotion” or “match form” 
(2 seconds). The faces images are presented from a set 12 different images (six per block, three 
of each gender) and are all derived from a standard set of pictures of facial affect. Stimulus 
presentation and responses were controlled using E-prime software (Psychology Software Tools, 
Inc., Pittsburgh).  
 
Explicit Emotion Regulation Task (IAPS) 
The main results of this task have been previously published in a smaller subset. Participants 
were shown emotionally neutral or negative images from the standardized International 
Affective Picture System (IAPS) and were instructed to either “Look” or “Decrease.” During the 
look instruction, participants were to view content naturally. During the decrease instruction, 
participants were instructed to reappraise the image to actively alter the elicited emotion. After 
each image they were asked to rate how negatively they felt from 1 to 5. The neutral (11 events), 
negative (15 events), negative regulate (15 events) conditions were interleaved and each event 
lasted 6 seconds. The images are presented from a set of images and stimulus presentation and 
responses were controlled using E-prime software (Psychology Software Tools, Inc., Pittsburgh). 
A master level instructor instructed participants on how to reappraise prior to entering the 
scanner.  
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Instructions for Resting State during pCASL and BOLD  
The following data was used to further understand the changes occurring during the emotional 
reactivity task. The results of these data have been previously published in a smaller subset. 
During resting state perfusion and BOLD, participants were instructed to lie awake in the 
scanner while viewing a white cross hair.  
7.3.4 Structural Processing 
All processing was conducted using statistical parametric mapping (SPM12) (Penny et al, 2011). 
Interpolation was conducted using 4th degree B-spline interpolation, normalized mutual 
information similarity metric for coregistration between images of different types, and mutual 
information similarity metric for motion correction unless otherwise stated. The FLAIR was 
coregistered to the MPRAGE (affine transform). Both images were input into a multi-spectral 
segmentation, which (after bias correction) segmented them into gray, white matter, 
cerebrospinal fluid, air, soft-tissue, and air. Due to high white matter hyperintensity burden the 
number of Gaussians used to identify white matter was two (which improved the segmentation) 
(Karim et al, 2016c). This process generates a deformation field that can be used to normalize 
other images to a standard anatomic space (Montreal Neurological Institute, MNI). An automatic 
mask for the intracranial volume was generated by thresholding the intracranial tissues with a 
probability of 0.1, filling the mask (imfill), and then performing a morphological closing 
operation (imclose, sphere of one voxel) in MatLab (MATLAB2016b, The MathWorks Inc., 
Natick, MA, 2000). This mask (intracranial volume, ICV) was applied to the MPRAGE to 
remove non-brain tissues (which improves functional-structural coregistration). The skull-
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stripped MPRAGE was normalized to MNI space. An average of all baseline structural images 
was generated to overlay all functional imaging results.  
To generate gray matter density images, we used DARTEL (Diffeomorphic Anatomical 
Registration using Exponentiated Lie algebra) (Ashburner, 2007). This leveraged the 
longitudinal data by first creating a subject specific template and then a study specific template 
and has been previously described in detail. After segmentation, we created a single template for 
each subject using DARTEL, which improved the coregistration between baseline and end 
structural data within a single subject. Those templates were then used to generate a study 
specific template across subjects. Briefly, this method iteratively creates averaged templates that 
slightly improve the coregistration process. This is thought to be important when calculating gray 
matter density maps especially in late-life studies that have greater gray/white matter 
deformations. The Jacobian of the transformations is multiplied by the final probability to 
generate a gray matter density image (instead of a probability). This is because the warping of 
tissue increases or decreases the actual density and needs to be adjusted for (e.g. thin cortical 
regions that are expanded to a larger template will have lower density as the gray matter was 
stretched) (Ashburner, 2007). The gray matter density images were smoothed using a Gaussian 
kernel of full-width at half-maximum (FWHM) of 6mm. The mean gray matter density was 
extracted from regions that we found in voxel-wise analyses of the face/shapes task– no voxel-
wise analyses of this data was conducted. This was used to demonstrate structural differences 
between groups in certain regions. 
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7.3.5 BOLD Pre-Processing 
The IAPS task and the resting state data were slice time corrected (temporally middle slice was 
used as reference) prior to performing motion correction. All functional BOLD data was motion 
corrected (rigid coregistration to the mean), coregistered to the skull-stripped MPRAGE (mean 
functional image used to calculate affine transformation), normalized to MNI space using the 
deformation field calculated previously (2mm isotropic resolution), and smoothed using a 
Gaussian kernel with FWHM of 8mm. All images were investigated by human eye to confirm 
that coregistration and normalization steps were accurate. Functional data from the first four 
scans utilized the baseline MPRAGE, while the end scan utilized its MPRAGE.  
Motion was evaluated using ArtRepair toolbox (Mazaika et al, 2007). During the 
emotional faces reactivity task, participants had low maximum translations [mean=1.26mm 
(std=1.21)], low root mean squared (RMS) [1.11mm (0.81)], and low percentage of volumes 
displaying head jerks above 0.5mm [6.2% (10.7%)]. During the resting state, participants had 
low maximum translations [1.27mm (1.26)], low root mean squared (RMS) [1.04mm (0.85)], 
and slightly higher percentage of volumes displaying head jerks above 0.5mm [10.9% (19.9%)] 
that were corrected for using wavelet-despiking in later stages. During the explicit emotion 
regulation task, participants had low maximum translations [1.87mm (1.91)], low root mean 
squared (RMS) [1.40mm (1.08)], and low percentage of volumes displaying head jerks above 
0.5mm [9.4% (30.8%)], except for a few particularly bad cases that were removed. 
For resting state BOLD, spike artifacts were removed using a previously established 
method that uses wavelets to filter spike artifacts (Patel et al, 2014). Five principal components 
of white matter and cerebrospinal fluid were extracted as well as 6 motion parameters and a 
vector to model the mean of the time series. Band-pass filtering was conducted by including 
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several regressors that represented cosines with all discrete frequencies except those within the 
standard expected resting state frequencies (0.008 to 0.15 Hz).  
7.3.6 Modeling Task Activation: Face/Shapes and IAPS 
Mass-univariate general linear modeling (i.e. each voxel is independently modeled) was 
performed to model the mean of each signal, faces task, shapes task, and six parameters of 
motion (from motion correction). The canonical hemodynamic response function was used to 
convolve the faces and shapes tasks to expected hemodynamic responses. A high-pass filter of 
1/128 Hz was utilized to account for low frequency noise. An autoregressive [AR(1)] filter was 
used to account for serial correlations due to aliased biorhythms and unmodelled activation. The 
contrast faces minus shapes was used to perform all voxel-wise group level analyses (i.e. regions 
that are active during faces relative to shapes and vice versa). Our voxel-wise analyses utilized 
only data from this contrast.  
Similarly, the IAPS task included similar parameters however it modeled the activation 
during the neutral and negative viewing tasks as well as the reappraisal task (during viewing of 
some negative images). The contrast of interest was negative reappraise minus negative viewing, 
which modeled the activation during reappraisal adjusting for activation during the negative 
viewing task. The activation of specific regions during explicit emotion regulation were 
extracted from regions that we found in voxel-wise analyses of the face/shapes task– no voxel-
wise analyses of this contrast was conducted. This was used to show how activation during 
explicit emotion regulation changed across the treatment trial. 
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7.3.7 Resting State BOLD: Eigenvector Centrality (EVC) 
Eigenvector centrality was calculated using the fastECM toolbox (Lohmann et al, 2010). Briefly, 
centrality is a measure of connectedness of a voxel or region. FastECM uses singular value 
decomposition to circumvent the calculation of large correlation matrices. The centrality at rest 
was extracted from regions that we found in voxel-wise analyses of the face/shapes task– no 
voxel-wise analyses of this data was conducted. This was used to show how centrality changed 
across the treatment trial. 
7.3.8 Pre-processing pCASL and Perfusion Calculation 
After performing motion correction and spatial smoothing of the pCASL data, we coregistered 
the skull-stripped MPRAGE to the mean ASL image and applied the transformation to the ICV 
mask and white matter segmentation. White matter segmentation was used to calculate the M0 
magnetization in the white matter while the ICV allowed for calculation only within the brain. 
The following parameters were used to calculate perfusion using ASL toolbox (Wang et al, 
2008b): label time = 1.1, delay time = 3.6x10-4, slice time = 37.25, and labeling efficiency = 
0.85. The mean perfusion image was calculated across the entire time series for each voxel then 
coregistered to the skull-stripped MPRAGE and normalized to MNI space using the standard 
deformation field (4 mm isotropic resolution). The perfusion at rest was extracted from regions 
that we found in voxel-wise analyses of the face/shapes task– no voxel-wise analyses of this data 
was conducted. This was used to show how perfusion changed across the treatment trial. 
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7.3.9 DTI Preprocessing and Mean Diffusivity 
After performing eddy correction via FSL, we coregistered the skull-stripped MPRAGE to the 
first b0 image and applied the transformation to the ICV mask (used to calculate mean diffusivity 
only in the brain). FSL (Jenkinson et al, 2012) was used to calculate mean diffusivity (an inverse 
measure of membrane density) and is calculated by adding the first three eigenvalues and 
dividing by three. The MD image was coregistered to the skull-stripped MPRAGE and 
normalized to MNI space (2 mm isotropic resolution). The mean diffusivity was extracted from 
regions that we found in voxel-wise analyses of the face/shapes task– no voxel-wise analyses of 
this data was conducted. This was used to demonstrate structural differences between groups in 
certain regions.  
7.3.10 Statistical Analysis 
Group differences in demographic and clinical variables were tested using the Statistical Package 
for Social Science (IBM Corp. Released 2013. IBM SPSS Statistics for Mac, Version 24.0. 
Armonk, NY: IBM Corp.). Independent t-tests (continuous data) or Fischer’s exact p-value 
(categorical data) was conducted where appropriate.  
Statistical non-parametric toolbox (SnPM12) was used to perform all voxel-wise 
statistical analyses, which computes non-parametric p-values which are then corrected using a 
cluster-wise inference method (cluster forming threshold of p<0.001) that controls the family 
wise error rate (FWE) at α=0.05 (Nichols and Holmes, 2002).  
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We conducted a one-sample t-test to test for the main effect of the task (areas activated 
more during faces than during shapes independent of group) to show that this task robustly 
activated the amygdala.  
We investigated whether group differences (independent t-test) existed at baseline, 
following a placebo, and at the end of the trial during the face/shapes task. As we sought to 
understand baseline differences in emotional reactivity, in regions that were significantly 
different between groups we extracted baseline gray matter density, mean diffusivity, perfusion, 
EVC, and activation during emotion reappraisal. We then tested (via SPSS) whether there 
existed group differences in any of these regions within each measure and controlled the false 
discovery rate (FDR) at alpha less than 0.05 using the Benjamini-Hochberg procedure.  
We conducted paired t-tests to investigate within group differences between baseline and 
end (as well as following a placebo and end). This reveals total changes across the entire 
treatment trial (i.e. effect of the medication).   
In the next set of analyses, we wanted to investigate whether any acute changes depended 
on group (interaction: independent t-test on the difference). We investigated whether groups 
differed on how activation changed acutely (between placebo and a single dose) as well as sub-
acutely (between placebo and following a week of treatment).  
We subsequently also extracted mean perfusion, EVC, and activation during emotion 
reappraisal in the clusters that showed significant change during the faces-shapes task across the 
entire treatment trial and those that showed early changes during faces-shapes after a single dose 
of anti-depressant. In these analyses, we tested whether there were significant differences 
between baseline and end as well as whether there existed associations between the acute 
changes in the emotional reactivity (face/shapes baseline minus single does) and total changes 
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(baseline minus end) in each of the other measures. We extracted mean diffusivity and gray 
matter density in these regions to test whether the changes were dependent on baseline structural 
measures.  
Functional imaging results were generated using xjview (Cui et al, 2011). Table 2 was 
generated by dividing significant clusters into regions in the automatic anatomic labeling (AAL) 
template (Tzourio-Mazoyer et al, 2002) and Brodmann areas were reported if they overlap with 
at least 30 percent of the cluster. The same principal was used to determine if a network 
[predetermined from an established set of resting state networks (Smith et al, 2009)] label should 
be assigned to that cluster. 
7.4 RESULTS 
7.4.1 Clinical Group Differences 
Remitters had significantly lower baseline depression severity, which we adjusted for in several 
analyses (see table 3). As expected, remitters had even lower depression severity by the end of 
the study as well as lower serum venla/des-venla levels (by design as non-responders had dosage 
increased). We found no differences at baseline between remitters/non-remitters in WMH 
burden.  
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Table 3. Group differences in clinical/demographic features (full sample). NOTE: CIRSG-
Cumulative illness rating scale for geriatrics; MMSE-Mini-mental state examination; MDD-
major depressive disorder; MADRS-Montgomery-Asberg Depression rating scale; WMH-white 
matter hyperintensities. 
 
Non-Remitter (N = 25) Remitter (N = 26) 
t-statistic, p-value 
Mean (Standard Deviation) or Number of Subjects 
Age 65 (6) 67 (7) t(49)=-1.1, p=0.297 
Gender 11 F 7 F p=0.249 
Race 21 CC 22 CC p=1.000 
Education 15 (3) 15 (3) t(49)=1.2, p=0.255 
Depression Type (Single/Recurrent) 10 single [N=24] 8 single [N=24] p=0.565 
CIRSG 9 (5) [N=24] 10 (4) t(48)=-0.7, p=0.494 
MMSE 29 (1) [N=24] 29 (2) t(48)=-0.01, p=0.987 
Serum Venla/Des-Venla End 333.5 (122.9) [N=22] 238.3 (101.4) [N=24] t(42)=2.8, p<0.01* 
MADRS Baseline 27 (5) 23 (8) t(49)=2.2, p<0.05* 
MADRS End 18 (7) 5 (4) t(47)=8.0, p<0.0001** 
WMH 3.04 (1.59) 2.56 (1.42) t(49)=1.2, p=0.256 
 
 
 
7.4.2 Faces-Shapes Task: Robust Activation of Emotional Circuits 
Independent of group, the task significantly activated the bilateral amygdala, visual cortex and 
secondary visual processing areas (including parietal cortex, precuneus, fusiform gyrus), 
hippocampus, parahippocampus, insula, as well as inferior and middle frontal.  
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Table 4. Results of all statistical analyses on emotion reactivity task. The analysis conducted and 
effect tested are reported as well as the significant regions (including hemisphere and 
BA/network, if applicable), number of voxels, the max value of the statistical test, and x, y, and z 
coordinates in MNI space. Regions are labeled with a BA or network if at least 30 percent of that 
cluster overlaps with the structural BA or functional network definitions. 
Analysis Effect Region Side Network BA 
# 
Voxel
s 
Max x, y, z 
In
te
ra
ct
io
n:
  
Ti
m
e 
by
 G
ro
up
 Baseline/Placebo by Group Not Significant 
Placebo/Single Dose by 
Group Parahippocampus L vDMN   191 5.5 -20, -38, -8 
Placebo/Week One by 
Group Not Significant 
Placebo/End by Group Not Significant 
Gr
ou
p 
Di
ffe
re
nc
es
 (I
nd
ep
en
de
nt
 T
-t
es
t)
 a
t B
as
el
in
e,
 P
la
ce
bo
, a
nd
 E
nd
 
Baseline                                  
Non-Remitter > Remitter                       
(Adjusting for Baseline 
Depression Severity) 
Caudate 
L     67 4.3 -18, 22, 0 
R     99 3.9 22, 24, 4 
Cerebellum Declive R   37 105 4.8 28, -56, -20 
Anterior Cingulate 
L dDMN, RECN 32 111 4.0 -2, 42, 16 
R   32 92 4.2 14, 50, 20 
Inferior Frontal (Orb) 
L RECN 47 269 4.8 -26, 34, -12 
R   47 106 4.0 34, 38, -6 
Inferior Frontal (Tri) L RECN 45, 47 271 4.1 -44, 28, 0 
Inferior Frontal (Orb) L   11, 47 74 4.9 -26, 36, -12 
Middle Frontal L ASN, RECN 46 547 4.8 -28, 44, 30 
Superior Frontal L   9 135 4.3 -18, 44, 30 
Superior Medial Frontal L   10 79 3.8 -10, 56, 26 
Heschl Gyrus R   48 50 4.4 40, -24, 18 
Hippocampus R   20 100 4.2 40, -22, -8 
Insula 
L ASN 48 104 4.1 -42, 8, -2 
R   48 226 4.5 38, 12, -12 
Rolandic Operculum R   48 120 5.3 44, -24, 20 
Inferior Temporal R   20 68 4.6 54, -4, -28 
Middle Temporal L   20, 21 226 5.4 58, -4, -22 
Superior Temporal Pole L ASN 38 82 5.1 -50, 12, -12 
Superior Temporal 
L   48 98 4.1 -50, 6, -12 
R   48 568 4.8 58, -8, 2 
Thalamus L     79 4.0 -2, -14, 6 
Placebo Group Differences Not Significant 
End Group Differences Not Significant 
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Table 4 (continued) 
Ti
m
e 
Di
ffe
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nc
es
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d 
T-
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) 
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Non-Remitters:  
Baseline > End 
Calcarine 
L   17, 18 194 4.4 2, -96, 8 
R   18 79 4.4 22, -94, -4 
Cerebellum Culmen R vDMN 37 60 4.4 20, -46, -14 
Cerebellum Declive R   18, 19 385 6.0 24, -78, -18 
Cerebellum Declive R   18 98 5.6 34, -76, -22 
Cuneus 
L   18 161 4.6 -10, -96, 18 
R   18 144 5.3 8, -92, 26 
Fusiform R   18, 19 159 5.6 24, -82, -16 
 
 
Insula 
L   48 85 4.6 -46, 2, 2 
L   19 122 5.0 -18, -52, -8 
Lingual R   18 275 5.1 22, -84, -14 
Inferior Occipital R   18, 19 106 4.4 30, -82, -16 
Middle Occipital 
L   18 129 4.6 -28, -94, 12 
R   18 88 4.8 26, -92, 12 
Superior Occipital 
L   17, 18 158 4.9 -12, -96, 20 
R   18 163 5.3 22, -92, 20 
Inferior Parietal L RECN 2, 3 76 4.8 -56, -22, 46 
Rolandic Operculum L   48 101 4.8 -50, 2, 4 
Thalamus 
L     76 4.9 -6, -8, 6 
R     50 4.7 6, -12, 6 
Remitters: End > Baseline Insula L ASN 13 132 5.4 -40, 14, -4 
Non-Remitters:  
Placebo > End Parahippocampus L vDMN   136 4.8 
-16, -24, -
10 
Remitters: Placebo = End Not Significant 
 
 
 
7.4.3 Baseline Hyperactivation in Non-Remitters Relative to Remitters 
We found that non-remitters had greater activation than remitters (even after adjusting for 
baseline depression severity) in the: bilateral caudate, anterior cingulate, inferior frontal (orbital), 
superior temporal, and insula; as well as the left thalamus, inferior, middle, and superior frontal; 
and the right hippocampus, rolandic operculum, and inferior temporal gyrus (figure 4 and table 
4). We found no group differences at placebo or the end of the treatment trial.   
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In each of these regions, we extracted mean gray matter density, mean diffusivity, resting 
perfusion, resting EVC, and activation during explicit emotion regulation and tested for group 
differences at baseline (adjusted for multiple comparisons by controlling the FDR). We found 
that in the right inferior orbital gyrus, remitters had lower mean diffusivity [t(55)=-2.9, 
punc=0.0056, FDR=0.028] than non-remitters. Thus, the group differences in activation may be 
partially driven by group differences in diffusivity in the right inferior orbital gyrus.  
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Figure 4. Group differences in emotion reactivity at baseline. Regions that were significantly 
more active during face/shapes task in non-remitters relative to remitters at baseline (adjusting 
for baseline depression severity). Colors indicate the value of the t-statistic (independent t-test), 
where lighter values indicate regions where non-remitters have greater activation than remitters 
(no regions in reverse direction). Non-remitters also showed group differences in right inferior 
frontal gyrus (orbital) mean diffusivity, but showed no other group differences in structural (gray 
matter density and mean diffusivity) or functional (resting perfusion, resting EVC, and activation 
during IAPS) measures in these regions.  
 
 
 
7.4.4 Decreased Activation Following Ineffective Pharmacotherapy (Non-Remitters) 
Non-remitters showed significant decreases in activation between baseline and the end of the 
trial in visual cortex and secondary visual processing areas (fusiform, inferior parietal), thalamus, 
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and bilateral insula (figure 5 and table 4). However, we only found that the left parahippocampus 
significantly decreased between placebo and the end of the trial in the non-remitters (table 4).  
 
 
 
 
 
Figure 5. Baseline vs. end emotion reactivity in non-remitters. Several clusters showed 
significant decreases from baseline to end (but no increases) in activation in non-remitters. 
Colors on the brain show the t-statistic for the paired t-test between baseline and the end of the 
trial.  
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7.4.5 Increased Insula Activation Following Effective Pharmacotherapy (Remitters) 
Remitters showed a significant increase in the left anterior insula between baseline and the end 
of the trial (figure 6 and table 4). To better understand this finding in the remitters we extracted 
resting perfusion, resting EVC, and activation during explicit emotion regulation in the left AI. 
We tested for total changes across the entire trial as well as whether total changes associated with 
acute changes in emotion reactivity.  
In the remitters, we found that the left anterior insula EVC significantly increased from 
baseline [t(23)=-2.3, p=0.0325], while the acute increase (following single dose relative to 
baseline) in activation was associated with total increase (end relative to baseline) in perfusion 
[r(23)=0.42, p=0.0385]. Of note, we found that the IAPS activation increased during the long-
term treatment period (end relative to a week after beginning treatment), but not significantly 
[t(23)=-1.83, p=0.0804]. We did not find any associations between structural features at baseline 
and either the acute or long-term changes in activation. Thus, the increase in left anterior insula 
activation during the emotion reactivity task was coupled with a more chronic change in explicit 
regulation, activation was associated with change in perfusion, and changes were independent of 
structural influence.  
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Figure 6. Baseline vs. end emotion reactivity in remitters. The left anterior insula showed 
significant increases in activation during face/shapes task in remitters. Colors on the brain show 
the t-statistic for the paired t-test between baseline and the end of the trial. While the entire 
course is plotted, the test was only done on two scans (baseline and end) in remitters and while 
we plotted the non-remitter data there was no test done (only plotted for reference). Violin plots 
show the voxel-wise variance for this cluster by plotting a mirrored histogram (i.e. a vertically 
mirrored histogram for the voxel-wise data in the cluster). We plot average changes in dotted 
lines. We found that the acute change in activation during face/shapes was associated with 
increased total perfusion and that the EVC of this region also significantly increased. While we 
found no significant baseline to end differences during IAPS, we did find a marginal effect 
showing differences between the end of the trial and a week after beginning treatment.  
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7.4.6 Single Dose Engagement in Parahippocampus 
We found that following a single dose of Venlafaxine relative to placebo there was an increase in 
activation in remitters that significantly differed than the decrease in activation in non-remitters. 
This increase was detected in the left parahippocampus (figure 7 and table 4). While we found no 
such changes (that depended on group) between placebo and after a week of treatment or at the 
end of the trial, we did find that the left parahippocampus qualitatively showed some effect in 
both analyses (i.e. a cluster appeared that did not pass multiple comparisons correction, p<0.001 
uncorrected).  
To better understand this effect in the remitters we extracted mean resting perfusion, 
resting EVC, and activation during IAPS in the parahippocampus and tested for significant 
changes across the entire trial. We found that only the IAPS task significantly increased from 
baseline in the remitters [t(23)=-3.9, p=0.0008]. We did not find any associations between 
structural features at baseline and either the acute or long-term changes in activation. Thus, the 
acute increase in activation in the left parahippocampus was coupled with a more chronic change 
in explicit regulation, but was independent of structural influence. 
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Figure 7. Acute single-dose changes in activation of the emotion reactivity task. The left 
parahippocampus showed a significant interaction between group (remitters and non-remitters) 
and time (after placebo and after single dose). While remitters and non-remitters showed a slight 
decrease following a placebo, they showed opposite changes following the initial dose (which 
seems to remain). Colors on the brain show the t-statistic for the independent t-test between the 
difference (placebo minus initial dose). While the entire course is plotted, the test was only done 
on two scans (placebo and single dose). Violin plots show the voxel-wise variance for this cluster 
by plotting a mirrored histogram (i.e. a vertically mirrored histogram for the voxel-wise data in 
the cluster). We plot average changes in dotted lines. We also found that the left 
parahippocampus showed a significant increase from baseline (relative to end) in this region.  
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7.5 DISCUSSION 
As expected, the face/shapes task robustly activated the amygdala as well as supporting 
structures during the emotion reactivity task, including structures such as the parahippocampus, 
insula, and executive structures (Groenewold et al, 2013). 
7.5.1 Baseline Hyperactivation 
At baseline, we found that non-remitters exhibited a heightened reactivity (as measured by the 
level of activation that was independent of their baseline depression severity) in a wide set of 
regions that did not include the amygdala. As hyperactivation of the amygdala is seen in MDD 
relative to never-depressed individuals, this may reflect a similar level of automatic reactivity – 
but a possible difference in either appraisal and/or regulation. Regions such as the caudate, 
insula, anterior cingulate, and frontal structures were hyperactive. Thus, this may reflect a greater 
level of the secondary appraisal processing that follows the initial amygdala reactivity (hence 
hyperactivation of the insula, caudate, anterior cingulate). Frontal structures (including 
orbitofrontral) and the anterior cingulate may reflect a greater need for emotional regulation as a 
result of hyperactivation in these other limbic structures. Interestingly, we found a lower mean 
diffusivity in the right inferior orbital gyrus in the remitters compared to non-remitters, and as 
this region is critical for both implicit and explicit aspects of regulation may reflect a difference 
in ability to regulate, but also a difference in remission capacity (at least to this regimen). 
Interestingly, there was no detected difference at placebo – which may reflect a difference in 
reactivity that is quickly tempered.  
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7.5.2 Decreased Activation in Non-Remitters 
Interestingly, non-remitters displayed a decrease in activation in visual processing areas (primary 
and fusiform/parahippocampus), insula, inferior parietal lobe, and thalamus. Notably, all 
participants in the study improved to some degree following treatment. Thus, non-remitters do 
display improvement to some degree in symptom severity and this decrease in limbic reactivity 
may be a possible mechanism of these changes. Several of these changes (including the insula 
and parahippocampus) occur early as well, which suggests that a decrease in these limbic 
structures may provide relief possibly through a change in reactivity. However, it does not allow 
for total remission of symptoms.  
7.5.3 Increased Left Anterior Insula Activation 
In contrast to non-remitters, remitters showed only a significant (steady) increase in the left 
anterior insula activation. This suggests that remission (at least to venlafaxine) has a specific 
neural signature and replicates similar previous findings but extends the changes to activation 
over a more acute period (Arce et al, 2008; Davidson et al, 2003; Wang et al, 2012). While there 
was not a significant change in perfusion, the increased activation was associated with an 
increase in perfusion. This supports the notion that there are meaningful changes occurring 
within this region in those who experience improvement in symptom severity. We argue that 
these changes reflect an improvement in the insula’s core function to relate external and internal 
stimuli to the self. Specifically, as this region has been associated with the amount of daily 
habitual implicit regulation there may be greater implicit regulation of emotional responses 
(Gross et al, 2003). This is further supported by significant changes in centrality (EVC) that 
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reflects a greater whole brain connectedness within this region, which may be involved in overall 
improvement even at rest. Notably, we did not find any changes in amygdala activation 
throughout the study in remitters. Thus, we can conclude that there is no change in reactivity but 
rather a change in the processes that follow. To further implicate these changes, we also found 
that there is a total change in explicit emotion regulation in a separate task that occurs over a later 
period (no early changes). As these changes were not related to baseline structural features, we 
can thus conclude that while there were no changes in reactivity there were important changes in 
how those emotions were regulated (implicit regulation acutely and explicit regulation 
chronically).  
7.5.4 Acute Parahippocampal Engagement 
Unlike the left anterior insula that showed a steady increase in activation, the left 
parahippocampus exhibited a strong acute (single dose) increase in the remitters (decrease in 
non-remitters) that remained for the entirety of the trial. The change occurred following only a 
single dose, thus it is a strong candidate as an early biomarker. As with the left anterior insula, 
this region also showed a significant increase in activation during the explicit regulation task in 
the remitters. Again, this supports a change in regulatory strategies and may reflect a change in 
how the stimuli are perceived contextually.  
7.5.5 Chronic Behavioral Changes and Implicit Improvement 
A well-known aspect of the treatment process is that while the anti-depressants are known to 
modulate (increase) serotonin levels acutely (within hours), the behavioral changes do not 
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present until a much later period (3-5 weeks in mid-life and 6-8 weeks in late-life) (Andreescu et 
al, 2011). These results may provide some insight, specifically that while there is a change in 
processing (neural processing of implicit regulation) there are no changes behaviorally after a 
single dose. Similarly, the changes in explicit emotion regulation, which requires conscious 
continuous effort, do not change either at the neural or behavioral level until a much later period. 
These results provide a possible mechanistic explanation (as these changes occur following one 
dose) of the changes occurring following treatment: modulation of serotonin changes the neural 
processing involved in implicit emotion regulation that is a marker of eventual changes in 
explicit emotion regulation (which may actually be an effect of remission).  
7.5.6 Relevance to Late-Life and Limitations 
We recruited a late-life sample thus while it is not clear whether these results would generalize to 
a mid-life sample there exists previous studies in mid-life that showed similar changes in the 
anterior insula. Further in this sample, we did not find any differences in white-matter 
hyperintensity burden between remitters and non-remitters even though we have in the past. 
Non-remitters displayed lower mean diffusivity than remitters in the right inferior orbital gyrus, 
which may reflect differences in remission capacity to this particular anti-depressant. While 
compared to other neuroimaging studies we have a good sample size, a larger study would help 
us better understand the generalizability of these results and more importantly their reliability. 
These changes may reflect changes following therapy to only this particular anti-depressant and 
may not generalize to other anti-depressants.  
Several mid-life studies have shown changes in amygdala reactivity following successful 
pharmacotherapy, but there are fewer studies that have shown a change in amygdala reactivity in 
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LLD. We could speculate that this is related to the difference in etiology – many older 
individuals have not (as youth or in mid-life) experienced any depressive symptoms, thus it may 
that older individuals have impairments in another process of the fearful/angry viewing 
paradigm, mainly the appraisal or implicit regulation steps. A lower ability to regulate implicitly 
could explain the worsened mood as well as hyperactivity of the amygdala. This is supported by 
studies that have found (in never depressed individuals) similar amygdala activation in young 
and elderly individuals but altered fusiform and insula activation (Wright et al, 2006). 
As the amount of time needed to determine whether patients are responding to a 
particular therapy is longer in late-life (6-8 weeks) and is associated with an increased risk of 
suicide, finding biomarkers of remission is of utmost importance. These changes may be an 
important step towards this goal.  
7.5.7 Conclusion 
We have identified two possible regions of interest: the left parahippocampus and the left 
anterior insula. We argue that these changes occur and are specific to the implicit emotion 
regulation neural circuitry that translates to eventual changes in the explicit emotion regulation 
neural circuitry. The left anterior insula in particular could be a target for transcranial magnetic 
stimulation (TMS) as with deep TMS we are now able to reach deeper and deeper structures. 
Overall, these may explain the chronic behavioral changes that occur overall a longer time scale 
compared to the acute neural changes in implicit regulation.  
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8.0 PREDICTING REMISSION IN LLD: MULTI-FACTOR KERNEL BASED 
MACHINE LEARNING 
This chapter focuses on the results of several models that attempt to predict remission. The 
models utilize the same dataset described in the last two chapters. Several parameters of the 
model fitting process are explored, including: single vs. multiple features, PCA vs. MFA for 
feature reduction (or kernel), and different combinations of feature sets (mainly demographic and 
clinical data, baseline structural imaging, baseline functional imaging, pharmacological change 
in functional imaging).  
8.1 INTRODUCTION 
Increased interest in machine learning approaches have resulted in many studies that have 
attempted to generate a model for predicting remission to depression. This has proven to be 
complicated with many models suffering from over-fitting and low generalizability due to high-
dimensional features and low sample sizes. A common problem is combining several feature sets 
in an intuitive fashion (e.g., neuroimaging and clinical data). One approach that has been widely 
utilized uses kernel-based machine learning models. These approaches typically reduce the 
feature set into a single kernel that can be used to model the observed outcomes.  
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 Principal components analysis (PCA) reduces high-dimensional features into low-
dimensional vectors (or eigenvectors), which explain a certain proportion of variance within the 
data (related to the eigenvalue). PCA reduces the matrix of features into a set of scores (which 
represent the original data in the low-dimensional feature space). These scores are then used to 
fit a model with the observed outcome. These models have several desirable properties. Consider 
a linear regression model that is either solved using the standard approach (ordinary least 
squares, OLS) or using the PCA approach. The first property is that any linear form of the 
principal components method has a lower variance than the OLS solution. The covariance matrix 
of the scores (from PCA) is identity, which means that none of the features are collinear. This 
completely resolves the multi-collinearity problem in regression. This method can be considered 
a regularized solution and is also an optimal regularized solution.  
 While the PCA kernel can be used to reduce a single feature, the problem of multiple 
feature sets is not resolved. Multi-factor analysis is an extension of this approach. Combining all 
the data into a single matrix then performing PCA is undesirable, as the components will be 
dominated by the matrices with the greatest number of features (e.g., including neuroimaging 
data will introduce a large number of voxels). By first performing a PCA on each individual data 
set (clinical/demographic and neuroimaging data separately) then using the scores to perform 
another PCA, the scores will be equally weighted on each individual data set rather than by the 
number of features within each individual set.  
 In this study, a cohort (N=51) of LLD individuals was recruited into an open-label trial of 
venlafaxine (a serotonin-norepinephrine reuptake inhibitor). Neuroimaging data was collected at 
baseline and following a single dose of venlafaxine (among 3 other time points – however they 
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are not utilized in this analysis). We used kernel-based machine learning approaches to predict 
treatment outcomes (remitters/non-remitters) at 12 weeks.  
8.2 METHODS 
The following sections have already been described in the previous chapter (7.3.1-7.3.9): Study 
Design and Participants, MRI Data Collection, Functional Tasks, Structural Processing, BOLD 
Pre-Processing, Modeling Task Activation: Face/Shapes and IAPS, Resting State BOLD: 
Eigenvector Centrality (EVC), Pre-processing pCASL and Perfusion Calculation, DTI 
Preprocessing and Mean Diffusivity. The only exception is in 7.3.9, where both mean diffusivity 
(MD) and fractional anisotropy (FA) are calculated. The following sections are split into: single 
feature set and multiple features set learning (mainly PCA vs. MFA as a feature reduction 
method). The theory behind these models is detailed in chapter 4.  
8.2.1 Single Feature Set: Principal Components Learning 
This method utilizes principal components analysis to reduce features and works well with 
‘single feature sets.’ The following single feature sets were evaluated: (1) demographic and 
clinical data (e.g., age, gender, education, MADRS, WMH burden, etc.); (2) baseline functional 
neuroimaging (each of the following was independently used: emotion reactivity, emotion 
regulation, EVC, and perfusion); (3) baseline structural imaging (each of the following was 
independently used: gray matter density, MD, FA); (4) difference in functional neuroimaging 
between baseline and placebo or first dose in each of the functional tasks.  
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 These models assume that a single feature matrix exists (X, n subjects by f features where 
f can be the number of clinical/demographic variables or the number of voxels depending on the 
feature set) and this is used to predict the outcomes (y, binary vector length n subjects). The 
model building process is reviewed graphically in figure 8. After determining the number of 
principal components (using Horn’s parallel analysis, HPA), then we perform PCA on the 
feature matrix to get a set of scores (U, n subjects by c components) and a set of coefficients (λ, c 
components by f features).  
 First we fit a single model between the outcomes (y) and the scores (U) using either 
logistic regression, step-wise logistic regression, or support vector machines. Support vector 
machines optimize the box constraint and the kernel scale using a random 25 percent of the 
samples. This step outputs a set of parameter estimates (β, length c components) that are 
projected back into the original space using the coefficients (B, length f features). The next two 
steps test the generalizability of the model (by computing area under the curve, AUC) and which 
features are most significantly predictive (using permutation testing).  
 A 10-fold cross-validation was utilized, where for each fold a set of training data (Utrain 
and ytrain) was used to fit a single model, which was used to predict on the test data (Utest) to fit a 
set of predicted outcomes (yhattest). After the cross-validation, a set of predicted outcomes (yhat) 
are output that can be compared to the actual outcomes (y) by calculating AUC of a receiver 
operating characteristic curve. However, it is possible that the cross-validation we have utilized 
is negatively/positively biased, thus we repeat this cross-validation a total of 50 times to get a 
range on the AUC statistic. This statistic tests for the generalizability of the full model, i.e., how 
well this model will perform given entirely new data.  
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 Permutation testing is performed (1000) to determine the significance of the parameters 
in original model (i.e., which features significantly contribute to the final model). For each 
permutation, the outcomes are permuted or shuffled (yp) then a model is fit (using U) to get a set 
of parameters (βp) that are projected into the original feature space (Bp). This is repeated for each 
permutation to get a set of 1000 values for each feature (Bp is f by 1000) that represents a 
distribution for each feature that can be used to compute a p-value. The p-value is the number of 
times the absolute value of the actual parameter estimates (B) are less than the absolute value of 
the permuted parameter estimates (Bp) divided by 1000.  
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Figure 8. Model building procedure for single feature sets.  
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8.2.2 Multiple Feature Sets: Multi-Factor Learning 
This method utilizes multiple factor analysis (MFA) to reduce features and works well with 
‘multiple feature sets.’ Consider two sets of predictive features (e.g., demographic data and 
genetics data) where one feature set is particularly larger than the other (genetics data has a high 
number of features). Combining these two sets together will ‘wash out’ the effect of the 
demographic data – though that feature set may be highly predictive. MFA attempts to 
ameliorate this by performing a PCA on each set of data independently then using the scores 
from each to perform another PCA (hence the name “multi”-factor). This allows for each feature 
set to weight the scores matrix equally. The following multiple feature sets were evaluated: the 
demographic and clinical data along with (1) each of the functional neuroimaging features 
(independently then all together); (2) each of the structural neuroimaging features (independently 
then all together); (3) each of the functional neuroimaging features along with the 
pharmacological difference in the neuroimaging data; and (4) each of the functional 
neuroimaging features along with the pharmacological difference in the neuroimaging data as 
well as all the structural neuroimaging data.  
 These models assume greater than one feature matrix exists (e.g., X, n by f and S, n by v) 
and this is used to predict the outcomes (y, binary vector length n subjects). The model building 
process is reviewed graphically in figure 9. The process is identical to the previous algorithm, 
with a few important changes. Most importantly the first step is to perform PCA on both feature 
sets independently to extract a set of scores (U and V) as well as coefficients (λ and δ).  
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Figure 9. Model building procedure for multiple feature sets.  
 
   136 
 The next step uses the scores from each feature set (U and V), combines them into a 
single matrix and performs yet another HPA analysis to determine the number of necessary 
components then a PCA on that matrix to get a set of scores (W) and coefficients (μ). Next, the 
model building procedure is exactly the same as before, however the new scores are used to fit 
the models. Another change is that the transformation back into the original feature space 
requires two transformations (using μ first then λ and δ to transform into X and S feature space, 
respectively).  
8.3 RESULTS 
The single feature models produced several models with sufficiently high AUC (reported in table 
5), specifically the demographic/clinical features with a step-wise logistic model resulted in the 
highest AUC (median 0.735). Two other features that performed well were: baseline emotion 
reactivity using a step-wise logistic model (median AUC of 0.766) and baseline MD using a 
step-wise logistic model (median AUC of 0.658). The ROC curves for each of these models are 
plotted in figure 10. The most significant predictors in the demographic and clinical model are 
reported in table 6 (ordered by most predictive to least). The voxels that were most predictive in 
the emotion reactivity model are reported in figure 11, while the voxels that were most predictive 
in the MD model are reported in figure 12. The emotion reactivity task showed the following 
regions to be predictive: bilateral visual cortex (angular, calcarine, cuneus, middle occipital), 
fusiform, precentral, supramarginal, middle and superior temporal, caudate, thalamus, putamen, 
insula, anterior and middle cingulate, inferior orbital and inferior triangular gyrii, middle and 
superior frontal, and superior medial frontal gyrii; as well as right amygdala, heschl gyrus, 
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hippocampus, precuneus, inferior temporal; and left parahippocampus, and inferior and superior 
parietal as well as parts of the cerebellum. The MD showed the following regions to be 
predictive: bilateral middle cingulate, superior orbital, insula, inferior parietal, pre-/post-central, 
and middle temporal; as well as right angular, inferior frontal, middle frontal, superior parietal, 
supplemental motor, and superior temporal; and left calcarine, anterior cingulate, hippocampus, 
lingual, precuneus, and supramarginal.  
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Table 5. AUC of each of the single feature models. NOTE: SVM=support vector machine; 
swLogistic=step-wise logistic model; AUC=area under the ROC curve; Hypothesize Mean=T-
test tests the null hypothesis that the AUC is greater than the hypothesized mean.  
Feature Model AUC median (IQR) One Sample  T-test (df=49) 
Hypothesized  
Mean p-value 
Demographic and 
Clinical Features 
SVM 0.655 (0.079) 7.2 0.6 1.60E-09 
Logistic 0.682 (0.029) 26.9 0.6 0 
swLogistic 0.735 (0.018) 15.6 0.7 0 
Baseline Emotion 
Reactivity 
SVM 0.618 (0.079) 1.8 0.6 0.0850 
Logistic 0.655 (0.040) 14.9 0.6 0 
swLogistic 0.766 (0.040) 17.1 0.7 0 
Baseline Emotion 
Regulation 
SVM 0.517 (0.045)       
Logistic 0.530 (0.046)       
swLogistic 0.575 (0.066)       
Baseline EVC 
SVM 0.426 (0.078)       
Logistic 0.325 (0.065)       
swLogistic 0.354 (0.062)       
Baseline Perfusion 
SVM 0.347 (0.058)       
Logistic 0.530 (0.058)       
swLogistic 0.547 (0.074)       
Baseline Gray Matter 
Density 
SVM 0.531 (0.063)       
Logistic 0.431 (0.060)       
swLogistic 0.263 (0.063)       
Baseline FA 
SVM 0.332 (0.062)       
Logistic 0.495 (0.043)       
swLogistic 0.442 (0.085)       
Baseline MD 
SVM 0.510 (0.058)       
Logistic 0.578 (0.045)       
swLogistic 0.658 (0.055) 11.8 0.6 2.77E-16 
phMRI Emotion 
Reactivity 
SVM 0.583 (0.063)       
Logistic 0.411 (0.052)       
swLogistic 0.275 (0.075)       
phMRI Emotion 
Regulation 
SVM 0.331 (0.069)       
Logistic 0.503 (0.071)       
swLogistic 0.297 (0.088)       
phMRI EVC 
SVM 0.501 (0.041)       
Logistic 0.571 (0.038)       
swLogistic 0.586 (0.088)       
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Table 5 (continued) 
phMRI Perfusion 
SVM 0.323 (0.0610)       
Logistic 0.313 (0.032)       
swLogistic 0.281 (0.066)       
 
 
 
 
Table 6. Features predictive in model that utilized clinical/demographic features. Features of the 
model that utilized demographic and clinical features and a step-wise logistic regression ordered 
by contribution to overall model. 
Feature Parameter Estimate (Z) p-value 
Negative Affect -2.936 0.004 
MADRS8 -0.280 0.004 
MADRS9 -0.268 0.004 
Education -0.266 0.004 
Gender 0.076 0.004 
MADRS1 -0.192 0.005 
MMSE -0.045 0.005 
MADRS -1.959 0.008 
MADRS2 -0.125 0.008 
Positive Affect 2.651 0.009 
MADRS3 -0.268 0.017 
MADRS7 -0.185 0.031 
MADRS4 -0.170 0.042 
CIRSG 0.284 0.047 
MADRS6 -0.190 0.047 
MADRS5 -0.183 0.047 
Age 0.695 0.048 
MADRS10 -0.098 0.048 
WMH 0.072 0.048 
Race -0.016 0.048 
Depression Type -0.004 0.048 
 
   140 
 
Figure 10. ROC curves for the most accurate models.  
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Figure 11. Most predictive voxels in emotion reactivity at baseline model. Regions during 
emotion reactivity (baseline) significantly contributing to the prediction of remission. Colorbar 
indicates value of the parameter estimate (Z-score).  
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Figure 12. Most predictive voxels in mean diffusivity at baseline model. MD (at baseline) of 
regions significantly contributing to the prediction of remission. Colorbar indicates value of the 
parameter estimate (Z-score). 
 
 
 
While some of the multiple feature models performed similarly (reported in table 7), they 
performed worse than their single feature counterparts. The best performing model amongst 
them combined the demographic/clinical features and the baseline emotion reactivity (median 
AUC of 0.661), however this is worse than either of the models separately. Similarly, the model 
that combined the demographic/clinical features and the baseline MD (median AUC of 0.602) 
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also performed worse than either model separately. We investigated the AUC of the full models 
(i.e., fitting a model on the full set of data and then predicting on that set as well) to understand 
whether this was possible due to over-fitting. We found that the AUC was highest for the MFA 
model combining demographic/clinical features and baseline emotion reactivity (AUC=1), but 
was much lower for both demographic/clinical features (AUC=0.785) and the emotion reactivity 
(AUC=0.834). This suggests that the models may have over-fit, which can occur when too many 
features are entered into the model.  
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Table 7. AUC of each of the multiple feature models. SVM=support vector machine; 
swLogistic=step-wise logistic model; AUC=area under the ROC curve. 
Feature Model AUC median (IQR) 
Demographic/Clinical and Baseline 
Emotion Reactivity 
SVM 0.609 (0.79) 
Logistic 0.661 (0.058) 
swLogistic 0.581 (0.082) 
Demographic/Clinical and Baseline 
Emotion Regulation 
SVM 0.500 (0.096) 
Logistic 0.483 (0.056) 
swLogistic 0.582 (0.077) 
Demographic/Clinical and Baseline 
EVC 
SVM 0.490 (0.096) 
Logistic 0.495 (0.076) 
swLogistic 0.510 (0.088) 
Demographic/Clinical and Baseline 
Perfusion 
SVM 0.489 (0.042) 
Logistic 0.510 (0.075) 
swLogistic 0.471 (0.082) 
Demographic/Clinical and Baseline 
Gray Matter Density 
SVM 0.343 (0.061) 
Logistic 0.439 (0.051) 
swLogistic 0.602 (0.080) 
Demographic/Clinical and Baseline 
FA 
SVM 0.386 (0.095) 
Logistic 0.500 (0.064) 
swLogistic 0.543 (0.091) 
Demographic/Clinical and Baseline 
MD 
SVM 0.430 (0.058) 
Logistic 0.464 (0.063) 
swLogistic 0.564 (0.083) 
Demographic/Clinical and Baseline 
Functional Neuroimaging 
SVM 0.342 (0.059) 
Logistic 0.465 (0.074) 
swLogistic 0.423 (0.093) 
Demographic/Clinical and Baseline 
and phMRI Emotion Reactivity 
SVM 0.447 (0.102) 
Logistic 0.568 (0.072) 
swLogistic 0.573 (0.082) 
Demographic/Clinical and Baseline 
and phMRI Emotion Regulation 
SVM 0.500 (0.000) 
Logistic 0.495 (0.058) 
swLogistic 0.517 (0.092) 
Demographic/Clinical and Baseline 
and phMRI EVC 
SVM 0.380 (0.060) 
Logistic 0.458 (0.070) 
swLogistic 0.262 (0.067) 
Demographic/Clinical and Baseline 
and phMRI Perfusion 
SVM 0.320 (0.060) 
Logistic 0.530 (0.066) 
swLogistic 0.540 (0.054) 
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8.4 DISCUSSION 
Kernel-based regression approaches are a promising approach to fitting models with a high 
number of features and limited sample size. These approaches reduce the feature space into a 
low-dimensional vector space (kernel), perform a model fitting approach, and then project back 
into the original space. Due to the ‘kernel’ trick, this fits models that behave non-linearly and by 
constraining the number of principal components used – only the vectors that explain the highest 
variance are used (which improves the overall generalizability of the models).  
 The single feature kernels performed well on both neuroimaging and demographic and 
clinical data, where a step-wise logistic regression model on the scores of the demographic and 
clinical data resulted in the best performing model (median AUC 0.735). The emotion reactivity 
task (at baseline) also performed well (median AUC 0.766). While some of the multiple feature 
sets performed well – they did not perform as well as either of their individual parts. This may 
either indicate a core flaw in the multi-factor based kernels or may be a result of the limited 
sample size. It is possible that the effectiveness of these kernels improves with a greater sample 
size as we can more robustly estimate the MFA kernel. A simulation-based study may help in 
better understanding the characteristics of such a machine learning approach and some of the 
possible assumptions.  
 Surprisingly, while the statistical results (chapter 6 and 7) suggested acute changes 
following a single dose of venlafaxine (i.e., the pharmacological effect), the models that utilized 
these neuroimaging data did not perform as well. This presents a clear difference between some 
of the statistical results and the models used to predict remission. While this may be a result of 
the poor performance of the MFA models, it is unclear why these features alone (using the single 
feature models) did not perform well. The difference between baseline and following single dose 
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neuroimaging was calculated and it is possible that a better measure relating these two imaging 
data can be computed (e.g., slope between baseline and single dose). Another limiting factor is 
that the kernel used may be diluted by non-specific (to the treatment effect) voxels as only a few 
regions indicated a specific response (i.e., insula or parahippocampus). A priori feature selection 
can help improve the specificity of the model.   
 Some of the most predictive clinical features were negative affect, MADRS items 8 
(inability to feel) and 9 (pessimistic thoughts), and education (among others). The model 
suggests that non-remitters have worse negative affect, inability to feel, or pessimistic thoughts. 
Further, non-remitters tended to have higher education. In figure 11 and 12, negative parameter 
estimates suggest that greater activation or MD at baseline (in those regions) is predictive of 
worse outcome. Subsequently, positive parameter estimates suggest that greater activation or 
MD (in these regions) at baseline is predictive of better outcome.  
 While kernel based approaches offer a promising approach to fitting high-dimensional 
models, combining multiple feature sets may require greater samples to sufficiently estimate the 
MFA kernels and to avoid over-fitting. Simulation-based studies may help elucidate the 
assumptions and characteristics of such models. Several promising models utilized 
clinical/demographic data or baseline emotion reactivity activation, and leveraging the 
predictability of both models as well as managing to efficiently use the phMRI effects may result 
in the best models.  
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9.0 SUMMARY AND CONCLUSIONS 
The current approach to treatment is an often-prolonged trial and error process that matches 
patients to a working regimen. A single trial may take several weeks before any sign or 
indication that the current regimen is working, and even then if the regimen is not working – 
patients are taken off that medication (which may take some time) and then another medication 
is used. This process is often lengthy and associated with patient worsening in a host of negative 
health outcomes (even sometimes their severity of depression). In LLD, this window is much 
longer and is associated with a greater risk of suicide. Thus, identifying useful biomarkers and 
generating machine learning models is critical for the future of personalized psychiatry.  
We have identified a unique pattern of resting state connectivity and emotion reactivity 
changes that occur following only a single dose of medication. These changes reflect the future 
change in functional connectivity and reactivity and thus may reflect an early engagement of the 
implicit networks via increased synaptic monoamine occupancy. It is well-known that there 
monoamine occupancy increases within hours of receiving medication – and while the 
behavioral change may occur much later, the change in functional connectivity and activation 
changes acutely. This may serve as an important biomarker for remission.  
Machine learning models have the unique capability of learning high dimensional ‘rules’ 
that are predictive of remission by using complex non-linear kernels. Our models have identified 
several key predictors of remission (in this sample), and future work can aim to increase the 
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sample sizes to properly fit more complex models. Ultimately, non-linear models can be 
generated with appropriately sized studies and these models are likely to be far better at 
predicting remission.  
Future studies should aim to collect: genetic, demographic, behavioral and psychological 
assessments, cognitive batteries, past history of treatment, actigraphy (sleep and activity 
assessment), as well as neuroimaging data. A true multi-modal approach can be used to fit more 
complex and robust models of remission.   
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